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I	   did	   my	   internship	   for	   my	   Master’s	   degree	   thesis	   at	   Rigshospitalet,	   University	   of	  
Copenhagen,	   Faculty	   of	   Health	   and	   Medical	   Sciences,	   Department	   of	   Pathology,	  
Laboratory	  of	  Molecular	  Pathology,	  after	  winning	  an	  Erasmus	  Placement	  scholarship.	  	  
Many	  studies	  have	  shown	  that	  aberrant	  expression	  of	  microRNAs	  (miRNAs)	  is	  involved	  in	  
the	  initiation	  and	  progression	  of	  cancer,	  and	  several	  miRNAs	  have	  been	  characterized	  as	  
tumor	  suppressor	  or	  oncogenes.	  Restoring	  the	  expression	  of	  tumor	  suppressor	  genes	  by	  
epigenetic	   therapy	  has	   great	  potential	   in	   cancer	   treatment	   and	   it	   has	  been	   shown	   that	  
the	   expression	   of	   some	  miRNAs	   in	   cancer	   cells	   can	   be	   directly	   regulated	   by	   epigenetic	  
changes	   in	   their	   own	   promoters.	   However,	   the	  majority	   of	   miRNAs	   are	   located	   within	  
intronic	  regions	  of	  transcription	  units	  and	   it	  remains	  unclear	   if	   intronic	  miRNAs	  can	  also	  
be	  epigenetically	  regulated.	  The	  miR-­‐126	  is	   located	  within	   intron	  7	  of	  the	  proangiogenic	  
Epidermal	   Growth	   Factor-­‐like	   domain	   7	   (EGFL7)	   gene	   that	   is	   highly	   expressed	   in	  
endothelial	   cells	   and	   vascularized	   tissues.	  MiR-­‐126	   acts	   as	   a	   tumor	   suppressor	   gene	   in	  
certain	   types	   of	   cancers	   while	   other	   reports	   have	   described	   an	   oncogenic	   role.	   These	  
contradictory	   findings	  suggest	   that	  miR-­‐126	  may	  have	  several	   functions	  specific	   to	  each	  
type	  of	  malignancy.	  Mature	  miR-­‐126	  can	  be	  generated	  from	  three	  different	  transcripts	  of	  
EGFL7	  with	  each	  one	  having	  its	  own	  promoter	  with	  CpG	  island,	  and	  different	  studies	  have	  
shown	  expression	  correlation	  between	  the	  miR-­‐126	  and	  its	  host	  gene.	  	  
	  
Since	   the	   Laboratory	   of	   Mol.	   Pathol.	   has	   recently	   found	   miR-­‐126	   down-­‐regulation	   in	  
Malignant	   Pleural	   Mesothelioma	   (MPM),	   an	   aggressive	   cancer	   originating	   from	   the	  
mesothelial	   cells	   lining	   the	  pleura,	   in	  my	   study,	  we	  used	  Real-­‐time	  quantitative	  RT-­‐PCR	  
(RT-­‐qPCR)	   	   to	   correlate	   the	   expression	   of	   miR-­‐126	   with	   one	   of	   EGFL7	   transcripts	   in	  
patient-­‐matched	  preoperative	  diagnostic	  pleura	  biopsies	  and	  surgical	  tissue	  specimens	  of	  
MPM	   as	   well	   as	   corresponding	   non-­‐neoplastic	   pleura	   (NNP).	   Patients	   diagnosed	   with	  
MPM	  typically	  have	  a	  history	  of	  long-­‐term	  exposure	  to	  asbestos	  and	  poor	  prognosis	  with	  
a	   median	   survival	   of	   only	   9-­‐12	  months	   from	   the	   time	   of	   diagnosis.	   Our	   attention	   was	  
placed	   also	   on	   studying	   chromatin	   structural	   changes,	   such	   as	  DNA	  methylation,	  which	  
are	   important	   in	   epigenetic	   research	   and	   clinical	   diagnostics	   because	   the	   aberrant	  
methylation	   has	   been	   associated	   with	   transcriptional	   inactivation	   of	   defined	   tumor	  
suppressor	   genes	   in	   human	   cancers.	   To	   adress	   this	   issue	   we	   have	   used	   two	   different	  
methods:	  Methylation	  Sensitive	  PCR	  (MSP)	  and	  pyrosequencing.	  	  
The	   results	   of	   RT-­‐qPCR	   show	   that	   the	   primary	   transcript	   of	  miR-­‐126	   corresponds	   to	   an	  
alternative	  transcript	  of	  EGFL7	  (S2)	  and	  these	  are	  concomitantly	  downregulated	  in	  MPM	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as	  compared	  to	  NNP.	  Our	  MSP	  and	  pyrosequensing	  data	  suggest	  that	  this	  could	  be	  due	  to	  
different	   regulation	   by	   DNA	   methylation	   of	   the	   two	   CpG	   islands,	   located	   in	   the	   S2	  
promoter	   and	  around	  miR-­‐126,	   as	  MPM	  show	  a	   greater	   level	   of	  methylation	   than	  NNP	  
samples.	  	  
This	   work	   has	   improved	   our	   comprehension	   of	   the	   mechanism	   by	   which	   miR-­‐126	   is	  
regulated	  in	  MPM.	  It	  would	  be	  interesting	  in	  the	  future	  to	  analyze	  histone	  modifications	  
in	   chromatin	   structure	   to	   confirm	   the	   importance	   of	   the	   epigenetic	   mechanisms	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1.1	   Mesothelium:	   embryological	   origin	   and	   morphological,	  
cytological	  features	  
	  
The	  mesothelium	  is	  a	  tissue	  composed	  of	  an	  extensive	  monolayer	  of	  specialized	  epithelial	  
cells	   called	   mesothelial	   cells	   (HMCs)	   that	   have	   the	   function	   to	   cover	   different	   serous	  
cavities	  of	  the	  human	  body	  (1).	  
HMCs	  extend	  over	  the	  entire	  surface	  of	  the	  three	  serosal	  cavities	  of	  the	  body	  forming	  the	  
pleura	   that	   lines	   the	   lung,	   the	   pericardium	   tha	   lines	   the	   the	   heart	   and	   finally	   the	  
peritoneum	   that	   covers	   the	   internal	   organs	   of	   the	   abdominal	   cavity	   fixing	   them	   to	   the	  
walls	  and	  helping	  to	  keep	  them	   in	  their	  natural	  position.	  Furthermore	  the	  HMCs,	   in	   the	  
male,	  cover	  the	  membranes	  that	  encircle	  the	  testes	  (2).	  
The	   embryological	   origin	   and	   the	   features	   of	   the	   cells	   that	   compose	   the	  mesothelium,	  
make	  this	  reference	  tissue	  very	  unusual.	  In	  fact,	  unlike	  all	  other	  epithelial	  tissues,	  it	  does	  
not	  develop	  from	  the	  ectoderm,	  but	  from	  mesoderm	  (1-­‐2).	  
For	   this	   reason,	   HMCs	   express	   the	   mesenchymal	   intermediate	   filaments	   vimentin	   and	  
desmin,	   as	   well	   as	   cytokeratins	   which	   are	   intermediate	   filaments	   characteristic	   of	  
epithelial	  cells	  with	  ectodermal	  origin	  (1,3).	  
Furthermore,	   the	  mixed	  phenothype	  of	   this	  kind	  of	  cells	  promotes	  several	  physiological	  
processes	  that	  are	  essential	  to	  maintain	  homeostasis.	  
In	   situ	   HMCs	   have	   usually	   a	   polygonal,	   flattened	   appearance,	   but	   can	   also	   exhibit	   a	  
cuboidal	  or	  squamous-­‐like	  pattern	  depending	  on	  their	  location	  and	  they	  are	  located	  on	  a	  
thin	  membrane	  maintained	   by	   connective	   tissue	   stroma	   that	   has	   different	   quality	   and	  
quantity	  in	  the	  three	  serous	  cavities,	  (3-­‐4).	  	  
Squamous-­‐like	   cells	   of	   about	   25	  μm	  diameter	  dominate	   the	  mesothelium,	  but	   cuboidal	  
cells	  can	  be	  found	  in	  various	  organs	  like	  liver	  and	  spleen	  and	  in	  mediastinal	  pleura	  close	  to	  
the	   septal	   folds.	   Besides,	   the	   cuboidal	   cells	   unlike	   squamous-­‐like	   cells	   show	   a	   more	  
metabolically	  active	  state	  (5).	  
An	  important	  characteristic	  of	  HMCs	  is	  the	  presence	  of	  well-­‐developed	  microvilli	  close	  to	  
luminal	  surface	  that	  have	  different	  shape,	  lenght	  and	  density.	  For	  this	  reason	  it	  is	  possible	  
to	  have	  microvilli	  on	  HMCs	  with	  different	  concentration	  on	  several	  organs,	  between	  cells	  
of	  the	  same	  tissue	  and	  on	  the	  surface	  of	  individual	  cells	  (6).	  
The	  boundaries	  between	  HMCs	  are	  tortuous,	  with	  adjacent	  cells	  often	  overlapping.	  They	  
have	   well-­‐developed	   cell–cell	   junctional	   complexes,	   including	   tight	   junctions,	   adherens	  
junctions,	  gap	  junctions	  and	  desmosomes.	  (3).	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The	  mesothelium	   is	   a	   particular	   tissue	   because	   has	   a	   very	   slow	   renewal	   but	  HMCs	   can	  
increase	  their	  turnover	  rate	  thanks	  to	  variety	  of	  agents	  and	  by	  direct	  physical	  damage.	  
The	   origin	   of	   new	  mesothelium	   is	   controversial	   in	   fact	   different	   hypotheses	   have	   been	  
reported	   different	   hypotheses	   like	  macrophages	   transformation,	  migration	   of	   HMCs	   or	  
submesothelial	   mesenchymal	   precursors,	   exfoliation	   of	   mature	   or	   proliferating	   HMCs	  
from	  different	  surfaces,	  presence	  of	  freefloating	  serosal	  reserve	  cells	  that	  replicate	  on	  the	  
wound	  surface	  and	  gradually	  differentiate	  into	  mature	  cells	  (1,3).	  
The	  main	   purpose	   of	   mesothelium	   is	   to	   produce	   a	   lubricating	   fluid,	   released	   between	  
layers,	   which	   favours	   intracoelomic	   movement	   making	   a	   slick,	   non-­‐adhesive,	   and	  
protective	  surface.	  	  
However,	   in	   last	   years	   several	   studies	   have	   allowed	   us	   to	   better	   understand	   other	  
functions	  of	  this	  tissue	  with	  dynamic	  characteristics	  in	  which	  cytological	  features	  of	  cells	  
that	  compose	  it	  have	  an	  essential	  role.	  	  
The	  mesothelium	  in	  fact	  plays	  an	  important	  role	  in	  transporting	  fluids	  and	  particulates	  by	  
pinocytic	   transport	   across	   the	   serosal	   cavities,	   in	   inflammatory	   processes	   through	  
leucocyte	   migration,	   in	   synthesis	   of	   mediators	   like	   cytokines,	   growth	   factors	   and	  
extracellular	  matrix	  proteins	   to	  help	   in	   serosal	   repair,	   	   in	   release	  of	   factors	   to	   facilitate	  
both	  the	  deposition	  and	  clearance	  of	  fibrin,	  in	  antigen	  presentation	  and	  connection	  with	  
tumour	  cells	  (2-­‐4).	  	  
Most	   studies	   in	   effect	   have	   focused	   on	   studying	   tumour	   recurrence	   following	   surgery,	  
reporting	   in	   understandable	   way	   that	   traumatized	   mesothelial	   surfaces	   are	   privileged	  
sites	  for	  tumor	  growth	  and	  dissemination	  of	  tumour	  (7).	  
HMCs	  modulate	  also	  the	  microcirculation	  by	  their	  ability	  to	  secrete	  vasodilators,	  such	  as	  
prostaglandins	   and	   nitric	   oxide,	   or	   vasoconstrictors,	   such	   as	   endothelin.	   Finally	   HMCs	  
have	  the	  capacity	  to	  uptake	  foreign	  matter	  by	  phagocytosis	  and	  this	   feature	  predispose	  





1.2	  	  	  	  Malignant	  Pleural	  Mesothelioma	  	  
1.2.1	  	  Definition	  and	  epidemiology	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The	   lungs	  are	   lined	  by	  a	  thin	  serous	  membrane,	  the	  pleura,	  which	  also	  covers	  the	   inner	  
surface	  of	  the	  chest	  wall.	  The	  pleural	  tissue	   lining	  the	   lungs	   is	  called	  visceral	  pleura	  and	  
the	  layer	  covering	  the	  chest	  names	  parietal	  pleura.	  The	  entire	  pleural	  tissue	  consists	  of	  a	  
single	   layer	   of	   mesothelium	   resting	   on	   a	   basal	   membrane	   with	   underlying	   connective	  
tissue.	   The	   latter	   is	   associated	   with	   many	   structures	   like	   lymphatic	   and	   blood	   vessels,	  
immune	  cells	  and	  fibroblast-­‐like	  cells.	  	  
The	   thin	   space	   between	   the	   two	   pleurae	   is	   known	   as	   the	   pleural	   cavity	   and	   normally	  
contains	  a	  small	  amount	  of	  pleural	  fluid	  that	  prevents	  that	  two	  pleural	  layers	  rub	  during	  
breathing	  (9).	  
This	  fluid,	  which	  has	  many	  characteristics,	  is	  produced	  by	  HMCs	  and	  continually	  circulates	  
passing	   through	   the	   intercostal	   arteries	   and	   then	   drains	   into	   the	   lymphatic	   circulation	  
(10).	  	  
The	   pleura	   is	   the	   place	   where	   many	   carcinogens	   and	   pathogens	   bring	   about	   a	   lot	   of	  
cellular	   injuries	   and	   for	   this	   reason	   the	   infectious	   and	   inflammatory	  processes	   are	   very	  
frequent	  and	  require	  diagnosis	  and	  treatments	  more	  and	  more	  specific	  (11).	  	  
Furthermore	   various	   pleural	   disorders,	   like	   chronic	   inflammation,	   are	   caused	   by	  
inhalation	   of	   industrial	   and	   natural	   fibres	   over	   a	   long	   period	   of	   time	   that	   can	   induce	  
cellular	  reactions	  both	  from	  the	  immune	  system	  and	  the	  mesothelium	  itself.	  
Cancer	  cells	  of	  many	  types,	  for	  example	  metastatic	  adenocarcinomas	  from	  other	  organs	  
can	  spreads	  into	  the	  pleural	  cavity	  but	  this	  area	  can	  be	  the	  location	  of	  different	  tumours	  
that	  arise	  from	  the	  pleural	  tissue	  (12).	  
The	   most	   common	   primary	   malignancy	   of	   pleural	   origin	   is	   the	   Malignant	   Pleural	  
Mesothelioma	  (MPM)	  that	   is	  considered	  a	  highly	  aggressive	  tumour	  with	  a	   low	  index	  of	  
incidence.	  
This	  kind	  of	  cancer	  has	  mortality	  rates	  really	  high	  compared	  with	  other	  cancers,	  in	  fact	  it	  
is	  associated	  with	  a	  poor	  prognosis	  and	  median	  survival	  of	  only	  9-­‐12	  months	  (12-­‐15).	   In	  
addition	   to	   pleura,	   malignant	   mesothelioma	   can	   develop	   in	   three	   other	   localizations:	  
peritoneum,	  pericardium	  and	  tunica	  vaginalis	  testis	  (13,16).	  	  
In	  this	  work	  I	  have	  analyzed	  the	  pleural	  form	  of	  malignant	  mesothelioma,	  which	  is	  by	  far	  
the	  most	  common,	  representing	  more	  than	  90%	  of	  all	  mesotheliomas.	  
Working	  with	  abstestos	  is	  the	  main	  risk	  factor	  for	  MPM	  and	  even	  though	  the	  use	  of	  this	  
material	   is	   forbidden	   in	   a	   large	  part	  of	   the	  world,	   the	  MPM	   incidence	   is	   still	   increasing	  
globally	  (16).	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There	   are	   also	   other	   factors	   relevant	   for	   the	   development	   of	   MPM	   including	   other	  
mineral	  fibers,	  radiation,	  thorotrast,	  genetic	  predisposition	  and	  presence	  of	  SV40	  (simian	  
virus	  40)	  (16-­‐18).	  
Epidemiologial	   studies	   showed	   that	  5%	  of	  people	  exposed	   to	  asbestos	  developed	  MPM	  
and	   more	   than	   80%	   of	   cases	   of	   MPM	   can	   be	   attributed	   to	   asbestos	   exposure,	   but	  
approximately	  20%	  of	  cases	  may	  be	  related	  to	  other	  factors	  (19).	  
The	  incidence	  of	  MPM	  is	  expected	  to	  rise	  worldwide	  in	  the	  next	  10-­‐20	  years	  as	  result	  of	  
widespread	   exposure	   to	   asbestos	   in	   past	   decades,	   continuing	   exposure	   in	   developing	  
countries	   that	  have	  not	  banned	   the	  use	  of	   asbestos	   yet,	   and	   the	   long	   latency	  between	  
exposure	  to	  asbestos	  and	  development	  of	  MPM	  (20	  to	  50	  years).	  
Many	   studies	   have	   estimated	   this	   rate	   of	   incidence	   in	  many	   coutries	   and	   for	   example	  
Australia	   has	   proven	   to	   be	   the	   country	   with	   the	   world’s	   highest	   national	   incidence	   of	  
MPM	   at	   circa	   35	   cases	   per	   million	   inhabitants,	   while	   the	   United	   States,	   where	  
approximately	  2000-­‐2500	  new	  cases	  are	  diagnosed	  every	  year,	  show	  an	  incidence	  range	  
of	  10	  per	  million	  inhabitants	  and	  the	  incidence	  might	  already	  have	  peaked	  (20-­‐22).	  
In	  Italy,	  where	  the	  use	  of	  asbestos	  has	  been	  banned	  in	  1992,	  the	  incidence	  range	  is	  at	  24	  
cases	  per	  million	  inhabitants	  but	  is	  expected	  to	  reach	  its	  peak	  in	  2024	  (22).	  
In	  Denmark	  the	  national	  incidence	  of	  MPM	  for	  men	  has	  continued	  to	  rise	  throughout	  the	  
67-­‐year	  study	  period,	  with	  a	  drastic	  increase	  up	  1.6	  per	  100,000	  person-­‐years	  in	  the	  most	  
recent	  period	  2008-­‐2009	   (23).	   The	   last	   report	   from	   the	  Danish	  Ministery	  of	  health	   says	  
100	  new	  cases	  every	  year,	  that	  is	  about	  2	  per	  100.000	  inhabitants.	  	  
For	   women,	   however,	   the	   incidence	   rate	   has	   remained	   more	   or	   less	   steady	   since	   the	  
1990s,	  peaking	  at	  0.5	  per	  100,000	  person-­‐years	  in	  1973-­‐1977.	  
MPM	  can	  have	  a	  long	  latency	  period	  which	  refers	  to	  the	  length	  of	  time	  it	  takes	  from	  being	  
exposed	   to	   asbestos	   until	   the	   time	   when	   the	   disease	   becomes	   apparent	   in	   a	   clinical	  
examination,	   for	   this	   reason	   the	   latency	   can	   be	   longer	   than	   20	   years	   (13),	   not	  
uncommonly	  up	  to	  40	  years	  or	  longer	  (26).	  	  	  
Furthermore	  MPM	   is	  diagnosed	   in	  people	  with	  a	  median	  age	  between	  72	  and	  74	  years	  	  
and	  this	  one	  is	  a	  demonstration	  of	  some	  characteristics	  of	  this	  disease	  like	  work-­‐related	  
exposure	  to	  asbestos	  and	  a	  long	  latency	  period	  (13-­‐26).	  	  
For	  this	  reason	  the	  lifetime	  risk	  of	  MPM	  remains,	  even	  after	  exposure	  has	  ended;	  in	  fact	  
this	  one	  does	  not	  occur	  for	  people	  who	  stop	  smoking	  in	  which	  it	  is	  possible	  to	  observe	  a	  
reduction	  of	  their	  lung	  tumour	  risk	  over	  the	  following	  years.	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Currently,	  MPM	  causes	  approximately	  3,000	  deaths	  each	  year	  in	  the	  United	  States	  and	  an	  
additional	  5,000	  deaths	  each	  year	  in	  Western	  Europe	  (28).	  	  
Cancer	  stage	  for	  MPM	  is	  not	  considered	  a	  correct	  predictor	  of	  survival,	  in	  effect	  survival	  
itself	  has	  not	   increase	  significantly	  during	  the	  past	   twenty	  years.	   (14).	  Many	  studies	  say	  
that	   five-­‐year	   survival	   for	   individuals	   who	   are	   affected	   by	  MPM	   is	   a	   real	   9%,	   although	  
some	  people	  may	  survive	  for	  10	  years	  or	  more	  (28).	  
	  
1.2.2	  	  Causes	  and	  pathophysiology	  
Asbestos	  exposure	  
	  
The	  term	  asbestos	  (from	  the	  Greek	  Amiantos	  -­‐	  invincible,	  incorruptible)	  indicates	  a	  group	  
of	  minerals,	  with	  a	  microcrystalline	  structure	  and	  a	   fibrous	  appearance;	   in	   fact	   they	  are	  
chemical	  compounds	  containining	  magnesium,	  silicates,	  calcium	  and	  iron.	  
Asbestos	   is	   found	   in	   nature	   combined	   with	   other	   minerals	   and	   it	   is	   extracted	   from	  
quarries	   and	  mines	   thanks	   to	   the	   chipping	  of	   rock,	   from	  which	   it	   is	   possible	   to	   get	   the	  
purified	  fiber.	  
Asbestos	   is	   resistent	   to	   high	   temperatures,	   action	   of	   chemical	   and	   biological	   agents,	  
traction	  and	  wear;	  it	  is	  also	  very	  elastic,	  durable	  and	  soundproof.	  
These	  and	  other	  properties,	  related	  to	  a	  low	  production	  costs,	  have	  allowed	  asbestos	  to	  
be	   an	   extremely	   versatile	  material	   to	   be	   used	   in	  many	   sectors	   like	   the	   construction	   of	  
means	  of	  transportation,	  building	  trade	  and	  automotive	  industry.	  
For	   that	   reason	   the	   exposure	   to	   this	   carcinogen	   is	   greater	   for	   people	   connected	   to	  
asbestos	  mines	  and	  shipyards,	  plumbers,	  electricians,	  construction	  workmen	  (14,15,29).	  
The	   first	   to	  study	  a	  possible	  correlation	  between	  MPM	  and	  asbestos	  was	   J.	  Christopher	  
Wagner,	   who	   in	   1960	   published	   in	   the	   “British	   Journal	   of	   Cancer”	   an	   article	   entitled	  	  
“Diffuse	   pleural	   mesothelioma	   and	   asbestos	   exposure	   in	   the	   North	   Cape	   Province”	   in	  
which	  he	  spoke	  about	  the	  miners	  of	  Kimberly	  in	  South	  Africa	  that	  had	  developed	  a	  pleural	  
tumor,	  called	  mesothelioma,	  after	  exposure	  to	  crocidolite	  (29).	  
The	   next	   step	   was	   to	   inoculate	   asbestos	   into	   experimental	   animals	   and	   in	   fact	   it	   was	  
showed	   in	   1965,	   the	   carcinogenecity	   of	   material,	   as	   animals	   treated	   with	   asbestos	  
became	  ill.	  
This	   work	   led	   to	   the	   first	   article	   of	   Selikoff	   in	   1965,	   in	   which	   it	   was	   confirmed	   the	  
correlation	  between	  asbestos	  exposure	  and	  cancer	  development	  (30).	  
Asbestos	  has	  been	  used	  intensively	  for	  commercial	  purpose	  between	  1930	  and	  1960	  (31-­‐
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32),	  but	  it	  has	  been	  forbidden,	  or	  intensely	  restricted,	  in	  many	  countries	  since	  in	  Western	  
Europe	  between	  1985	  and	  1995	  (32).	  	  
However,	  as	  it	  is	  a	  low-­‐cost	  material	  –	  at	  any	  rate	  in	  the	  short	  term	  –	  many	  countries	  of	  
Eastern	  Europe,	  Latin	  America	  and	  Asia	  import	  and	  consume	  asbestos	  even	  today,	  despite	  
the	   relationship	   with	   MPM	   is	   one	   of	   the	   most	   evident	   between	   a	   carcinogen	   and	   its	  
related	  tumour	  (32-­‐33).	  	  
Despite	  the	  use	  of	  asbestos	  in	  the	  Western	  world	  has	  been	  reduced	  considerably,	  many	  
developing	   countries	   have	   increased	   its	   sale	   and	   usage,	   perhaps	   forecasting	   of	   yet	  
another	  mesothelioma	  epidemic	  to	  come.	  
The	  development	  of	  MPM	  depends	  on	  the	  concentrantion,	   the	  size,	   the	  shape,	  and	  the	  
solubility	  of	  asbestos	  fibers.	  
There	  are	  six	  chemically	  and	  physically	  distinct	  fibres	  as	  serpentines	  (white	  asbestos)	  that	  
include	   chrysotile	   and	   they	   are	   curly	   and	   flexible	  or	   amphiboles,	   stiff	   and	   straight,	   that	  
include	   crocidolite,	   amosite,	   anthophyllite,	   actinolite	   and	   tremolite	   and	   represent	   blue	  
asbestos	  (19).	  
The	   latter	  form	  seems	  to	  be	  the	  most	  dangerous	  while	  white	  asbestos	   is	  the	  most	  used	  
form	  which	  includes	  in	  fact	  90%	  of	  the	  world’s	  entire	  asbestos	  consumption.	  	  
Can	   the	  white	   form	   lead	   to	  MPM?	   This	   question	   has	   ignited	   a	   deep	   debate	   about	   this	  
argument	  and	  some	  studies	  have	  shown	  that	  exposure	  to	  this	  asbestos	  form	  predisposes	  
people	   to	   smoking-­‐induced	   bronchogenic	   lung	   tumours	   and	   the	   statistical	   data	  
demonstrate	   an	   increased	   overall	   cancer	   incidence	   and	   mortality	   in	   exposed	   cohorts;	  
moreover	  it	  is	  important	  to	  remember	  that	  blue	  asbestos	  can	  also	  contaminate	  the	  white	  
asbestos.	  
Finally	  an	  another	  difference	  between	  these	  two	  kind	  of	  asbestos	  is	  that	  serpentines	  can	  
undergo	   fragmentation	   by	   organic	   acids	   and	   be	   removed	   by	   the	   lymphatic	   system,	  
whereas	  the	  amphiboles	   	  may	   	  remain	   	  unchanged	  for	  decade	  (34-­‐36).	  The	  amphiboles,	  
once	  inhaled,	  have	  	  the	  	  capacity	  	  to	  	  reach	  	  the	  	  pleura	  either	  	  through	  	  the	  	  lymphatics	  	  or	  	  
by	  	  direct	  	  penetration,	  	  and	  	  to	  	  cause	  	  MPM	  (37-­‐38).	  
Epidemiological	   evidence	   shows	   that	   the	   fibre	   shape	   and	   length-­‐to-­‐width	   ratio	   are	  
important	  physical	  characteristics	  that	  determine	  how	  deeply	  into	  the	  lung	  the	  fibres	  are	  
inhaled	  and	  whether	  they	  have	  the	  capacity	  to	  penetrate	  the	  lung	  epithelium	  and	  enter	  
or	  irritate	  the	  pleural	  space	  (39-­‐41).	  
Asbestos	   fibres	   have	   the	   feature	   to	   be	   inhaled	   and	   reach	   the	   alveoli	   where	   they	  
accumulate	   in	   the	   lung	   tissue;	   over	   time,	   these	   fibres	   can	  migrate	   out	   to	   parietal	   and	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visceral	  pleura.	  	  
Studying	  asbestos-­‐related	  diseases,	  it	  is	  possible	  to	  observe	  encapsulated	  asbestos	  fibres	  
in	   tissue	   samples	  by	  different	  histological	   techniques;	   the	   fibres	  appear	   like	   thin	   spears	  
which	  have	  the	  capacity	  to	  penetrate	  plasma	  membranes	  without	  killing	  the	  cells	  (41).	  	  
Asbestos	   fibres	   can	   also	   interfere	  with	   the	  mitotic	   spindle,	   disrupting	  mitosis,	  which	   in	  
turn	   may	   lead	   to	   aneuploidy	   and	   other	   forms	   of	   chromosome	   damage	   like	   structural	  
rearrangements	  with	  possible	  malignant	  outcome	  (42).	  	  
Many	  studies	  have	  also	  demonstrated	   that	   the	  asbestos	   fibres	   themselves	   in	  HMCs	  can	  
directly	   activate	   the	   epidermal	   growth	   factor	   receptor	   (EGFR),	   a	   well-­‐known	   cellular	  
membrane	   receptor	   that	   generally	   responds	   to	   different	   ligands;	   however	   its	   altered	  
activation	  can	  be	  the	  cause	  of	  many	  cancers.	  	  
Blue	   asbestos	   fibres	   indeed	   can	   determine	   the	   dimerization	   of	   EGFRs	   leading	   to	  
autophosphorylation	  and	  thereby	  bring	  about	   induction	  of	  extracellular	  signal-­‐regulated	  
kinases	   (ERK)	   1	   and	  2	   that	   cause	   induction	  of	   c-­‐fos	   (43-­‐45).	   The	   stabilization	  of	   c-­‐fos	   is	  
regulated	   by	   fra1	   and	   this	   protein	   is	   needed	   for	   the	   specific	   transcription	   factor	   AP-­‐1	  
dependent	  HMCs’	  growth,	  migration	  and	  transformation	  (45).	  	  
After	   exposure	   to	   asbestos,	   there	   is	   generally	   an	   inflammatory	   reaction	   with	   a	   large	  
component	   of	   mononuclear	   phagocytes.	   After	   these	   cells	   have	   differentiated	   into	  
macrophages,	  they	  phagocytize	  asbestos	  and	  this	  process	  is	  associated	  with	  deposition	  of	  
proteins	   and	   of	   haemoglobin-­‐derived	   iron,	   resulting	   in	   the	   formation	   of	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
ferruginous	  bodies	   (46)	   (Fig.	   1).	   Phagocytosis	  of	   asbestos	   fibres	   also	   leads	   to	   release	  of	  
numerous	   cytokines	   and	   reactive	   oxygen	   species/reactive	   nitrogen	   species	   (ROS/RNS),	  
that	   are	   cytotoxic	   and	  potentially	   clastogenic,	   causing	   chronic	   inflammation	   in	   the	   lung	  
and	  pleura.	  	  
These	   ROS/RNS	   produced	   through	  
phatocytosis,	   may	   cause	   cellular	  
toxicity	   and	   carcinogenicity	  
possibly	   by	   inducing	   lipid	  
peroxidation,	   altering	   signal	  
transduction	   pathways,	   as	   well	   as	  
damaging	   the	   DNA	   (47-­‐48).	   ROS	   also	  
cause	   the	   formation	   of	   8-­‐hydroxy-­‐2´-­‐deoxyguanosine	   (8OHdG)	   adducts,	   which	   are	  
elevated	   in	   white	   blood	   cells	   of	   individuals	   with	   former	   asbestos	   exposure	   (49).	   The	  
generation	   of	   oxidants	   by	   asbestos	   fibres	   results	   in	   cell	   injury,	   activation	   of	   signaling	  
	  	  	  	  	  	  	  Fig.	   1	   Multiple	   ferruginous	   bodies	   with	  	  	  	  	  	  	  	  	  	  	  	  	  	  
xxx	  inflammatory	  	  reaction.	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pathways	  such	  as	  ERK	  and	  mitogen	  activated	  protein	  kinases	  (MAP),	  increased	  expression	  
of	   inflammatory	  cytokine.	  Activation	  of	  the	  ERK1/ERK2	  via	  phosphorylation	  also	   induces	  
expression	   of	   early	   response	   proto-­‐oncogenes	   such	   as	   c-­‐fos	   and	   c-­‐jun	   (43,50).	   The	   ERK	  
cascade	  has	  been	  associated	  with	  early	  injury	  and	  subsequent	  proliferation	  of	  HMCs	  (43).	  
The	   response	   of	   the	   cells	   to	   oxygen-­‐	   and	   nitrogen-­‐based	   free	   radicals	   can	   vary	  widely.	  
Common	   reactions	   are	   mitochondrial	   dysfunction,	   and	   increased	   expression	   of	   death	  
receptors,	   and/or	   their	   ligands	   (TNF-­‐α,	   Fas	   ligand)	   (51).	   The	   cytokine	   TNF-­‐α,	   has	   been	  
linked	  to	  asbestos	  pathogenesis,	  but	  the	  mechanisms	  are	  still	  unclear.	  	  
When	  the	  asbestos	  fibres	  are	  engulfed	  by	  macrophages,	  these	  cells	  release	  IL1β	  and	  TNF-­‐
α	  and	  at	  the	  same	  time,	  asbestos	  stimulates	  HMCs	  to	  secrete	  TNF-­‐α	  (both	  paracrine	  and	  
autocrine	  effects)	  and	  express	  TNF	  receptors	  (TNF-­‐R1)	  and	  IL1β	  receptors.	  TNF-­‐α	  activates	  
the	  nuclear	   factor	  kappa-­‐light-­‐chain-­‐enhancer	  of	  activated	  B	  cells	   (NF-­‐κB)	   that	   increases	  
cell	   survival,	   and	   allows	   the	   cells	   to	   divide	   rather	   than	   die	   and,	   if	   sufficient	   genetic	  
damage	  has	  accumulated,	  to	  eventually	  develop	  into	  a	  MPM	  (52)	  (Fig.	  2).	  
NF-­‐κB	   and	   its	   signaling	  
pathways	   are	   also	   critical	  
regulators	   for	   cell	   lineage	  
development,	   growth,	  
differentiation,	   apoptosis	  
and	   tumourigenic	  
transformation.	  
In	   fact,	   NF-­‐κB	   is	   an	  
important	   transcription	  
factor	   implicated	   in	   the	  
transcriptional	   	   	   	   	   	   	   	   	   	   	   up-­‐
regulation	   of	   cytokines,	  
adhesion	   molecules,	   growth	   factors,	   oncogenes,	   antiapoptotic	   proteins,	   some	  
proapoptotic	  factors,	  and	  even	  certain	  viral	  genes.	  
Asbestos-­‐induced	  ROS	  play	  a	  key	  role	   in	  enhancing	  the	   inflammation	  through	  activation	  
and	  phosphorylation	  of	   the	   redox	   sensitive	  NF-­‐κB	   in	   various	   inflammatory	  diseases	  and	  
effectively	   it	   has	   been	   reported	   that	   NF-­‐κB	   can	   regulate	   the	   inflammatory	   and	   cell	  
proliferative	  responses	  to	  asbestos	  (53).	  
Furthermore,	  MPM	   is	   also	  often	   connected	   to	   increased	   levels	  of	  many	  growth	   factors	  and	  
cytokines	  like	  PDGF,	  HGF,	  FGF,	  VEGF;	  IL6,	  IL8	  and	  TGFβ	  that	  can	  be	  secreted	  by	  HMCs	  during	  
xxxxFig.	  2	  Hypothetical	  model	  of	  MPM	  pathogenesis.	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inflammatory	  processes	  in	  order	  to	  aid	  survival	  when	  they	  act	  in	  autocrine	  manner,	  and/or	  to	  
support	  angiogenesis	  and	  invasion	  when	  they	  reach	  the	  surrounding	  stroma.	  Indeed	  different	  
forms	  of	  PDGF	  have	  shown	  to	  interact	  with	  HMCs	  proliferation	  and	  chemotaxis	  (54-­‐55).	  	  
In	   brief,	   the	   clastogenic	   properties	   of	   the	   inhaled	   asbestos	   fibres	   that	   enter	   the	   lung,	  
irritate	   the	   pleural	   cell	   lining	   and	   can	   increase	   ROS	   production	   causing	   chronic	  
inflammation,	   act	   via	   several	   different	   possible	   mechanism,	   causing	   ,injury,	   repair	   and	  
local	   inflammation.	   This	   repeated	   scratching	  may	   thus	   evoke	   the	   formation	  of	   plaques,	  












Fig.	  3	  Pathophysiology	  of	  mesothelioma.	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Combination	  of	  anti-­‐apopotic	  pathway	  and	  DNA	  damage	  results	  in	  malignant	  trasfromation	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Simian	  Virus	  40	  (SV40)	  may	  act	  as	  a	  co-­‐carcinogen	  along	  with	  asbestos	  fibres	  resulting	  in	  
the	   development	   of	  MPM	  but	   about	   20%	   of	   cases	   have	   no	   prior	   exposure	   to	   asbestos	  
(56).	  This	  suggests	  that	  other	  factors	  may	  be	  involved	  in	  the	  etiology	  of	  this	  tumor.	  	  	  
SV40	  is	  a	  DNA	  tumor	  virus	  that	  can	  induce	  MPM	  and	  other	  tumors	  in	  hamsters,	  and	  	  also	  	  
transform	  HMCs	   in	   vitro	   in	   fact	   SV40	   infection	   results	   in	   cell	   survival	   (56-­‐58).	   The	  SV40	  
proteins	   associated	   with	   transformation	   and	   oncogenesis	   are	   its	   early	   gene	   products:	  
large	   T	   antigen	   (Tag)	   and	   small	   T	   antigen	   (tag).	   Tag	   is	   directly	   mutagenic	   and	   causes	  
numerous	  chromosomal	  alterations.	  Tag	   is	  also	  capable	  of	  binding	  and	   inactivating	  p53,	  
retinoblastoma	   protein	   (pRb)	   and	   other	   tumor	   suppressor	   gene	   (TSG)	   products.	   In	  
addition,	   tag	   inhibits	   phosphatase	   2A	   (PP2A),	   which	   normally	   dephosphorylates	   and	  
inactivates	  the	  cellular	  kinases	  such	  as	  ERK	  (59)	  (Fig.	  4).	  Furthermore,	  cells	  infected	  with	  
SV40,	   when	   exposed	   to	   asbestos	   fibres	   may	   result	   in	   production	   of	   toxic	   oxygen	   free	  
radicals	  causing	  malignant	  transformation	  (60).	  	  	  
	  It	   has	   been	   also	  
demonstrated	   that	   a	  
mesothelioma	   cell	  
line	   expressing	   SV40	  
Tag	   was	   intrinsically	  
more	   resistant	   to	  
apoptosis	   when	  
exposed	   to	   asbestos	  
resulting	   in	   cell	  
survival.	   In	   presence	  
of	   Tag,	   the	   cell	   survival	   was	   mediated	   through	   activation	   of	   PI3K/AKT	   pathway	   either	  
independently	  or	  in	  response	  to	  growth	  factors	  (61).	  
SV40-­‐like	  DNA	   sequences	   and	   SV40	   Tag	  were	   detected	   in	   60%	   of	  MPM	  by	   polymerase	  
chain	   reaction	   (PCR)	   analysis	   and	   immunohistochemistry,	   respectively	   in	   some	   studies	  
(63)	  but	  others	  failed	  to	  demonstrate	  the	  presence	  of	  SV40	  large	  T	  in	  MPM	  (62-­‐64).	  
For	   this	   reason	   the	   role	  of	   SV40	   in	  MPM	   remains	   controversial.	   Finally	   the	  presence	  of	  
SV40	  sequences	  in	  MPM	  shows	  geographic	  differences,	  which	  may	  be	  related	  to	  the	  fact	  
that	  SV40-­‐contaminated	  polio	  vaccines	  were	  mainly	  distributed	  in	  the	  United	  States	  and	  
parts	  of	  Europe	  (65-­‐67).	  
Other	  etiologic	  factors	  
	  
Fig.	  4	  Molecular	  pathways	  altered	  by	  SV40	  infection.	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There	  are	  various	  other	  factors	  which	  are	  known	  to	  cause	  MPM	  such	  as	  radiation	  therapy,	  
erionite	   exposure	   and	   genetic	   predisposition.	   MPM	   is	   known	   to	   occur	   as	   secondary	  
malignancy	  in	  patients	  with	  primary	  cancers	  such	  as	  lymphomas	  and	  breast	  cancers	  who	  
have	  received	  therapeutic	  radiation	  therapy	  and	  has	  a	  median	   latency	  of	  4.3	  years	  (68).	  
MPM	  is	  found	  to	  be	  endemic	  in	  the	  Cappadocia,	  Turkey,	  resulting	  in	  50%	  of	  the	  deaths	  in	  
three	   small	   villages	   (69).	   Pedigree	   studies	   have	   demonstrated	   an	   autosomal	   dominant	  
pattern	  of	  inheritance	  among	  the	  families	  suffering	  from	  MPM.	  The	  Cappadocian	  region	  is	  
also	  dominated	  by	  volcanic	  rocks	  having	  a	  high	  concentration	  of	  the	  asbestos-­‐like	  mineral	  
erionite.	   The	   houses	   of	   the	   villages	   are	   made	   out	   of	   stone	   taken	   from	   the	   nearby	  
mountains	  or	  rivers	  and	  have	  a	  high	  content	  of	  erionite.	  Exposure	  to	  erionite	  is	  strongly	  
associated	  with	  the	  development	  of	  MPM	  in	  vivo	  studies.	  MPM	  was	  seen	  in	  100%	  (40/40)	  
rats	  injected	  with	  erionite	  compared	  with	  48%	  (19/40)	  of	  rats	  injected	  with	  asbestos	  (70).	  
The	  MPM	  epidemic	   in	   the	  Cappadocian	  region	   is	   likely	  due	   to	  high	  erionite	  exposure	   in	  
genetically	  predisposed	  individuals.	  
	  
1.2.3	  	  Genetic	  alterations	  in	  MPM	  
	  
As	  it	  has	  already	  been	  said,	  only	  a	  small	  proportion	  of	  people	  that	  are	  strongly	  exposed	  to	  
asbestos	  fibres	  contracts	  MPM.	  
Thus	   this	   may	   suggest	   the	   presence	   of	   different	   elements	   that	   make	   individuals	  
susceptible	   to	   effect	   of	   this	  material:	   two	   of	   these	   could	   be	   the	   presence	   of	   a	   specific	  
genetic	   heritage	   and	   various	   relationships	   with	   environmental	   factors	   (e.g.	   duration	   of	  
asbestos	  or	  radiation	  exposure	  or	  SV40	  infection).	  
All	  tumours	   including	  MPM	  develop	  because	  of	  many	  	  genetic	  changes	  and	  aberrations;	  
for	  this	  reason	  it	  is	  necessary	  to	  know	  and	  describe	  well	  these	  molecular	  processes.	  
Conventional	   karyotypic	   and	   comparative	  genomics	  hybridization	   (CGH)	   studies,	   as	  well	  
as	   high-­‐resolution	   studies	   using	   microarrays	   have	   demonstrated	   that	   MPM	   samples	  
display	  numerous	  chromosomal	  alterations.	  
Many	  regions	  of	  chromosomal	  gains	  and	  losses	  have	  been	  reported,	  and	  losses/deletions	  
are	  more	   frequently	   reported	   than	  gains.	   The	  accumulation	  of	   numerous	   chromosomal	  
deletions/losses	   in	   most	   MPM	   might	   suggest	   a	   multistep	   process	   of	   tumourigenesis,	  
characterized	  by	  the	  loss	  and/or	  inactivation	  of	  multiple	  TSGs.	  
Losses	  have	  been	  reported	  at	  1p,	  3p,	  6q,	  9p,	  13q,	  14q	  and	  22	  while	  chromosomal	  gains	  
which	  are	  less	  common	  than	  losses	  are	  reported	  at	  sites	  such	  as	  1q,	  5p,	  8q,	  15q	  (71-­‐76).	  	  
Many	  studies	  have	  hypothesize	  that	  some	  oncogenes	  and	  tumor	  suppressor	  genes	  (TSGs)	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have	  a	  role	  in	  MPM	  carcinogenesis	  (77).	  	  
The	  TSGs	  Ras	  association	  domain	   family	  1	   isoform	  A	   (RASSF1A),	  Neurofibromin	  2	   (NF2),	  
and	  	  Cyclin-­‐dependent	  kinase	  inhibitor	  2A	  (CDKN2A),	  as	  well	  as	  the	  growth	  factors/proto-­‐
oncogenes/signaling	   molecules	   c-­‐fos,	   c-­‐jun,	   EGF,	   VEGF,	   c-­‐Met,	   c-­‐myc,	   and	   fra-­‐1	   are	  
important	  in	  many	  malignancies	  (78-­‐79).	  	  
Since	   most	   of	   the	   copy	   number	   changes	   are	   losses,	   including	   many	   areas	   harbouring	  
TSGs,	  this	  is	  probably	  a	  central	  event	  in	  MPM	  carcinogenesis.	  	  
One	  of	   the	   genes,	  RASSF1A,	   encodes	   a	   pro-­‐apoptotic	   tumour	   suppressor	   and	   its	   loss	   is	  
associated	  with	  many	  cancers	  including	  MPM	  (77).	  	  
The	  most	  common	  loss/deletion	  is	  at	  9p21,	  including	  the	  tumour	  suppressors	  p16INK4a	  and	  
p14ARF	  (encoded	  by	  alternative	  reading	  frames	  of	  CDKN2A)	  (79-­‐81).	  
These	   tumour	   suppressors	   are	   the	   product	   of	   exon	   splicing	   and	   they	   are	   linked	   to	   the	  
development	   of	   several	   cancers;	   furthermore	   loss	   of	   p16	   expression	   is	   considered	   an	  
essential	   event	   in	   the	   development	   of	   MPM	   (81-­‐83),	   indeed	   this	   protein	   impedes	  	  	  
phosphorylation	  of	  pRB	  by	  binding	  CDK4/6,	  which	  in	  turn	  prevents	  the	  transition	  of	  cells	  
from	   the	   G1	   to	   S	   phases.	   The	   alternative	   splice	   variant	   p14	   is	   linked	   to	   MDM2	  
sequestering	   and/or	   degradation	   and	   it	   promotes	   both	   pRB	   and	   p53	   stabilisation	   and	  
stops	   in	   this	   way	   cells	   in	   G1	   and	   G2	   cell	   cycle	   phases.	   So	   p14	   plays	   an	   important	   role	  
because	   its	   loss	   prevents	   activation	   of	   p53	   that	   is	   otherwise	   not	   deleted	   or	   mutated	  
frequentely	  in	  MPM	  (82-­‐84).	  	  
CDKN2A	  was	  found	  to	  be	  more	  commonly	  deleted	  in	  MPM	  than	  in	  peritoneal	  MM,	  and	  it	  
was	  claimed	  to	  be	  a	  possible	  marker	  for	  distinguishing	  MPM	  from	  pleural	  effusions	  (85).	  
The	   BRCA1-­‐associated	   protein	   1	   (BAP1)	   gene	   is	   located	   at	   3p21	   and	   it	   encodes	   a	  
deubiquitinase	  which	  enters	  the	  nucleus	  and	  binds	  to	  the	  BRCA1	  protein.	  	  
Recent	  articles	  have	  demonstrated	  a	  connection	  between	  BAP1	  deletion	  or	  mutation	  and	  
MPM,	  indeed	  one	  of	  these	  has	  shown	  BAP1	  mutations	  in	  12	  of	  53	  mesothelioma	  patients,	  
whereas	   the	   Phosphatase	   and	   tensin	   homolog	   (PTEN)	   and	   p53,	   	   famous	   tumor	  
suppressors,	  	  had	  no	  mutations	  (86).	  	  
Another	   important	  confirmation	  was	  that	  people	  who	  have	  germline	  mutations	  of	  BAP1	  
are	  often	  predisposed	  to	  develop	  MPM	  (87).	   	  Moreover	  the	  mutations	  of	  BAP1	  in	  MPM	  
appear	  to	  be	  more	  linked	  to	  the	  epithelioid	  phenotype,	  with	  81%	  of	  these	  patients	  having	  
mutations	  in	  respect	  to	  14%	  who	  show	  an	  another	  histological	  subtype	  (88).	  
Loss	   of	   17p	   is	   a	   common	   event	   in	  MPM,	   with	   TP53	   localized	   on	   17p13.1,	   but	   TP53	   is	  
reported	   not	   to	   be	   included	   in	   the	   critical	   region	   (73).	   This	   is	   important	   since	   TP53	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mutations	  have	  been	  detected	  in	  many	  tumours,	  but	  they	  are	  only	  observed	  occasionally	  
in	  MPM.	  Some	  studies	  have	  demonstrated	   that	  TP53,	  as	  well	  as	   the	  Rb	   family	  of	  genes	  
remain	  genetically	  intact	  in	  MPM	  (67,84,	  89).	  
The	   TGS	   NF2	   is	   located	   at	   22q12.2,	   and	   loss	   of	   chromosome	   22	   was	   shown	   to	   be	   a	  
recurrent	  cytogenetic	  abnormality	  in	  ~50	  %	  of	  the	  MPM	  cases	  (90).	  	  
The	  NF2	  encodes	  merlin,	  which	  plays	  a	  role	  in	  the	  connection	  between	  the	  cytoskeleton	  
and	   components	   of	   the	   plasmatic	   membrane;	   in	   fact	   it	   links	   actin	   filaments	   to	   cell	  
membrane	   or	   membrane	   proteoglycans.	   Merlin	   has	   also	   been	   suggested	   to	   be	   an	  
inhibitor	  of	  the	  Ras-­‐ERK	  pathway	  by	  exhibiting	  tumour	  suppressor	  function	  and	  inhibiting	  
PAK-­‐induced	  cyclin	  D1	  expression	  (91-­‐92).	  
MPM	  has	   an	  unusual	  molecular	   pathology	  with	   loss	   of	   TSGs	  being	  more	   common	   than	  
activation	  of	  oncogenes	  but	  high-­‐level	  gain	  at	  1p32.1	  including	  amplification	  of	  jun	  proto-­‐
oncogene	  has	  been	  reported	  in	  MPM	  and	  also	  fos	  proto-­‐oncogene	  expression	  was	  found	  	  
mostly	  up-­‐regulated	  simultaneously	  with	  jun	  (93).	  KRAS	  mutations	  are	  common	  in	  human	  
cancers,	   but	   do	   not	   appear	   to	   be	   widely	   involved	   in	   MPM,	   although	   one	   study	   did	  
propose	  that	  the	  Ras	  pathway	  could	  be	  affected	  in	  HMCs	  (94).	  	  
	  
	  1.2.4	  	  Pathological	  features	  
	  
According	  to	  the	  WHO	  classification	  2004,	  MPM	  can	  be	  classified	  as	  epithelioid	  (MPM-­‐E),	  
biphasic	   (MPM-­‐B),	   and	   sarcomatoid	   (MPM-­‐S).	   In	   addition	   there	   is	   a	   subtype	   of	   MM-­‐S	  
called	  desmoplastic	  (46)	  (Fig.	  5).	  
These	   groups	   show	   significant	   differences	   in	   their	   histological	   and	   clinical	   features,	   for	  
example,	  patients	  who	  have	  MPM-­‐E	  show	  a	  median	  survival	  time	  of	  12	  months	  compared	  
to	   only	   4	   months	   of	   patients	   with	   MPM-­‐S	   and	   patients	   affected	   by	   desmoplastic	  
mesotheliomas	  are	  characterized	  by	  an	  even	  shorter	  survival	  compared	  with	  MPM-­‐E	  and	  
MPM-­‐S.	  
The	  majority,	  about	  50	  %,	  of	  MPM	  is	  of	  the	  epithelioid	  subtype,	  10%	  are	  sarcomatoid	  and	  
the	   rest	   are	   biphasic.	   Actually,	   these	   fractions	   could	   be	   conditioned	   by	   the	   diagnostic	  
procedures	   and	   the	   size	   and	   number	   of	   examined	   samples;	   indeed	   the	   biphasic	  
phenotype	  could	  be	  more	  prevalent	  if	  MPMs	  were	  even	  more	  attentively	  analyzed.	  
MPM-­‐E	  usually	   shows	  well-­‐differentiated	   tubopapillary	   or	   trabecular	   structures	   or	   solid	  
sheets,	  with	  round	  polygonal	  tumour	  cells	  with	  abundant	  densely	  eosinophilic	  cytoplasm	  
and	   the	   rather	   open	   nuclei	   show	   few	   or	   no	  mitoses.	  MMP-­‐S	   display	   spindle-­‐shaped	   or	  
oval	  morphology,	   and	   amphophilic	   cytoplasm,	   arranged	   in	   fasicles	   or	   having	   a	   random	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distribution.	  Malignant	  osteoid	  and	  cartilage	  may	  be	  present.	  
Desmoplastic	  MM	   is	   characterized	  by	  dense	   collagenized	   tissue	  arranged	   in	  a	   storiform	  
pattern,	  this	  being	  easily	  confused	  with	  benign	  fibrosing	  pleuritis.	  	  	  	  	  	  
MPM-­‐B	   contain	   both	   epithelioid	   and	   sarcomatoid	   patterns	   in	   about	   30%	   of	   cases.	   Any	  
combination	   of	   the	   patterns	   noted	   above	   may	   be	   present.	   Each	   component	   should	  
represent	   at	   least	   10%	   of	   the	  
tumour	   to	   warrant	   the	   term	  
biphasic	  (46).	  	  
	  
MPM	   is	   distinct	   from	  other	   solid	   tumor	   and	   starts	   as	   a	   localized	   	   tumor,	   	   but	   	   spreads	  	  
rapidly	   	   along	   	   mesothelium-­‐lined	   	   surfaces	   	   to	   	   involve	   pericardium,	   	   contralateral	  	  
hemithorax,	  	  and	  	  peritoneal	  	  cavity	  	  by	  	  invasion	  	  through	  diaphragm.	  The	  resulting	  tumor	  
often	   forms	   diffuse	   thickening	   of	   involved	   surfaces	   rather	   than	   solitary	   rounded	   lesion	  
seen	  in	  other	  neoplasms	  (46).	  
Invasion	   	   through	   	  needle	   	  biopsy	   	   tracts	   	   and	   	   incisions	   	   in	   	   thoracic	   	  wall	   	   are	   	   typical	  
features	  in	  this	  kind	  of	  cancer.	  
MPM	  	  invades	  also	  	  	  the	  	  	  underlying	  	  	  basement	  	  	  membrane	  	  	  and	  produce	  metastases	  in	  
up	  to	  75%	  of	  patients,	   indeed	   it	  may	  metastasize	  to	  the	  pulmonary parenchyma	  and	  to	  
hilar	  and	  mediastinal	  lymph	  nodes	  (95). 
During	  the	  invasion	  process,	  mesothelioma	  cells	  must	  interact	  with	  ECM	  proteins,	  growth	  
factors	  embedded	  in	  it,	  and	  stromal	  cells,	  which	  participate	  in	  synthesis	  and	  modifications	  
of	  this	  microenvironment.	  
	  
1.2.5	  	  TNM	  staging	  system	  
	  
A	   B	  
C	   D	  
Fig.	  5	  MPM:	  epithelioid	  type	  (A),	  sarcomatoid	  type	  (B),	  desmoplastic	  type	  (C),	  	  
biphasic	  type	  (D).	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Doctors	  utilize	  staging	  systems	  to	  better	  design	  potential	  treatment	  options	  for	  patients.	  
Depending	   on	   the	   stage	   and	   nature	   of	   the	   cancer,	   different	   surgery	  
and	  chemotherapy	  options	  may	  be	  available.	  An	  internationally	  accepted	  staging	  system	  
allows	  doctors	   to	   standardize	   the	  diagnosis	  of	  MPM,	  which	  helps	  medical	  professionals	  
plan	  treatment	  procedures	  that	  are	  more	  beneficial	  to	  the	  patient.	  
An	   ideal	   staging	   system	   of	  MPM	   is	   difficult	   to	   define	   as	  MPM	   has	   an	   unusual	   growth	  
pattern.	  It	  tends	  to	  grow	  along	  the	  parietal	  and	  visceral	  pleura	  invading	  the	  surrounding	  
structures	  making	  it	  difficult	  to	  assess	  the	  volume	  and	  spread	  of	  the	  tumour.	  
In	   1995,	   the	   International	  Mesothelioma	   Interest	   Group	   (IMIG)	   adapted	   the	   traditional	  
TNM	  system	  for	  MPM	  because	  of	  the	  lack	  of	  an	  universally	  accepted	  staging	  system	  (96).	  
Also	   called	   the	   IMIG	   Staging	   System,	   the	   TNM	   system	   is	   the	  most	  widely	   used	   staging	  
system;	  though	  it	  is	  also	  used	  for	  other	  types	  of	  mesothelioma	  (Fig.	  6).	  
The	  abbreviation	  TNM	  signifies	  three	  different	  parts	  of	  diagnostic	  staging	  and	  each	  TNM	  
combination	  is	  grouped	  and	  correlated	  to	  specific	  stages	  I	  through	  IV.	  
Developed	  by	  IMIG	  as	  the	  International	  Mesothelioma	  Staging	  System,	  the	  different	  parts	  
of	  the	  staging	  include:	  
Ø (T)	  determined	  by	  the	  size	  and/or	  location/extension	  of	  the	  tumor.	  
Ø (N)	  describes	  whethr	  or	  not	  lymph	  nodes	  have	  been	  affected	  by	  metastatis.	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Fig.	  6	  International	  Mesothelioma	  Interest	  Group	  Staging	  System	  for	  MPM.	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1.2.6	  	  Clinical	  presentation	  and	  diagnosis	  
	  
The	  diagnosis	  of	  mesothelioma	   is	  often	  difficult	  and	  delayed	  easy	  because	  many	  of	   the	  
symptoms	   MPM	   patients	   are	   not	   specific	   and	   common	   to	   a	   variety	   of	   other	   diseases	  
affecting	   the	   respiratory	   system.	  Because	  of	   the	  difficulty	   in	   diagnosing	  MPM	   less	   than	  
50%	  of	  patients	  survive	  over	  one	  year	  after	  this	  diagnosis	  is	  made.	  
The	  majority	   of	   patients	  with	  MPM	  present	   initially	  with	   dyspnea	   (breathlessness)	   and	  
chest	   pain.	   These	   symptoms	   are	   caused	   by	   an	   accumulation	   of	   fluid	   in	   the	   (normally	  
virtual)	  pleural	  cavity	  located	  between	  the	  visceral	  pleura	  lining	  the	  lung	  and	  the	  parietal	  
pleura	   lining	   the	   chest	   cavity,	   known	   as	   pleural	   effusion,	   that	   constricts	   the	   underlying	  
lung	  parenchyma	  (11-­‐15)	  (Fig.	  7).	  
Many	   of	   the	   patients	   have	   a	   significant	  
history	  of	  asbestos	  exposure	  20-­‐40	  years	  
prior	   to	   their	   clinical	   presentation.	  
Constitutional	  symptoms	  such	  as	  weight	  
loss	   and	   fatigue	   can	   be	   present,	   but	  
these	   generally	   appear	   later	   in	   the	  
course	   of	   disease.	   As	   the	   disease	  
progresses,	   the	   effusion	   becomes	  
loculated	   and	   the	   pleural	   space	   is	  
replaced	  by	  tumor.	  
In	  MPM	  diagnostics,	  chest	  	  	  	  radiography	  
[X	   ray],	   computed	   tomography	   [CT],	  
magnetic	   resonance	   imaging	   [MRI],	   or	  
positron	   emission	   tomography	   [PET]	  
scan	   and	   IHC	   panels	   are	   the	   most	   widely	   used	   tools	   to	   detect	   if	   there	   is	   a	   positive	  
indication	  for	  the	  presence	  of	  a	  tumor,	  i.e.	  pleural	  thickening	  and	  the	  possible	  presence	  of	  
an	  effusion.	   In	  the	   latter	  case,	  the	  accumulated	  fluid	   is	  removed	  to	  relieve	  the	  patient’s	  
symptoms	   (thoracocentesis)	   and	   to	  be	   cytologically	   analyzed.	   Even	   though	   the	  possible	  
finding	   of	  many,	   abnormal	  mesothelial	   cells	   in	   the	   fluid	  would	   in	   this	   case	   support	   the	  
suspicion	  of	  MPM,	   cytological	   analysis	   of	   pleural	   effusion	   is	   not	   a	   conclusive	  diagnostic	  
procedure	   for	  MPM,	   as	   non-­‐neoplastic	   reactive	  mesothelial	   proliferation	   due	   to	   severe	  
inflammation	   can	   cytologically	   resemble	   MPM.	   Indeed,	   the	   most	   certain	   criterion	   for	  
sssssFig.	   7	   Normal	   condition	   of	   pleura	   (A),	  
…….sthe	   pleura	   cavity	   is	   virtual.	   In	   MPM	  	  
sssssthe	  pleural	  space	  can	  be	  filled	  with	  up	  
sssssto	   several	   liters	  of	   fluid	   and	  by	   tumor	  
ssssstissue	  (B).	  
A	   B	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MPM	   is	   deep	   invasion	   of	   mesothelial	   cells	   into	   the	   pleura	   and	   fat	   tissue	   underneath,	  
which	  obviously	  cannot	  be	  analyzed	  on	  cytological	  samples	  (97).	  	  
Thus,	   in	   these	   circumstances	   of	   suspect	  MPM	   a	  more	   invasive	   procedure	   is	   needed	   in	  
order	   to	   remove	   tissue	   sample	   (by	   thoracoscopy	   surgical	   biopsy,	   or	   by	   transthoracic	  
needle	   biopsy).	   This	   is	   considered	   to	   be	   the	   most	   effective	   and	   conclusive	   ways	   of	  
diagnosing	  MPM,	  as	  it	  is	  possible	  on	  a	  well	  representative	  pleural	  biopsy	  to	  histologically	  
demonstrate	  deep	  invasion	  by	  mesothelial	  cells.	  
However,	   it	   may	   be	   difficult	   to	   make	   an	   early	   diagnosis	   of	   MPM	   using	   the	   currently	  
available	  diagnostic	   imaging	  techniques	  and	  it	  would	  be	  beneficial	  to	  have	  identification	  
of	  tumour	  markers	  and	  a	  method	  for	  early	  diagnosis	  using	  these	  markers.	  
The	  diagnosis	  of	  MPM	  is	  dependent	  on	  a	  consideration	  of	  clinical	  and	  radiological	  findings	  
in	  combination	  with	  pleural	  fluid	  cytopathology	  and	  especially	  pleural	  biopsy.	  Even	  when	  
thoracoscopy	  is	  used	  to	  obtain	  sufficient	  tissue,	  the	  histological	  differential	  diagnosis	  may	  
still	  prove	  difficult	  on	  small	  pleural	  biopsies.	  It	   includes	  distinguishing	  well-­‐differentiated	  
MMP-­‐E	   from	   reactive	   mesothelial	   proliferation	   and	   sarcomatoid	   or	   desmoplastic	  
mesothelioma	   from	   reactive	   pleural	   fibrosis.	   To	   date,	   there	   are	   no	   generally	   accepted	  
diagnostic	  biomarkers	  specific	  for	  distinguishing	  MPM	  from	  these	  non-­‐neoplastic	  reactive	  
pleural	   processes	   (that	   is,	   no	   markers	   can	   distinguish	   malignant	   from	   benign	  
mesothelium-­‐derived	   cells)	   and	   the	   proposed	   MPM-­‐markers	   have	   not	   shown	   enough	  
specificity	  and	  reproducibility	  or	  need	  further	  validation	  (97).	  
Furthermore,	   MMP-­‐E	   needs	   to	   be	   diagnostically	   differentiated	   from	   metastatic	   or	  
pseudomesotheliomatous	   (showing	   a	   diffuse	   mesothelioma-­‐like	   growth	   pattern)	  
carcinoma,	   usually	   pulmonary	   adenocarcinoma	   or	   adenocarcinoma	   from	   other	   organs	  
(breast,	  gastrointestinal	  tract	  etc.)	  (98).	  
In	   this	   case,	   immunohistochemistry	   (IHC)	   has	   indeed	   proved	   most	   valuable	   in	   the	  
differential	  diagnoses	  between	  MPM	  and	  metastatic	  adenocarcinomas,	  but	  despite	  many	  
antibodies	   are	   useful	   for	   this	   purpose,	   no	   antibody	   shows	   absolute	   specificity	   or	  
sensitivity	  for	  either	  tumour	  type	  (99-­‐101).	  
Therefore,	  the	  IMG	  recommends	  an	  IHC	  panel	  of	  antibodies	  as	  most	  valuable	  diagnostic	  
approach	   for	   achieving	   optimal	   sensitivity	   and	   specificity	   in	   the	   differential	   diagnosis	  
between	  MPM	  and	  other	  cancer	  types.	  	  	  
The	  range	  of	  antibodies	  included	  in	  this	  panel	  varies	  for	  their	  specificities	  and	  sensitivities	  
in	  MPM	  and	  adenocarcinoma.	  	  
According	  to	  the	  diagnostic	  algorithm	  recommended	  by	  the	  IMIG,	  the	  diagnosis	  of	  MPM	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is	  most	   likely	  when	  there	   is	  positive	  reaction	  for	  at	   least	  2	  mesothelial	  markers	  (such	  as	  
calretinin,	  WT-­‐1,	  D2-­‐40,	   CK5/6,	   vimentin,	  mesothelin	  or	   thrombomodulin)	   and	  negative	  
reaction	  for	  at	  least	  2	  adenocarcinoma	  markers	  (such	  as	  BerEp4,	  MOC31,	  CEA,	  TTF-­‐1)	  (97)	  
(Table	  I).	  	  
	  
































Table	   I	  Antibodies	  used	   in	  differential	   diagnostics	   of	  MPM	  and	  metastatic	   pulmonary	  
adenocarcinoma.	  CK:	  cytokeratin;	  WT-­‐1:	  Wilms	  tumor	  antigen-­‐1;	  CEA:	  carcinoembryonic	  
antigen,	  TTF-­‐1:	  thyroid	  transcription	  factor-­‐1.	  (*	  CK7	  is	  often	  positive	  also	  in	  MPM,	  thus	  
not	  specific	  for	  adenocarcinoma).	  
	  
It	  is	  often	  a	  diagnostic	  challenge	  to	  distinguish	  between	  MPM	  and	  adenocarcinoma	  and	  in	  
cytologic	  specimens.	  Many	  techniques,	  such	  as	  cell	  block	  preparation	  (making	  cell	  pellets	  
out	   of	   pleural	   fluid	   samples),	   histochemical,	   IHC	   and	   ultrastructural	   analysis	   have	   been	  
used	  to	  try	  to	  resolve	  these	  diagnostic	  problems.	  	  
As	  mentioned	  above,	   even	  more	  problematic	   is	   the	  differential	   diagnosis	   between	  MPM	  
and	   reactive	   mesothelial	   proliferation,	   since	   reactive	   mesothelial	   cells	   may	   exhibit	  
features	  usually	  associated	  with	  malignancy,	  such	  as	  increased	  cellularity,	  pleomorphism	  
and	  mitotic	  activity	  but	  typically	   form	  smaller,	   less	  complex	  groups	  than	  those	  of	  MMP,	  
which	  show	  larger,	  more	  complex	  aggregates.	  	  
Therefore,	   differentiation	   of	   MPM	   from	   benign	   mesothelial	   hyperplasia	   with	   reactive	  
atypia	  may	   be	   very	   difficult	   or	   impossible	   in	   cytologic	   specimens,	   since	   tissue	   invasion	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1.2.7	  	  Treatment	  
	  
MPM	  is	  difficult	  to	  diagnose	  at	  an	  early	  stage	  and	  practically	  all	  available	  single	  modality	  
treatment	  options	  (surgery,	  radiotherapy,	  chemotherapy,	  immunotherapy,	  gene	  therapy)	  
are	  ineffective.	  
For	   this	   reason,	  oncologists	  usually	  use	   the	  so-­‐called	   tri-­‐modal	  protocol	  comprising	  pre-­‐
operative	   chemotherapy,	   surgery	   and	   post-­‐operative	   radiotherapy	   in	   the	   treatment	   of	  
MPMs.	   Physicians,	   in	   fact	   determine	   a	   treatment	   regimen	   for	   any	   particular	   patient	   by	  
taking	   into	   account	   the	   stage	   of	   the	   disease,	   age	   of	   the	   patient,	   and	   other	   health	  
problems	  the	  patient	  has	  (102).	  
The	  patients	  with	   low-­‐stage	  disease	  (T1-­‐T3,	  NO-­‐N1),	  good	  performance	  status	  adequate	  
cardio-­‐pulomanry	   function,	   age	   <	   70	   years,	   and	   epithelioid	   histology	   are	   eligible	   for	  	  	  	  	  	  	  	  	  
tri-­‐modal	  therapy	  which	  is	  at	  the	  moment	  the	  best	  option	  to	  treat	  MPM.	  
Cytoreduction”	  or	  “debulking”	  are	  terms	  used	  to	  describe	  the	  removal	  of	  much,	  but	  not	  
all,	  of	  the	  malignant	  mass.	  This	  is	  sometimes	  the	  best	  the	  toracic	  surgeon	  can	  do	  because	  
the	  diffuse	  nature	  of	  the	  tumor	  growth.	  Surgery	  can	  take	  a	  good	  portion	  of	  the	  tumorous	  
tissue	  out.	   This	   can	  help	   the	  patient	   feel	   better	   –	   it	   reduces	  pain	   and	  makes	  breathing	  
easier.	   It	   might	   also	   slow	   the	   progression	   of	   the	   cancer	   in	   a	   small	   measure,	   however	  
surgery	  	  often	  cannot	  fully	  remove	  the	  cancer	  tissue	  in	  the	  case	  of	  MPM.	  
Common	   surgical	   procedures	   utilized	   in	   the	   management	   of	   MPM	   are	  
pleurectomy/decortication	   (P/D)	   and	   extrapleural	   pneumonectomy	   (EPP).	  
Pneumonectomy	  is	  a	  general	  procedure	  utilized	  not	  only	  in	  patients	  of	  MPM,	  but	  also	  for	  
those	  battling	  lung	  cancers	  or	  related	  lung	  conditions.	  	  
Pleurectomy	   by	   decortication	   is	   a	   more	   limited	   procedure	   than	   EPP	   and	   requires	   less	  
cardiorespiratory	  reserve;	   it	   involves	  dissection	  of	   the	  parietal	  pleura,	  and	  decortication	  
of	  the	  visceral	  pleura	  as	  well	  as	  possible	  resection	  of	  parts	  of	  pericardium	  and	  thoracic	  or	  
diaphragmatic	   muscle	   tissue	   if	   tumor-­‐infiltrated,	   followed	   by	   reconstruction.	   This	   this	  
procedure	  has	  a	  post-­‐operative	  mortality	  rate	  (3-­‐7%)	  which	  is	  less	  than	  the	  mortality	  rate	  
for	  EPP	  (103).	  
P/D	  can	  therefore	  be	  a	  “lung	  sparing”	  procedure,	  which	  is	  good	  for	  the	  patient’s	  general	  
health.	  It	  can	  in	  a	  few	  cases	  result	  in	  air	  leakage	  in	  the	  pulmonary	  system	  (subcutaneous	  
emphysema	  or	  pneumothorax)	  after	  surgery	  and	  empyema.	  
On	   the	   other	   hand,	   EPP	   is	   a	   much	   extensive	   procedure	   than	   P/D	   pleurectomy	   and	   is	  
associated	   with	   higher	   mortality	   (3-­‐15%);	   this	   procedure	   involves	   dissection	   of	   the	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parietal	  pleura	  and	  division	  of	  the	  pulmonary	  vessels,	  as	  well	  as	  en	  bloc	  resection	  of	  the	  
lung	  (or	  section	  of	  a	  lung),	  pleura,	  pericardium,	  lymph	  nodes,	  and	  diaphragm,	  followed	  by	  
reconstruction	  (pericardiunm	  and	  diaphragm	  are	  replaced	  by	  gore-­‐tex	  patches).	  
Although	  being	  a	  more	  radical	  surgery	  EPP	  was	  previously	  considered	  the	  most	  efficient	  
approach	   against	   MPM,	   the	   use	   of	   this	   very	   aggressive	   surgical	   procedure	   has	   been	  
questioned	   in	   most	   recent	   years.	   Even	   ifit	   can	   result	   in	   increased	   survival	   of	   younger	  
patients	  with	   optimal	   perfomance	   status	   and	   residual	   cardiopulmonary	   function	   (14-­‐28	  
months),	   it	   is	   associated	   with	   considerable	   post-­‐operative	   complications	   and	   mortality	  
risk	  	  in	  the	  majority	  of	  typical	  MPM	  patients	  (older	  >	  60	  years,	  compromised	  lung	  function	  
etc.)	  (103).	  
Chemotherapy	  is	  often	  used	  before	  surgery	  as	  a	  part	  of	  the	  tri-­‐modal	  protocol	  and	  alone	  
is	  recommended	  for	  patients	  with	  stage	  I-­‐IV	  disease	  who	  are	  not	  candidates	  for	  surgery	  
and	  for	  patients	  with	  sarcomatoid	  histology	  who	  are	  considered	  inoperable	  (103).	  
Chemotherapy	   for	  MPM	  has	   improved	   in	   the	   past	   decade	  with	   the	   introduction	   of	   the	  
antifolate	  agent	  pemetrexed,	  marketed	  as	  Alimta.	  	  
Pemetrexed	   is	   chemically	   similar	   to	  folic	   acid	  and	   is	   in	   the	   class	  of	   chemotherapy	  drugs	  
called	  folate	   antimetabolites.	   It	   works	   by	   inhibiting	   three	   enzymes	   used	  
in	  purine	  and	  pyrimidine	  synthesis.	   By	   inhibiting	   the	   formation	   of	   precursor	   purine	   and	  
pyrimidine	  nucleotides,	  pemetrexed	  prevents	   the	   formation	  of	  DNA	  and	  RNA,	  which	  are	  
required	  for	  the	  growth	  and	  survival	  of	  both	  normal	  cells	  and	  cancer	  cells.	  
Studies	  have	  shown	  that	  a	  combination	  regimen	  of	  pemetrexed	  with	  cisplatin	  results	  in	  a	  
better	  response	  rate	  than	  the	  use	  of	  either	  one	  by	  itself	  and	  the	  trimodality	  therapy	  with	  
neoadjuvant	   pemetrexed	   plus	   cisplatin,	   followed	   by	   radiotherapy	   is	   feasible	   with	   a	  
reasonable	   long-­‐term	   survival	   rate,	   particularly	   for	   patients	  who	   completed	   all	   therapy	  
(104).	  
Cisplatin	   acts	   as	   alkylating	   agent	   and	   binds	   to	   DNA	   to	   form	   intrastrand	   crosslinks	   and	  
adducts	   that	   bring	   about	   variations	   in	   the	   structure	   of	   the	   DNA	   and	   influence	   DNA	  
replication.	   Other	   functions	   of	   cisplatin	   comprise	   mitochondrial	   damage,	   decreased	  
ATPase	  activity,	  and	  alteration	  of	  cellular	  transport	  mechanisms.	  	  
Furthermore	   cisplatin	   determines	   cell	   cycle	   arrest	   in	   the	   G2-­‐phase	   and	   in	   addiction	  
facilitates	  apoptosis	  
Other	  combination	  therapies	  that	  have	  also	  been	  used	  for	  patients	  unfit	  for	  cisplatin	  are	  
carboplatin,	   a	   slightly	   less	   toxic	   platinum	  drug	   that	   interact	  with	  DNA	   to	   interfere	  with	  
DNA	  repair,	  and	  pemetrexed	  but	  the	  survival	  time	  remained	  the	  same	  (105).	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Combination	   cisplatin	   and	   gemcitabine,	   which	   interferes	   with	   DNA	   and	   RNA	   synthesis,	  
may	  be	  used	  if	  patients	  cannot	  take	  pemetrexed.	  
Unfortunately,	   MPM	   is	   highly	   resistant	   to	   all	   chemotherapy	   regimens	   adopted	   so	   far,	  
although	  selection	  of	  better	  responsive	  patients	  through	  potential	  predictive	  biomarkers	  
has	  been	  proposed	  (106).	  
MPM	   unfortunately	   resists	   traditional	   also	   radiotherapy,	   which	   is	   reccomended	   after	  
surgery	  and/or	  in	  conjunction	  with	  chemotherapy.	  
The	   tumor	   grows	   as	   a	   diffuse	   sheet	   throughout	   the	   pleural	   cavity	   and	   radiation	   can	  
damage	  healthy	  lung	  tissue.	  Intensity-­‐modulated	  radiotherapy	  is	  used	  in	  conjunction	  with	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2.	  MicroRNAs:	  critical	  mediators	  of	  genes	  regulation	  
2.1	  	  	  	  Introduction	  to	  the	  world	  of	  microRNAs	  
	  
MicroRNAs	   (miRNAs)	   are	   ~	   22-­‐nucleotide-­‐long	   small	   RNA	  molecules	   that	   usually	   act	   as	  
endogenous	  repressors	  of	  gene	  activity	  as	  they	  predominantly	  bind	  to	  the	  3’	  untranslated	  
region	  (3’UTR)	  of	  messenger	  RNAs	  (mRNAs)	  to	  inhibit	  their	  translation	  or	  to	  induce	  their	  
cleavage.	   Even	   though	  miRNAs	  were	   initially	   discovered	   in	   the	   nematode	  C.	   elegans	   in	  
1993	  (107),	  then	  they	  have	  been	  studied	  in	  many	  organisms	  and	  now	  they	  are	  considered	  
to	  be	  expressed	  in	  all	  metazoan	  eukaryotes.	  
Most	   miRNAs	   in	   plants	   have	   almost	   perfect	   complementarity	   to	   their	   targets	   and	   this	  
characteristic	  allows	  the	  identification	  of	  miRNA-­‐target	  interactions,	  while	  in	  animals	  the	  
target	   prediction	   is	   more	   complicated	   since	   very	   few	   miRNAs	   are	   perfectly	  
complementary	  to	  their	  targets	  (108).	  	  
The	   location	  of	  miRNAs	  within	   the	  genome	  can	  be	  different	  because	   they	  can	   locate	   in	  
non-­‐coding	  regions	  between	  known	  genes	  and	  in	  this	  case	  they	  are	  intergenic	  or	  they	  can	  
be	   intronic	   when	   are	   located	   within	   protein	   coding	   genes	   (109)	   (Fig.	   8).	   Probabily	   the	  
intergenic	  miRNAs	   are	   transcribed	   from	   their	   own	   promoters	   and	  many	   are	   located	   in	  
miRNA	  clusters	  that	  produce	  long	  polycistronic	  transcipts.	  The	  intronic	  miRNAs	  are	  often	  
coordinately	   expressed	  with	   their	   host	   genes	   and	   for	   this	   reason	   are	   regulated	   by	   the	  
same	   factors	  as	   the	  host	  gene.	   In	  addition,	  many	  miRNAs	  can	  be	  expressed	   in	  a	   tissue-­‐
specific	   or	   developmental	   stage-­‐specific	   manner,	   indicating	   the	   importance	   of	  












Fig.	  8	  Genomic	  locations	  of	  miRNAs.	  miRNAs	  may	  be	  located	  in	  almost	  any	  region	  of	  
the	  genome.	  They	  may	  be	  grouped	  into	  clusters	  or	  situated	  alone.	  	  
A,	  an	  intergenic	  single	  miRNA	  may	  be	  located	  many	  kb	  away	  from	  coding	  genes	  and	  
transcribed	  as	  a	  pri-­‐miRNA,	  such	  as	  it	  is	  the	  case	  with	  miR-­‐203.	  	  
B,	   polycistronic	   miRNAs	   may	   be	   grouped	   into	   a	   cluster	   and	   transcribed	   as	   a	   pri-­‐
miRNA,	  which	  yields	  several	  miRNAs.	  This	  occurs	  with	  the	  miR-­‐431~136	  cluster.	  	  
C,	   intronic	   miRNAs	   are	   located	   in	   canonical	   genes	   and	   are	   part	   of	   an	   intron.	   The	  
mature	  miRNA	  may	  be	  processed	  from	  the	  intron	  of	  the	  host	  gene	  
transcript.	  This	  occurs	  when	  miR-­‐126	  is	  processed	  from	  the	  EGFL7	  transcript.	  Arrow,	  
transcription	  start	  site;	  rectangle,	  exon;	  hairpin,	  pre-­‐miRNA.	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2.2	  	  	  	  MiRNAs	  biogenesis	  and	  basic	  functions	  
	  
Recent	   studies	   in	   the	   last	   year	   have	   shown	   that	   miRNA-­‐mediated	   activities	   are	   really	  
complex	  and	  that	  an	  intricate	  network	  of	  factors	  or	  cellular	  events	  rigorously	  drive	  miRNA	  
processing	  and	  biological	  activities	  in	  both	  negative	  and	  positive	  ways.	  This	  is	  the	  opposite	  
to	   the	   initial	   belief	   that	   miRNAs	   had	   very	   simple	   mechanisms	   to	   control	   target	   gene	  
expression.	  
These	   mechanisms	   depend	   on	   the	   system	   of	   post-­‐transciptional	   regulation	   used	   by	   a	  
miRNA	   that	   it	   is	   connected	   to	   the	   level	  of	   interaction	  with	   the	  messenger	  RNA	   (mRNA)	  
target	   in	   a	   sequence-­‐specific	   manner.	   For	   example,	   miRNAs	   that	   bound	   with	   nearly	  
perfect	  complementarity	  to	  their	  mRNA	  target,	  usually	   located	  within	  the	  coding	  region	  
of	   the	   mRNA,	   control	   mRNA	   cleavege	   (“slicing”)	   between	   the	   tenth	   and	   eleventh	  
nucleotides	  of	  the	  binary	  complex	  causing	  mRNA	  degradation.	  On	  the	  contrary,	  miRNAs	  
that	  bound	  with	  incomplete	  complementarity	  to	  their	  targets,	  occuring	  within	  the	  3’UTR	  
of	  the	  transcript,	  direct	  translational	  inhibition	  of	  their	  targets	  but	  do	  not	  have	  an	  effect	  
on	  total	  mRNA	  stability.	  Additional	  studies	  also	  suggest	  that	  even	  though	  animal	  miRNAs	  
identify	  their	  targets	  with	  incomplete	  complementarity,	  they	  need	  a	  perfect	  base	  pairing	  
of	   nucleotides	   2-­‐8	   in	   the	   5’	   portion	   of	   the	  mature	  miRNA,	   named	   “seed”	   sequence,	   to	  
modulate	  target	  expression.	  
In	   the	   human	   genome	   alone,	   there	   have	   been	   discovered	  more	   than	   2000	  miRNA	   and	  
thus	   account	   for	   1-­‐4	   %	   of	   expressed	   genes.	   Bionformatic	   programs	   looking	   for	   “seed”	  
matches	   in	   the	   3’UTR	   of	   protein-­‐coding	   messages	   for	   the	   purpose	   of	   finding	   miRNA	  
targets,	  suggest	  that	  a	  single	  miRNA	  could	  regulate	  hundreds	  of	  distinct	  targets	  and	  it	   is	  
evaluated	  that	  more	  or	  less	  a	  third	  of	  all	  animal	  genes	  are	  under	  miRNAs	  control.	  
Certainly,	  the	  high	  number	  of	  analyzed	  miRNAs,	  shows	  that	  they	  can	  direct	  a	  big	  range	  of	  
cellular	   processes	   linked	   to	   differentiation	   and	   growth,	   apoptosis,	   aging,	  metabolic	   and	  
immune	   responses.	   For	   this	   reason	   the	   dysregulation	   of	   miRNA	   expression	   is	   strictly	  
connected	  to	  human	  pathologies,	  for	  instance	  tumours,	  and	  different	  studies	  suggest	  that	  
these	  molecules	  act	  as	  tumor	  suppressor	  gene	  and	  oncogenes;	  thereby,	  miRNAs	  appear	  
to	  be	  useful	  diagnostic	  and	  therapeutic	   tools	  and	   in	   this	  manner	   in	   the	   future	   it	  will	  be	  
necessary	  to	  better	  understand	  the	  mechanism	  leading	  to	  miRNA	  maturation	  and	  target	  
modulation.	  	  	  
The	  miRNA	  biogenesis	  pathway	  has	   lately	  been	  determined	  in	  animals	  and	  involves	  two	  
different	  processing	  events,	  first	  in	  the	  nucleus	  and	  later	  in	  the	  cytoplasm	  for	  the	  purpose	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of	   generating	   the	   ~	   22	   nucleotide	  mature	   single-­‐stranded	  miRNAs	   (112-­‐113).	   Generally	  
miRNA	   genes	   are	   transcribed	   by	   Polimerase	   II	   (although	   there	   are	   examples	   of	  
Polymerase	   III	   transcription)	   causing	   the	   precense	   of	   a	   pri-­‐miRNA	   precursor	   averaging	  
100-­‐1000s	  nucleotides	  in	  lenght.	  	  
These	   pri-­‐miRNA	   transcripts	   are	   often	   capped,	   spliced,	   and	   polyadenylated,	   and	   can	  
encode	   sequences	   for	   multiple	   miRNA	   genes.	   Within	   the	   nucleus,	   the	   Drosha	  
Microprocessor	  complex,	  which	   is	   formed	  by	  the	  Rnase	   III	   type	  endonuclease	  Drosha	   in	  
association	  with	  the	  DiGeorge	  syndrome	  critical	  region	  gene	  8	  (DGCR8)	  as	  well	  as	  other	  
cofactors,	   e.g.	   the	   DEAD	   box	   RNA	   helicase	   p68/DDX5	   and	   p72/DDX17,	   identify	  
stemlooped	   secondary	   structures	   within	   the	   pri-­‐miRNA	   resulting	   in	   the	   excision	   and	  
release	   of	   	   ~	   70	   nucleotides	   hairpin	   precursors	   termed	   pre-­‐miRNAs.	   Finally,	   the	   pre-­‐
miRNA	  is	  exported	  out	  of	  the	  nucleus	  by	  the	  Exportin-­‐5/Ran-­‐GTP	  complex	  that	  specifically	  
recognizes	   dsRNAs	   (Fig.	   9).	   Once	   in	   the	   cytoplasm,	   the	   pre-­‐miRNA	   link	   with	   a	   second	  
Rnase-­‐III	   type	   enzyme	   called	   Dicer	   and	   its	   co-­‐factor,	   the	  mammalian	   TAR	   RNA-­‐binding	  
protein	   (TRBP)	   and	   possibly	   the	   Argonaute	   protein,	   resulting	   in	   the	   processing	   and	  
liberation	  of	  a	  ~	  22	  nucleotide	  miRNA-­‐miRNA*	  duplex	  (114).	  
Only	  one	  strand	  of	  the	  miRNA	  duplex,	  considered	  as	  the	  “guide”	  strand	  and	  usually	  the	  
thermodynamically	   least	   stable	   strand	   at	   the	   5’terminus,	   is	   in	   a	   preferential	   manner	  
loaded	   	   into	   a	   large	   multi-­‐protein	   miRNA	   ribonucleoprotein	   complex	   (miRNP,	   also	  
referred	   to	   as	   the	  miRISC	   complex)	  with	   the	  help	  of	  RNA	  helicase	  proteins,	   and	   is	   now	  
ready	   to	   control	   target	   gene	  expression.	   The	   “passenger”	   strand	  of	   the	  miRNA-­‐miRNA*	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The	  key	   functional	   component	  of	   the	  miRNP	  complex	   is	   the	  Argonaute	  proteins	   (AG01-­‐
4/eIFC2),	   for	   example	   AGO2	   is	   the	   only	   Argonaute	   protein	   with	   “slicer”	   activity	   and	   is	  
responsible	   for	   the	   miRNA-­‐directed	   cleavage	   of	   the	   target	   midway	   into	   the	  
complementary	   region.	   Nevertheless,	   all	   four	   Argonaute	   proteins	   can	   control	   miRNA-­‐
mediated	   translational	   repression	   and	  modulate	   the	  mRNA	   stability	   of	   their	   targets	   via	  
mechanisms	   different	   from	   “slicer”	   activity.	   In	   addiction	   to	   the	   Argonaute	   protein,	   the	  
miRNP	  complex	   requires	  addictional	  proteins	  such	  as	   the	  RNA-­‐binding	  protein	   fragile-­‐X-­‐
mental-­‐retardation	   protein	   (FMRP)	   (116),	   the	   p-­‐body	   marker	   GW182	   (117)	   and	   the	  
decapping	  activator	  RCK/p54	   (118),	  which	   in	  defined	  combinations	  probabily	  determine	  
by	  which	  miRNAs	  control	  target	  expression	  either	  at	  the	  mRNA	  or	  protein	  level.	  	  
Several	   studies	  have	   shown	  different	  mechanisms	   to	   clarify	  how	  miRNAs	  perform	  post-­‐
transcriptional	  regulation	  over	  their	  targets.	  	  
MiRNAs	  that	  down-­‐regulate	   the	  expression	  of	   their	   targets	  at	   the	  protein	   level	  seem	  to	  
act	  in	  	  two	  ways:	  either	  at	  the	  level	  of	  translation	  initiation	  or	  at	  the	  post-­‐initiation	  phases	  
of	  translation.	  The	  choice	  between	  the	  two	  is	  probably	  determinated	  by	  the	  presence	  of	  
specific	  cofactors	  in	  the	  cellular	  environment	  at	  the	  time	  of	  miRNP	  formation.	  In	  order	  to	  
stop	   the	   beginning	   of	   translation,	   AGO2	   can	   be	   involved	   to	   out-­‐compete	   eukaryotic	  
Fig.	   9	   miRNA	   biogenesis.	   MiRNAs	   are	   transcribed	   by	   RNA	   polymerase	   II	   as	   long	  
precursors	  (pri-­‐miRNA).	  Precursors	  are	  processed	  twice,	  once	  in	  the	  nucleous	  by	  the	  
Drosha	  enzyme	  that	  gives	  rise	  to	  the	  pre-­‐miRNA,	  and	  finally	  in	  the	  cytoplasm	  by	  the	  
Dicer	  enzyme	  in	  order	  to	  obtain	  the	  short	  duplex	  microRNA	  molecule.	  One	  of	  the	  two	  
strands	  of	  the	  miR	  duplex	  is	   loaded	  in	  the	  multiprotein	  RISC	  complex	  and	  is	  able	  to	  
recognize	  the	  target	  sequence.	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initiation	   factor	  4E	   (eIF4E)	   for	  binding	   to	   the	  m7G	  cap	  of	   the	  mRNA	  (	  119-­‐120)	  and	  can	  
link	  with	  eIF6	  to	  block	  the	  association	  of	  the	  40S	  and	  60S	  ribosomial	  subunits	  (121).	  Other	  
studies	  has	  shown	  that	  translational	  initiation	  may	  advance	  in	  normal	  way,	  but	  when	  the	  
miRNP	  complex	  is	  formed,	  it	  can	  slow	  down	  the	  elongantion	  or	  stop	  ribosomial	  activit	  by	  
unknown	  mechanism	  causing	  nascent	  polypeptide	  chain	  degradation	  (122).	  	  
In	   the	   end	  miRNPs	   have	   the	   capacity	   to	  modulate	  mRNA	   stability	   of	   their	   targets	   even	  
thoughit	   is	   unclear	   if	   mRNA	   degradation	   is	   a	   secondary	   effect	   of	   miRNA-­‐mediated	  
translational	   repression.	   Degradation	   of	  mRNAs	   connected	  with	  miRNP	   complexes	  may	  
include	  deadenylation,	  mRNA	  cleavage	  (distinct	  from	  “slicing”,	  i.e.	  cleavage	  outside	  of	  the	  
region	   of	   miRNA	   complementarity),	   and/or	   decapping	   followed	   by	   5’-­‐3’	   degradation	  
(123).	  
	  
2.3	  	  	  	  The	  role	  of	  miRNAs	  in	  cancer	  
	  
Tumours	   are	   caused	   by	   uncontrolled	   proliferation	   and	   the	   inappropriate	   survival	   of	  
damaged	   cells,	   which	   cause	   cancer	   growth.	   Cells	   have	   developed	   many	   safeguards	   to	  
control	  that	  cell	  division,	  differentiation	  and	  death	  occur	  accurately	  and	  in	  a	  coordinated	  
manner,	  both	  during	  development	  and	  in	  the	  adult	  body.	  	  
Many	   cellular	   factors	   switch	   on	   or	   off	   genes	   that	   modulate	   cellular	   proliferation	   and	  
differentiation	  and	  damages	  to	  these	  genes,	  which	  are	  called	  tumour-­‐suppressor	  genes	  or	  
oncogenes,	  are	  necessary	  for	  the	  beginning	  of	  the	  tumor	  process.	  	  
Most	  tumour	  suppressor	  genes	  and	  oncogenes	  are	  first	  transcribed	  from	  DNA	  into	  RNA,	  
and	  are	  subsequently	  translated	  into	  protein	  to	  play	  their	  effects;	  the	  same	  situation	  can	  
occur	  with	  the	  miRNAs,	  therefore	  they	  could	  act	  	  as	  tumour	  suppressors	  and	  oncogenes.	  	  	  
In	   normal	   tissues	   the	   correct	   miRNA	   transcription,	   processing	   and	   binding	   to	  
complementary	  sequences	  on	  the	  target	  mRNA	  determine	  the	  repression	  of	  target-­‐gene	  
expression	   through	   a	   block	   in	   protein	   translation	   or	   altered	  mRNA	   stability.	   	   The	   total	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Like	  proteins-­‐coding	  genes,	  miRNAs	  act	  as	  tumor	  suppressors	  when	  their	  function	  loss	  can	  
initiate	  or	  contribute	  to	  the	  malignant	  transformation	  of	  normal	  cells.	  Thi	  loss	  may	  be	  due	  
to	   many	   mechanisms,	   like	   genomic	   deletion,	   mutation,	   epigenetic	   silencing,	   and/or	  
miRNA	   processing	   alterations	   (125-­‐126).	   A	   reduction	   or	   elimination	   of	  mature	  miRNAs	  
levels	   can	   involve	   the	   inappropriate	   expression	   of	   the	  miRNA-­‐target	   oncoproteins.	   The	  
total	   result	   could	   detemine	   increased	   proliferation,	   invasiveness	   or	   angiogenesis,	  
decreased	   levels	  of	  apoptosis,	  or	  undifferentiated	  or	  de-­‐differentiated	   tissue	  and	   in	   the	  
end	  cause	  tumour	  formation.	  	  
The	  amplification	  or	  overexpression	  of	  miRNAs	  which	  have	  an	  oncogenic	  role	  would	  also	  
result	  in	  cancer	  developement.	  In	  this	  situation,	  increased	  levels	  of	  miRNAs,	  which	  might	  
be	   produced	   at	   inappropriate	   times	   or	   in	   the	   wrong	   tissues,	   would	   eliminate	   the	  
expression	   of	   a	   miRNA-­‐target	   tumour-­‐suppressor	   gene.	   Increased	   levels	   of	   mature	  
miRNAs	  might	  occur	  because	  of	  amplification	  of	  the	  miRNA	  genes,	  uncontrolled	  activity	  of	  
promoters,	  increased	  efficiency	  in	  miRNAs	  processing	  or	  increased	  stability	  of	  miRNAs.	  
The	   first	   sign	   that	   miRNAs	   could	   act	   as	   tumour	   suppressors	   came	   from	   a	   study	   that	  
showed	  that	  patients	  with	  B-­‐cell	  chronic	  lymphocytic	  leukemia	  (CLL),	  often	  have	  deletions	  
or	   downregulation	   of	   two	   clustered	   miRNA	   genes,	   mir-­‐15	   and	   mir-­‐16-­‐1	   (127).	   These	  
miRNAs	   are	   located	   within	   the	   intron	   of	   a	   non-­‐protein-­‐coding	   RNA	   gene	   of	   unknown	  
Fig.	  10	  MiRNAs	  can	  function	  as	  tumour	  suppressors	  and	  oncogenes.	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function,	  which	  is	  called	  LEU2	  in	  the	  13q14.2	  region	  and	  negatively	  regulate	  BCL2,	  which	  
is	  an	  anti-­‐apoptotic	  gene	  that	   is	  often	  overexpressed	   in	  many	  types	  of	  human	  tumours,	  
including	   leukaemias	   and	   lymphomas.	   Indeed	   it	   seems	   that	   the	   deletion	   or	  
downregulation	  of	  mir-­‐15a	  and	  mir-­‐16-­‐1	  results	  in	  increased	  expression	  of	  BCL2,	  causing	  
leukaemogenesis	  and	  lymphomagenesis	  in	  haematopoietic	  cells	  (128).	  	  
In	  a	  similar	  vein,	  the	  let-­‐7	  family	  of	  miRNAs	  is	  downregulated	  in	  many	  cancers	  located	  in	  
the	  lung	  and	  the	  breast.	  These	  miRNA	  map	  in	  fragile	  genomic	  and	  functionally	  block	  the	  
mRNAs	  of	  well-­‐characterized	  oncogenes,	  such	  as	  the	  Ras	  family,	  HMGA2,	  and	  c-­‐myc,	  and	  
determine	  apoptosis	  and	  cell	  cycle	  arrest	  when	  overexpressed	   in	   lung	  and	  colon	  cancer	  
and	  in	  Burkitt	  lymphoma	  cell	  lines	  (129-­‐132).	  
The	  miR-­‐29	   family	  members	  have	  been	  shown	  to	  be	  downregulated	  in	  CLL,	   lung	  cancer,	  
invasive	  breast	   cancer,	  AML,	  and	  cholangiocarcinoma	   (133-­‐135)	  and	  has	   three	   isoforms	  
arranged	   in	   two	   clusters:	  miR-­‐29b-­‐1/miR-­‐29°	   in	   chromosome	   7q32	   and	  mir-­‐29b-­‐2/miR-­‐
29c	  in	  chromosome	  1q23.	  	  
It	   is	   interesting	   that	  chromosome	  7q32	   is	  a	   frequent	  area	  of	  deletion	   in	  myelodysplasia	  
and	  therapy-­‐related	  acute	  myeloid	  leukemia	  (AML).	  	  	  
The	  list	  of	  miRNAs	  that	  act	  as	  oncogenes	  is	  short,	  but	  many	  studies	  showed	  that	  their	  role	  
in	  tumoral	  progression	  is	  very	  powerful.	  	  
MiR-­‐155	  was	  one	  of	  the	  first	  described	  and	   it	   is	   located	   in	  chromosome	  21q23	  within	  a	  
host	  noncoding	  RNA,	  named	  the	  B	  cell	  integration	  cluster	  (BIC).	  Many	  reports	  have	  shown	  
that	  miR-­‐	  155	  is	  highly	  expressed	  in	  pediatric	  Burkitt	  lymphoma,	  Hodgkin	  disease,	  primary	  
mediastinal	  non-­‐Hodgkin	  lymphoma	  (136-­‐138),	  AML	  (134),	  lung	  cancer	  (139),	  and	  breast	  
cancer	  (140).	  
An	  another	  example	  of	   	  miRNA	   that	   functions	  as	   an	  oncogene	   is	  miR-­‐21,	   indeed	   this	   is	  
upregulated	  in	  a	  wide	  variety	  of	  hematological	  malignancies	  and	  solid	  tumors,	  like	  acute	  
myeloid	   leukemia	   (AML)	   (134),	   CLL	   (141),	   glioblastoma,	   and	   tumours	   of	   the	   pancreas,	  
prostate,	   stomach,	   colon,	   lung,	  breast	  and	   liver	   (142-­‐144).	   Furthermore,	  overexpressing	  
miR-­‐21	   in	  glioblastoma	  cells	   inhibits	  apoptosis,	  while	  silencing	   its	  expression	   in	  cultured	  
liver	   glioblastoma	   and	   breast	   cancer	   cells	   using	   antisense	   oligonucleotides	   stops	   cell	  
growth,	   triggers	   activation	   of	   caspases,	   and	   increases	   apoptotic	   cell	   death	   by	   targeting	  
tumor	  suppressor	  genes	  such	  as	  PTEN	  and	  PDCD4	  (programmed	  cell	  death	  4)	  (144-­‐147).	  
The	  miR-­‐17-­‐92	   cluster,	  which	   comprises	   six	  molecules	   (miR-­‐17,	  miR-­‐18a,	  miR-­‐19a,	  miR-­‐
20a,	  miR-­‐19b-­‐1,	   and	  miR-­‐92-­‐1),	   is	   an	   another	   instance	  of	   this	   kind	  of	  miRNAs,	  which	   is	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located	   within	   800	   base	   pairs	   in	   the	   noncoding	   gene	   at	   13q31.3	   and	   it	   is	   frequently	  
amplified	  in	  follicular	  lymphoma	  and	  diffuse	  large	  B	  cell	  lymphoma	  (148).	  	  
Moreover	   these	   miRNAs	   in	   the	   miR-­‐17-­‐92	   cluster	   have	   an	   important	   role	   in	   lung	  
development	  and	  in	  regulation	  of	  the	  immune	  and	  hematopoietic	  systems	  (149-­‐151)	  and	  
are	  also	  highly	  expressed	  in	  a	  variety	  of	  solid	  cancers	  and	  hematological	  malignancies,	  like	  
tumours	   of	   the	   breast,	   colon,	   lung,	   pancreas,	   prostate,	   and	   stomach	   as	   well	   as	  
lymphomas	  (143).	  They	  promote	  proliferation,	  induce	  tumor	  angiogenesis,	  and	  cooperate	  
with	   c-­‐myc,	   an	   oncogene	   that	   is	   often	   activated	   in	   cancer	   (152-­‐154).	   An	   another	  
important	   role	   of	   this	   cluster	   is	   the	   down-­‐modulation	   of	   two	   validated	   targets:	   the	  
antiapoptotic	  protein	  Bim	  and	  the	  tumor	  suppressors	  PTEN	  and	  p21	  (150-­‐151).	  	  
	  
2.4	  	  	  	  MiRNAs	  involved	  in	  MPM	  
	  
The	   definitive	   identification	   of	   MPM	   has	   significant	   clinical	   implications	   since	   other	  
cancers	  often	   involve	   the	  pleura,	   confounding	   the	  diagnosis	  of	  MPM.	   In	   the	  absence	  of	  
accurate	   markers,	   MPM	   can	   be	   difficult	   to	   distinguish	   from	   peripheral	   lung	  
adenocarcinoma	   and	   metastatic	   epithelial	   cancers.	   For	   this	   reason	   studying	   miRNAs	  
expression,	  that	  is	  tissue-­‐specific,	  could	  be	  highly	  informative	  for	  identifying	  tumor	  origin. 
MiRNAs	   are	   often	   used	   as	   potential	   biomarkers	   in	   diagnostic	   analysis	   and	   they	   can	   be	  
studied	   in	   tissue	   samples	   utilized	   for	   routine	   pathology	   because	   of	   their	   stability	   that	  
allows	  them	  to	  be	  quantified	  in	  formalin-­‐fixed	  paraffin-­‐embedded	  (FFPE)	  material	  by	  PCR	  
and	  in	  situ	  hybridization	  (ISH)	  techniques	  (143,	  155-­‐158).	  	  
Others	  and	  we,	  in	  the	  Laboratory	  of	  Molecular	  Pathology	  of	  the	  Pathology	  Department	  at	  
Rigshospitalet	   in	   Copenhagen,	   have	   recently	   repported	   miRNAs	   that	   may	   distinguish	  
between	  MPM	  or	  among	  different	  histological	  subtypes	  of	  MPM	  (159-­‐168).	  Nevertheless,	  
it	   is	  not	  still	   clear	   if	  we	  can	  consider	   these	  miRNA	  data	  useful	   to	  distinguish	  MPM	  from	  
non-­‐neoplastic	   mesothelial	   proliferations	   (RMPs)	   (168)	   that	   is	   the	   main	   diagnostic	  
problem	  when	  pleural	  biopsies,	  extracted	  from	  patients	  with	  clinical	  suspect	  of	  MPM,	  are	  
analyzed.	  	  
In	  order	  to	  identify	  different	  diagnostic	  miRNAs	  that	  could	  function	  as	  diagnostic	  markers	  
of	  MPM	  and	  aid	  in	  the	  difficult	  differential	  diagnosis	  with	  RMPs,	  it	  has	  been	  performed	  a	  
quantitative	   RT-­‐PCR	   (RT-­‐qPCR)	   screening	   of	   742	   miRNAs	   and	   validation	   of	   the	   miRNA	  
expression	   in	   patient-­‐matched	   diagnostic	   pleura	   biopsies,	   surgical	   tissue	   specimens	   of	  
MPM	   and	   corresponding	   non-­‐neoplastic	   pleura	   (NNP).	   Results	   have	   showed	   that	   4	  
miRNAs	   (miR-­‐126,	   miR-­‐143,	   miR-­‐145	   and	   miR-­‐652)	   are	   significantly	   down-­‐regulated	   in	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resected	  MPM	  and	  diagnostic	  tumor	  biopsies	  as	  compared	  to	  NNP	  or	  non-­‐neplastic	  RMP	  
induced	  by	  pneumothorax	   (169)	   (Fig.	  11).	   In	  addition,	  binary	   logistic	   regression	  analysis	  
on	  the	  RT-­‐qPCR	  data	  for	  the	  4	  miRNAs	  has	  shown	  that	  by	  combining	  the	  4	  miRNAs	  in	  a	  4-­‐
miRNA-­‐classifier,	   it	   is	   possible	   to	   distinguish	   	  MPM	   from	  NNP	  with	   high	   sensitivity	   and	  
specificity.	   Finally	   it	   has	   been	   shown	   that	   the	   level	   of	   miR-­‐126	   in	   MPM	   is	   inversely	  
correlated	  with	  that	  of	   its	  known	  target,	  the	   large	  neutral	  amino	  acid	  transporter,	  small	  
subunit	  1	  (LAT1).	  Overall,	  these	  results	  indicate	  that	  miR-­‐126,	  miR-­‐143,	  miR-­‐145,	  and	  miR-­‐
652	  may	   be	   suitable	   biomarkers	   for	   distinguishing	  MPM	   from	  RMP	   (169).	   Some	   of	   the	  
miRNAs	  in	  MPM	  identified	  to	  be	  differentially	  expressed	  in	  MPM	  also	  appear	  to	  correlate	  









Fig.	   11	   Tukey-­‐boxplots	   of	  miR-­‐126	   (A),	  miR-­‐143	   (B),	  miR-­‐145	   (C),	   and	  miR-­‐652	   (F)	  
levels	   in	   tissue	   samples	   of	   diagnostic	   biopsies	   (DB),	   malignant	   pleural	  
mesothelioma	   (MPM),	   non-­‐neoplastic	   pleura	   (NNP)	   and	   reactive	   mesothelial	  
proliferation	  after	  pneumothorax	  (PTHX).	  Plots	  are	  based	  on	  real-­‐time	  qPCR	  data.	  
The	   box	   delimits	   the	   25th	   and	   75th	   percentiles.	   Horizontal	   lines	   inside	   the	   boxes	  
mark	   the	   median.	   Vertical	   lines	   mark	   the	   interval	   between	   10th	   and	   90th	  
percentiles.	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3.	  MiR-­‐126	  and	  its	  host	  gene	  EGFL7:	  new	  players	  in	  cancer	  
3.1	  	  	  	  EGFL7:	  structure	  and	  expression	  pattern	  
	  
The	  main	   processes	   connected	   to	   growth	   of	   new	  blood	   vessels	   are	   vasculogenesis	   and	  
angiogenesis.	  Vasculogenesis	  is	  the	  first	  step	  and	  requires	  the	  development	  of	  endothelial	  
precursor	   cells	   (angioblasts)	   from	   mesodermal	   cells	   while	   angiogenesis	   entails	   the	  
formation	   of	   primitive	   blood	   vessels	   that	   are	   then	   modified	   and	   converted	   into	   a	  
functional	  vascular	  network.	  
Many	  factors	  can	  modulate	  these	  cellular	  programes	  and	  for	  this	  reason	  different	  studies	  
in	  cardiovascular	  research	  have	  focused	  on	  their	   identification,	  for	  example	  recently	  has	  
been	   identified	   a	   new	   molecular	   player	   in	   the	   field	   of	   blood	   vessel	   formation	   called	  
EGFL7,	  a	  protein	  also	  known	  as	  VE-­‐statin,	  MEGF7,	  Notch4-­‐like	  protein	  or	  Zneu1.	  
An	  Initial	  report	  on	  the	  function	  of	  EGFL7	  in	  the	  vascular	  system	  showed	  that	  EGFL7	  had	  
the	   capacity	   to	   inhibit	   the	  migration	   but	   not	   the	   proliferation	   of	   human	   aortic	   smooth	  
muscle	  cells	  in	  vitro	  (170);	  therefore	  this	  first	  study	  suggested	  that	  EGFL7	  may	  have	  a	  role	  
as	  a	  modulator	  of	  blood	  vessel	  growth.	  Nevertheless,	  an	  another	  study	  of	  2004	  showed	  
that	  EGFL7	  can	  act	   as	   an	   important	   tubulogenic	   factor	   in	   the	  process	  of	   vasculogenesis	  
(171).	  
This	  protein	  is	  conserved	  among	  vertebrates	  but	  an	  orthologue	  is	  also	  found	  in	  Drosophila	  
melanogaster	   (CG7447)	  while	   two	  alternative	   splice	   variants	  have	  been	  analyzed	   in	   the	  
mouse	  genome	  (170).	  	  
The	   analysis	   of	   human	   EGFL7	   gen	   displayed	   its	   location	   on	   chromosome	   9	   and	   the	  
presence	   of	   10	   exons,	   but	   only	   exons	   3–9	   encode	   for	   the	   EGFL7	   protein	   that	   shows	   a	  
modular	  structure	  with	  an	  N-­‐terminal	  signal	  secretion	  peptide	  (SS),	  followed	  by	  an	  Emilin-­‐
like	  domain	  (EMI)	  that	  is	  succeeded	  by	  two	  EGF-­‐like	  domains	  (EGF).	  	  
One	  of	  the	  these	  EGF-­‐like	  domains	  comprises	  a	  region	  that	  is	  similar	  to	  the	  Delta-­‐Serrate-­‐	  
LAG-­‐2	  domain,	  a	   sequence	   that	   is	   conserved	   in	   ligands	   that	  bind	  Notch,while	   the	  other	  
domain	  binds	  Ca2+.	  In	  the	  end	  there	  is	  a	  C-­‐terminal	  coiled-­‐coil	  structure	  (170-­‐172)	  (Fig	  12).	  
Fig.	  12	  Domain	  organization	  of	  
EGFL7.	   The	   modular	   assembly	  
of	   EGFL7's	   domains	   is	  
conserved	   among	   vertebrate	  
species.	   The	   EGFL7	   orthologue	  
CG7447	   in	   Drosophila	  
melanogaster	   shares	   the	   same	  
overall	   structure	   but	   differs	   in	  
total	  length.	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Several	  studies	  demonstrated	  also	  the	  existence	  of	  three	  alternative	   isoforms	  of	  human	  
EGFL7	   that	   have	   the	   same	   open	   reading	   frame	   but	   are	   transcribed	   from	   separate	  
promoters	  (173).	  In	  addition	  EGFL7	  gene	  encodes	  the	  biologically	  active	  miRNAs	  miR-­‐126	  
and	   miR-­‐126*	   (its	   complement)	   that	   are	   relevant	   for	   the	   development	   of	   the	  
cardiovascular	   system	  and	  have	  been	   involved	   in	   cardiovascular	  diseases	  as	  well	   as	   the	  
formation	  and	  progression	  of	  different	  tumour	  types	  (174-­‐177)	  (Fig.	  13).	  
	  
Initially	   EGFL7	   was	   described	   as	   a	   protein	   exclusively	   secreted	   by	   vascular	   endothelial	  
cells	   at	   all	   stages	  of	  mouse	  development	   (172,	   178)	   but	   subsequently	   its	   presence	  was	  
demonstrated	  in	  the	  primordial	  germ	  cells	  during	  homing	  into	  the	  gonads	  and	  in	  several	  
kinds	  of	  cells	  (179).	  	  
Interestingly,	  EGFL7	  is	  expressed	  also	  within	  the	  neurons	  of	  adult	  mice	  and	  this	  indicates	  
that	  EGFL7	  could	  have	  an	   important	  role	   in	  many	  biological	  processes	   in	  various	  tissues	  
and	  not	  only	  in	  the	  vascular	  system	  (80).	  	  
During	  mouse	   development	   EGFL7	   becomes	  measurable	   at	   the	   blastocyst	   stage	  with	   a	  
marked	   increase	   in	   expression	   levels	   at	   embryonic	   day	   E7.5	   to	   E8.5	   and	   later	   his	  
expression	  continues	  to	  be	  at	  a	  constant	  level	  (170,	  172).	  	  
Upon	  birth,	  EGFL7	  becomes	  downregulated	  in	  the	  vascular	  system	  and	  high	  levels	  of	  the	  
protein	   can	   be	  measured	   in	   a	   subset	   of	   vessels	   in	   the	   lung,	   heart,	   kidney,	   spleen	   and	  
uterus.	  	  
In	  the	  adult	  vasculature	  its	  expression	  is	  maintained	  restricted	  to	  areas	  of	  active	  vascular	  
remodeling,	  e.g.	  during	  menstruation	  and	   in	   the	  uterus	  during	  pregnancy	   (physiological	  
angiogenesis)	  or	   alternatively,	  under	  pathological	   conditions	  of	   vessel	   formation	  due	   to	  
arterial	  injury	  (178),	  or	  in	  human	  solid	  cancers(171).	  	  
Fig.	   13	   Localization	   of	   miR-­‐
126/miR-­‐126*	   within	   the	  
primary	   human	   EGFL7	  
transcript.	  This	  is	  a	  schematic	  
representation	   of	   three	  
alternative	   primary	   human	  
EGFL7	   transcripts,	   which	  
initiate	   from	   separate	  
promoters	   but	   contain	   the	  
same	   open	   reading	   frame.	  
Non-­‐coding	   exons	   are	  
indicated	  in	  uncolored	  boxes,	  
coding	  exons	  in	  colored	  ones.	  
miR-­‐126	   and	   miR-­‐126*	   are	  
localized	   within	   intron	   7	   of	  
EGFL7	  in	  all	  vertebrates.	  
Fig.	   12	   Domain	   organization	  
of	   EGFL7.	   The	   modular	  
assembly	  of	  EGFL7's	  domains	  
is	   conserved	   among	  
vertebrate	   species.	   The	  
EGFL7	   orthologue	   CG7447	   in	  
Drosophila	   melanogaster	  
shares	   the	   s me	   overall	  
structure	   but	   differs	   in	   total	  
length.	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In	  sum,	   the	  expression	  pattern	  of	  EGFL7	  suggests	   that	   this	   factor	   is	  necessary	   for	  blood	  
vessel	  formation	  and	  remodeling	  and	  differently	  from	  other	  secreted	  angiogenic	  proteins,	  
EGFL7	   has	   a	   peculiar	   characteristic	   because	   it	   is	   mainly	   expressed	   by	   and	   acts	   on	  
endothelial	  cells.	  
Conversely	   various	   types	   of	   cells	   like	   macrophages,	   epithelial	   cells,	   and	   aortic	   smooth	  
muscle	  cells	  can	  express	  e.g.	  VEGF	  and	  endothelial	  cells	  are	  only	  a	  minor	  source	  of	   this	  
factor	  while	  FGF-­‐2	  is	  even	  more	  widely	  expressed	  and	  is	  described	  in	  almost	  all	  tissues	  of	  
mesodermal	  and	  neuroectodermal	  origin.	  
In	   addition	   the	   analogy	   of	   the	   EGFL7	   expression	   profile	   to	   that	   of	   the	   angioblast	   and	  
endothelial	   cell	   marker	   VEGFR2,	   indicates	   that	   EGFL7	   could	   be	   an	   excellent	   candidate	  
marker	  of	  endothelial	  cells	  and	  their	  precursors	  (171,	  172,	  178).	  
Recent	   publications	   suggest	   that	   EGFL7	   may	   modulate	   blood	   vessel	   development	   by	  
creating	   a	   permissive	   environment	   for	   angiogenesis	   facilitating	   endothelial	   cell	  
proliferation,	  migration,	  sprouting,	  and	  invasion	  (171,	  178,	  181).	  
This	   could	   occur	   because	   EGFL7	   has	   the	   capacity	   to	   remodel	   the	   extracellular	   matrix	  
(ECM)	   and	   probabily	   it	   is	   produced	   by	   sprouting	   vessels	   and	   deposited	   around	  
extracellular	  environment	  (Fig.	  14).	  
Furthermore,	   EGFL7	   deposition	   into	   the	   ECM	   is	   favoured	   by	   fibronectin	   and	   type	   I	  
collagen,	   both	   of	  which	   belong	   to	   a	   group	   of	   ECM	  proteins	   that	   the	   nascent	   vessel	   on	  
tissue	  invasion	  can	  encounter	  (181).	  	  
EGFL7	  also	  controls	   the	  rigidity	  of	   the	  ECM	  by	  blocking	  the	  deposition	  of	  mature	  elastic	  
fibers	   and	   by	   repressing	   lysyl	   oxidase	   (LOX)–mediated	   conversion	   of	   tropoelastin	   into	  
elastin	  (182).	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Fig.	   14	   Model	  
depicting	   the	   role	  
of	   EGFL7	   in	  
angiogenesis.	  	  
(A-­‐B)	   EGFL7	   is	   a	  
protein	   that	   is	  
expressed	   by	  
endothelial	   cells,	  
including	   the	  stalk	  
and	   tip	   cells	   of	  
sprouting	  vessels.	  
One	   secreted,	   EGFL7	   binds	   to	   the	   ECM	   and	   shows	   overlapping	   expression	   with	  
fibronectin	   and	   collagen	   type	   IV.	   (A)	   EGFL7	   controls	   endothelial	   cell	   sprouting,	  
migration,	   and	   proliferation.	   (B).	   EGFL7	   also	   signals	   to	   the	   ECM	   and	  modulates	   its	  
rigidity	   by	   inhibiting	   lysyl	   oxidase	   (LOX)–mediated	   conversion	   of	   tropoelastin	   into	  
elastin.	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Thus,	  it	  seems	  clear	  that	  EGFL7	  has	  an	  important	  role	  in	  angiogenic	  growth	  by	  influencing	  
both	  endothelial	  cell	  behavior	  and	  specific	  signaling	  to	  the	  ECM	  environment.	  
Another	  interesting	  evidence	  about	  the	  role	  of	  EGFL7	  in	  angiogenesis	  is	  the	  link	  between	  
EGFL7	  and	  Notch	  signaling	  (180).	  	  
The	   Notch	   pathway	   is	   evolutionarily	   conserved	   and	   controls	   basic	   processes	   such	   as	  
development,	  cell-­‐fate	  determination,	  and	  differentiation.	  	  
Notch-­‐mediated	  signal	  transduction	  is	  based	  on	  several	  key	  factors:	  four	  Notch	  receptor	  
isoforms	   (Notch1-­‐4)	   and	   five	   ligands	   of	   the	   Delta	   (Dll1,	   3	   and	   4)	   or	   the	   Jagged	   type	  
(Jagged1	  and	  2).	  
Signaling	   in	   this	   pathway	   progresses	   through	   ligand-­‐receptor	   binding	   that	   determines	  
intra-­‐membrane	  proteolysis	  of	  the	  Notch	  receptor	  and	  release	  of	  the	  Notch	  intracellular	  
domain	  (NICD).	  The	  activated	  C	  terminus	  of	  the	  Notch	  receptor	  moves	  into	  the	  nucleus,	  
where	  it	  connects	  to	  the	  DNA-­‐binding	  protein	  CSL	  to	  support	  transcription.	  
The	  Notch	  pathway	  has	  an	  essential	   role	   in	   the	   tip-­‐stalk	   cell	  decision	  during	  angiogenic	  
sprouting	   since	   high	   levels	   of	   Dll4	   expressed	   on	   filopodia-­‐rich	   tip	   cells	   that	   drive	   the	  
angiogenic	  sprout	  activate	  Notch	  receptors	  situated	  on	  the	  adjacent	  stalk	  cells.	  	  
Even	  though	  it	  is	  not	  completely	  understood	  how	  this	  suppresses	  the	  tip	  cell	  phenotype,	  
it	   seems	   that	   the	   activation	   of	   the	   Notch	   pathway	   causes	   a	   downregulation	   of	   the	  
expression	   of	   VEGF	   receptors	   and	   therefore	   affects	   the	   response	   of	   stalk	   cells	   to	   the	  
surrounding	  VEGF	  (183).	  
Jagged1	   has	   been	   suggested	   to	   be	   exclusively	   expressed	   on	   stalk	   cells	   where	   it	  
antagonized	   Dll4-­‐mediated	   activation	   of	   Notch	   receptors	   in	   fact	   elevated	   levels	   of	  
Jagged1	  cause	  increased	  angiogenesis	  and	  tip	  cell	  numbers	  (184).	  	  
In	  this	  contest	  a	  study	  demonstated	  that	  EGFL7	  can	  act	  as	  an	  inhibitor	  of	  Notch	  receptor	  
activation	   by	   competition	   with	  
Jagged-­‐type	   ligands	   and	   preliminary	  
data	  suggested	  a	  selective	  binding	  of	  
EGFL7	  to	  Dll4	  	  (181)(Fig	  15).	  	  
	  
Fig.	   15	   Model	   describing	   the	  
putative	   role	   of	   EGFL7	   in	   Notch	  
signaling.	   EGFL7	   antagonizes	  
Notch/ligand	   interaction	   by	   either	  
binding	   to	   the	   receptor	   or	   its	  
corresponding	   ligand	   and	   inhibits	  
target	  gene	  expression.	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These	   findings	   showed	   that	   EGFL7	   could	   modulate	   vascular	   Notch	   signaling	   during	  
angiogenic	  sprouting	  since	  it	  reduces	  Notch	  target	  gene	  expression	  and	  induces	  a	  regular	  
hyperangiogenic	   response,	   similar	   to	   what	   has	   been	   observed	  when	   Notch	   signaling	   is	  
blocked	  (184).	  
As	  we	  have	  underlined	  previously,	  EGFL7	  is	  expressed	  in	  several	  cancers	  	  included	  kidney	  
tumors,	  malignant	  gliomas,	  hepatocellular	  carcinomas	   (HCCs),	  and	  colon	  cancers	  and	   its	  
possible	   role	   in	   promoting	   tumor	   angiogenesis	   make	   EGFL7	   a	   potential	   target	   for	  
antiangiogenesis	  therapy.	  	  
The	  idea	  of	  antiangiogenic	  strategies	  is	  to	  avoid	  that	  cancer	  obtains	  essential	  nutrients	  in	  
order	  to	  inhibit	  new	  vessel	  growth	  and	  break	  existing	  ones.	  
A	   typical	   instance	   is	   the	   anti-­‐VEGF	   treatment	   that	   combined	   with	   chemotherapy,	   has	  
revealed	  to	  be	  of	  clinical	  benefit	  in	  the	  context	  of	  solid	  cancers	  (185).	  Anti-­‐VEGF	  therapy	  
cuts	   preexisting	   vessels	   but	   also	   stops	   the	   growth	   of	   new	   ones;	   in	   addition,	   it	   causes	  
vessel	  normalization	  seein	  as	  increases	  in	  mural	  cell	  recruitment	  and	  vessel	  maturation.	  	  
The	  resulting	  normalized	  cancer	  vasculature	  facilitates	  the	  delivery	  of	  cytotoxic	  drugs	  but	  
lately	  	  this	   improvement	  appeared	  to	  be	  transient	  as	  prolonged	  VEGF	  blockade	  basically	  
cuts	  most	  of	  the	  vessels,	  including	  the	  normalized	  ones.	  
Recent	  preclinical	  studies	  that	  used	  a	  combination	  of	  anti-­‐VEGF	  therapy	  and	  humanized	  
monoclonal	  Abs	  against	  EGFL7	  showed	  how	  it	  is	  possible	  to	  increase	  additional	  inhibition	  
of	  cancer	  growth	  in	  mouse	  models,	  compared	  with	  anti-­‐VEGF	  treatment	  alone.	  	  
At	  the	  present,	  clinical	  trials	  are	  being	  conducted	  to	  analyze	  the	  effect	  of	  combined	  anti-­‐
EGFL7	  and	  Avastin	  (anti-­‐VEGF	  Ab)	  therapy	  on	  cancer	  vascular	  function	  and	  growth.	  	  
Although	   the	  potential	   for	  anti-­‐EGFL7	   therapy	   is	  promising,	   the	   long-­‐term	  result	  and	   its	  
possible	  effect	  on	  Notch	  signaling	  must	  still	  be	  analyzed	  but	   it	   is	  expected	  that	  blocking	  
EGFL7	   signaling	   in	   conjunction	   with	   anti-­‐VEGF	   will	   supply	   additional	   inhibition	   of	  
angiogenesis	   since	   anti-­‐EGFL7	   therapy	   could	   also	   stimulate	   normalization	   of	   the	  
vasculature.	  	  
	  
3.2	  	  	  	  Mir-­‐126	  and	  *mir-­‐126	  
	  
MiR-­‐126	   (also	   referred	   to	  as	  miR-­‐126-­‐3p)	  and	   its	  complement	  miR-­‐126*	   (miR-­‐126-­‐5p	  or	  
miR-­‐123)	   are	   located	   within	   intron	   7	   of	   EGFL7	   gene	   in	   all	   vertebrates	   and	   both	   are	  
conserved	  among	  species	  (186-­‐187).	  	  
Several	   research	   groups	   identified	  miR-­‐126	   as	   the	  only	  miRNA	   known	   to	  be	   specifically	  
expressed	  in	  the	  endothelial	  cell	  lineage,	  hematopoietic	  progenitor	  cells,	  and	  endothelial	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cell	   lines	   (186-­‐189).	   Unfortunately,	   only	   little	   specific	   information	   on	   miR-­‐126*	   is	  
available.	  	  
MiR-­‐126	  appear	  to	  be	  expressed	  in	  highly	  vascularized	  tissues	  such	  as	  heart,	  liver,	  or	  lung,	  
or	   in	   human	   umbilical	   vein	   endothelial	   cells	   (HUVEC)	   (188,	   190-­‐192)	   and	   in	   general	   it	  
seems	  to	  be	  coexpressed	  with	  its	  host	  gene	  EGFL7,	  as	  they	  share	  a	  common	  mRNA	  (176).	  
However,	   there	   are	   studies	   that	   revealed	   that	   miR-­‐126	   expression	   could	   be	   regulated	  
independently	   from	  EGFL7,	   suggesting	   the	  existence	  of	  a	   separate	  promoter	   that	  might	  
drive	  the	  expression	  of	  miR-­‐126/miR-­‐126*(193).	  	  
Recently	  many	  studies	  have	  tried	  to	  analyze	  the	  expression	  pattern	  of	  miR-­‐126/miR-­‐126*	  
and	   results	   have	   shown	   that	   these	   miRNAs	   can	   have	   an	   important	   role	   in	   various	  
processes	   included	   developmental	   angiogenesis,	   but	   also	   in	   carcinogenesis	   and	  
inflammation.	  
	  
3.2.1	  	  Mir-­‐126/	  *mir-­‐126	  and	  inflammation	  
	  
Epidemiological	   data	   suggest	   that	   up	   to	   25%	   of	   all	   tumors	   are	   caused	   by	   infectious	  
processes	   (194).	   During	   inflammation	   within	   the	   cellular	   environment,	   oncogenes	   and	  
tumor-­‐suppressor	  genes	  can	  change	  their	  level	  of	  expression	  and	  this	  is	  possible	  also	  for	  
miRNAs.	  
Currently,	  two	  studies	  on	  miR-­‐126	  have	  revealed	  a	  	  possible	  role	  of	  in	  inflammation.	  	  
The	   first	  has	   shown	   that	  miR-­‐126	   can	   stop	   the	  expression	  of	   the	  vascular	   cell	   adhesion	  
molecule	   (VCAM1)	   in	  endothelial	   cells	  and	  block	  adhesion	  and	   infiltration	  of	   leukocytes	  
into	   the	  vasculature	  wall	   (189).	   The	  Second	  has	   reported	  an	  altered	  expression	  of	  miR-­‐
126	  in	  ulcerative	  colitis	  and	  indicated	  a	  possible	  role	  for	  miR-­‐126	  in	  the	  development	  of	  
colon	  cancer	  (195).	  
	  
3.2.2	  	  Mir-­‐126/	  *mir-­‐126	  in	  angiogenesis	  
	  
The	  role	  of	  miR-­‐126/miR-­‐126*	  in	  angiogenesis	  is	  still	  controversial	  and	  many	  publications	  
tried	   to	   elucidate	   how	   they	   are	   involved	   in	   this	   physiological	   process	   of	   tissue	  
homeostasis	  .	  	  
MiR-­‐126	  knock-­‐down	  studies	  in	  zebrafish	  (196)	  and	  mice	  (186,197)	  showed	  that	  miR-­‐126	  
is	  neccessary	   for	   the	  maintenance	  of	  vascular	  structure	   in	  vivo	  because	   it	  can	  modulate	  
specific	  aspects	  of	  endothelial	  cell	  biology,	  including	  cell	  migration	  during	  vessel	  growth,	  
organization	  of	  the	  cytoskeleton,	  capillary	  network	  stability,	  and	  cell	  survival	  (198).	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In	   this	   context	   miR-­‐126	   can	   control	   VEGF-­‐induced	   signals	   inhibiting	   directly	   its	   targets	  
Sprouty-­‐related	   EVH1	   domain–containing	   protein	   1	   (SPRED1)	   and	   a	   subunit	   of	   PI3K	  
(PI3KR2,	  synonym:	  p85β)	  in	  order	  to	  facilitate	  VEGF	  signaling.	  Both	  factors	  block	  receptor	  
tyrosine	  kinase–induced	  signaling	  via	  the	  MAPK	  and	  PI3K	  pathways	  (186-­‐187)	  (Fig.	  16).	  	  	  
	  	  	  	  	  Thus,	   miR-­‐126	   promotes	  
VEGF	   signaling,	  
angiogenesis	   and	   vascular	  
integrity	   by	   inhibiting	  
protein	   production	   of	  
endogenous	   VEGF	  
repressors	   within	  
endothelial	  cells.	  
On	   the	   contrary	   other	  
study	   revealed	   that	  
downregulation	   of	   miR-­‐
126	   can	   have	   specific	  
effects	  in	  	  	  some	  tumors,	  as	  
it	   can	   induce	   angiogenesis	  
and	   lymphangiogenesis	   in	  
oral	  cancer	  by	  activation	  of	  VEGF-­‐A	  and	  can	  inhibit	  the	  same	  molecule	  in	  the	  three	  lung	  
cancer	   cell	   lines	   	   causing	   cell	   cycle	   arrest	   in	   the	  G1-­‐phase	   and	   stopping	   	   the	   growth	  of	  
tumor	  also	  in	  vivo	  (199-­‐200).	  	  
In	  sum,	  miR-­‐126	  supports	  the	  development	  of	  the	  cardiovascular	  system	  and	  its	  role	  has	  
been	   intensively	  assessed	   in	  order	  to	  study	  the	  formation	  of	  vascular	  disorders,	  such	  as	  
abnormal	  angiogenesis	  and	  vascular	  leakage	  in	  various	  types	  of	  neoplastic	  diseases.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3.2.3	  	  Mir-­‐126/	  *mir-­‐126	  in	  cancer	  
	  
Many	   publications	   showed	   that	  miR-­‐126	   has	   a	   critical	   role	   in	   tumorigenesis	   but	   is	   also	  
important	  in	  tumor	  progression	  and	  metastasis.	  
In	   one	   of	   these,	   miR-­‐126	   expression	   was	   reported	   to	   be	   lost	   in	   human	   breast	   cancer.	  
Retroviral	   restoration	   of	   miR-­‐126	   levels	   in	   primary	   breast	   cancer	   cells	   suppressed	   the	  
overall	  tumor	  growth	  and	  metastasis	  to	  the	  bone	  and	  lung	  in	  nude	  mice	  (201).	  Notably,	  
patients	  with	  primary	  breast	   tumors	  characterized	  by	   low	  miR-­‐126	  expression	  displayed	  
very	   poor	   overall	   metastasis-­‐free	   survival	   as	   compared	   to	   patients	   with	   tumors	   that	  
Fig.	   16	   Putative	   Model	   of	   miR-­‐126	   function	   in	  
endothelial	   cells.	   MiR-­‐126	   represses	   SPRED1	   and	  
PIK3R2,	   which	   negatively	   regulate	   VEGF	   signaling	   (and	  
possibly	  other	  growth	  factor	  signaling	  pathways)	  via	  the	  
MAP	  kinase	  and	  PI3	  kinase	  pathways,	  respectively.	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exhibited	  high	  miR-­‐126	  levels.	  This	  finding	  suggests	  a	  clinical	  correlation	  between	  the	  loss	  
of	  miR-­‐126	  and	  metastasis-­‐free	  survival.	  	  	  
Subsequent	   reports	   showed	   also	   that	   miR-­‐126	   targeted	   the	   oncogene	   IRS-­‐1	   (insulin	  
receptor	  substrate-­‐1)	  in	  breast	  cancer	  cells	  (202).	  
Consistently,	  down-­‐regulation	  of	  miR-­‐126	  in	  cancerous	  vs.	  noncancerous	  tissues	  has	  been	  
reported	  for	  cancers	  of	  the	  lung	  (158),	  stomach	  (203),	  cervix	  (204),	  bladder	  and	  prostate	  
(176)	  and	   in	   leukemia	  where	   it	   	   targets	  HOXA9,	   the	  overexpression	  of	  which	   correlates	  
with	  poor	  prognosis	  in	  acute	  myelogenous	  leukemia	  (205).	  	  
Likewise,	   loss	   of	  miR-­‐126*	   has	   been	   reported	   for	   colon	   (206),	   lung	   (158),	   and	   prostate	  
cancer	   cell	   lines	   (177).	   However,	   the	   functions	   of	  miR-­‐126/miR-­‐126*	   in	   these	   types	   of	  
cancer	  appear	  to	  be	  diverse	  and	  largely	  unknown.	  	  
Recently,	  miR-­‐126	   has	   been	   suggested	   as	   a	   tumor	   suppressor	   in	   human	   gastric	   cancer	  
since	  miR-­‐126	  inhibited	  tumor	  growth	  and	  metastasis	  in	  vivo	  and	  in	  vitro	  (203).	  Partially,	  
this	  effect	  was	  mediated	  by	  down-­‐regulation	  of	  Crk,	  a	  component	  of	  the	  focal	  adhesion	  
network	   involved	   in	   integrin	   signaling.	   Interestingly,	  decreased	  Crk	   expression	  has	  been	  
shown	  to	  suppress	  tumor	  cell	  proliferation	  and	  invasion	  (207-­‐208).	  	  
Instead	  in	  human	  colon	  cancer,	   it	  was	  reported	  an	  association	  between	  the	  loss	  of	  miR-­‐
126	  and	  an	   impaired	  signaling	  via	  phosphatidylinositol	  3-­‐kinase	  (PI3K)	  due	  to	  the	  down-­‐
regulation	  of	  its	  regulatory	  subunit	  p85β	  (206).	  	  
Finally	  in	  our	  laboratory	  in	  Copenaghen	  we	  have	  analyzed	  the	  relationship	  between	  miR-­‐
126	  and	  the	  amino	  acid	  transporter	  LAT1	  in	  MPM	  (169).	  
A	  previous	  study	  reported	  LAT1	  up-­‐regulation	  in	  50%	  of	  MPMs	  and	  associated	  high	  LAT1-­‐
expression	  with	  poor	  prognosis	   (209).	   In	  agreement	  with	  this,	  we	  observed	  a	  significant	  
up-­‐regulation	  of	  LAT1	  in	  MPM	  and	  an	  inverse	  correlation	  with	  miR-­‐126	  level.	  An	  inverse	  
relationship	  between	  miR-­‐126	  and	  LAT1,	  which	  is	  a	  known	  target	  gene	  of	  miR-­‐126	  in	  small	  
cell	   lung	   cancer	   cells,	   suggests	   an	  equivalent	   regulatory	  mechanism	  of	  miR-­‐126	   in	   LAT1	  
expression	   in	   MPM	   cells.	   However,	   further	   studies	   involving	   manipulation	   of	   miR-­‐126	  
levels	  in	  MPM	  cell	  lines	  are	  needed	  to	  confirm	  LAT1	  as	  a	  miR-­‐126	  target	  in	  MPM.	  
A	  growing	  body	  of	  evidence	   indicates	  that	  miRNAs	  convey	  a	  novel	  and	  efficient	  way	  for	  
the	   regulation	   of	   gene	   expression,	   thus	   being	   involved	   in	   multiple	   aspects	   of	   cellular	  
processes.	   Especially,	   miR-­‐126	   and	   miR-­‐126*	   have	   been	   intensively	   studied	   and	   have	  
been	   attributed	   significant	   roles	   in	   different	   physiological	   and	   pathological	   processes,	  
including	  inflammation,	  blood	  vessel	  growth,	  and	  cancer.	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It	  has	  been	  shown	  that	  miR-­‐126/miR-­‐126*	   inhibited	  tumor	  growth	  by	  the	  prevention	  of	  
cancer	  cell	  proliferation,	  migration,	  and	  invasion.	  	  
The	   tumor-­‐suppressive	   functions	   of	   miR-­‐126/miR-­‐126*	   have	   been	   studied	   in	   different	  
types	   of	   neoplastic	   diseases.	   However,	   it	   is	   difficult	   to	   connect	   the	   functions	   of	   miR-­‐
126/miR-­‐126*	   in	   cancer	   cells	   to	   the	   physiological	   functions	   of	   both	   miRNAs	   in	   the	  
vasculature.	   In	   fact,	   it	   has	   been	   described	   in	   several	   animal	   models	   that	   miR-­‐126	   is	  
essential	   for	   endothelial	   cells	   to	   respond	   to	   growth	   factors,	   thus	   acting	   as	   a	  promoting	  
factor	  for	  endothelial	  cell	  proliferation	  and	  migration	  (210).	  	  
Unfortunately,	  in	  this	  moment	  there	  are	  few	  information	  about	  the	  role	  of	  miR-­‐126/miR-­‐
126*	   in	   tumor	   neoangiogenesis.	   It	   has	   been	  well	   established	   that	   blood	   vessel	   growth	  
represents	  one	  of	  the	  key	  features	  in	  the	  pathogenesis	  of	  cancer;	  therefore,	  it	  is	  of	  great	  
interest	  to	  compare	  the	  effects	  of	  miR-­‐126	  in	  tumor	  cells	  to	  the	  functions	  of	  miR-­‐126	  in	  
the	  tumor	  vasculature	  and	  in	  the	  surrounding	  vessels	  of	  the	  tumor	  periphery.	  
In	   case	   miR-­‐126/miR-­‐126*	   is	   up-­‐regulated	   in	   the	   tumor	   vasculature	   during	   tumor	  
progression,	   this	   might	   promote	   vessel	   neoangiogenesis	   to	   support	   tumor	   growth	   and	  
metastasis;	  vice	  versa,	  if	  it	  is	  down-­‐regulated	  in	  tumor	  vessels,	  this	  might	  lead	  to	  defects	  
in	  the	  vascular	  integrity,	  which	  could	  partially	  explain	  abnormal	  tumor	  vessel	  phenotypes	  
(Fig.	  17).	  	  
Fig.	   17	   Putative	   effects	   of	  
miR-­‐126/miR-­‐126*	   on	   the	  
progression	   of	   cancer.	   (A)	  
High	   levels	   of	   miR-­‐126/miR-­‐
126*	   drive	   proper	   vessel	  
formation	   by	   modulation	   of	  
the	   response	   of	   endothelial	  
cells	   to	   vascular	   growth	  
factors	   and	   restriction	   of	  
leukocyte	   adhesion.	   (B)	   Loss	  
of	   the	   tumor-­‐suppressor	  
miR-­‐126/miR-­‐126*	   during	  
cancer	   progression	   may	  
result	   in	   elevated	   tumor	   cell	  	  
proliferation,	  migration	   	   and	  
survival	   enhanced	   formation	  
of	  metastasis	  and	  an	  increase	  
in	   leukocyte	   adhesion	  
followed	   by	   their	   infiltration	  
into	   the	   vascular	   wall.	  
Further,	  loss	  of	  miR-­‐126/miR-­‐
126*	   might	   disturb	   vascular	  
integrity,	   leading	   abnormal	  
tumor	  vasculature.	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However,	   these	   actions	   remain	   highly	   speculative,	   since	   there	   are	   no	   current	   studies	  
published	  on	  the	  role	  of	  miR-­‐126/miR-­‐126*	  in	  tumor	  neoangiogenesis.	  	  
The	   tumor-­‐suppressive	   functions	   of	   miR-­‐126/miR-­‐126*	   may	   offer	   the	   opportunity	   to	  
utilize	   these	  miRNAs	  as	  novel	   cancer	   therapeutics,	   since	   the	   restoration	  of	  endogenous	  
miR-­‐126/miR-­‐126*	   may	   offer	   help	   to	   directly	   target	   distinct	   pathways	   that	   promote	  
cancer	  progression.	  
It	  might	   also	   be	   an	   alternative	   to	  monoclonal	   antibody–based	   anti-­‐VEGF	   therapies	   like	  
bevacizumab,	   sunitinib,	   and	   sorafenib,	   that	   are	   clinically	   tested,	   but	  whose	   therapeutic	  
benefits	   are	   often	   transient	   and	   followed	   by	   a	   rapid	   restoration	   of	   tumor	   growth	   and	  
progression	  (211).	  	  
In	  conclusion,	  the	  role	  of	  miR-­‐126/miR-­‐126*	  in	  the	  complex	  process	  of	  cancer	  formation	  
remains	  largely	  unknown	  at	  the	  moment.	  In	  the	  future,	  it	  will	  be	  very	  interesting	  to	  study	  
the	   role	  of	  both	  miRNAs	   in	  cancer	  development,	  and	   to	  analyze	  how	  they	  affect	   tumor	  
cells	   themselves	   and	   the	   blood	   vessels	   these	   cells	   attract.	   This	   might	   lead	   to	   the	  
development	  of	  novel	   tools	  that	  simultaneously	   inhibit	   tumor	  cell	  growth	  and	  stimulate	  
the	  maturation	  of	  blood	  vessels.	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  4.	  Aims	  of	  the	  thesis	  
	  
The	  aims	  of	  the	  thesis	  were	  to	  elucidate	  the	  epigenetic	  regulation	  in	  MPM	  of	  the	  tumor	  




1.	   	   To	   analyze	   chromatin	   structural	   changes,	   such	   as	   DNA	   methylation	   status	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
of	  the	  S2	  (an	  alternative	  transcript	  of	  EGFL7)	  CpG	  island	  promoter;	  
	  
2.	  	  	  	  	  	  To	  examine	  level	  of	  DNA	  methylation	  of	  CpG	  islands	  around	  miR-­‐126;	  
	  
3.	   	   	  To	  study	  the	  expression	  of	  EGFL7	  S2	  transcript	  and	  to	  correlate	  this	  results	  with	  the	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5.	  Materials	  and	  methods	  
5.1	  	  	  	  Patients	  samples	  
	  
All	   samples	   analyzed	   in	   this	   work	   originate	   from	   patients	   operated	   for	   MPM	   at	  
Rigshospitalet,	   Copenhagen	   University	   Hospital,	   Denmark	   during	   2007	   –	   2012,	   which	  
represents	  one	  of	  the	  most	  specialized	  center	  for	  MPM	  treatment	  in	  the	  north	  of	  Europe,	  
especially	  in	  the	  Scandinavian	  countries.	  
The	  patients’	  age	  ranged	  from	  33	  to	  78	  years	  with	  a	  median	  age	  of	  65	  years.	  
The	   analyses	   were	   performed	   on	   54	   tissue	   samples	   including	   preoperative	   diagnostic	  
biopsies,	   surgically	   removed	   tumor	   tissue	   and	   (when	   possible)	   surrounding	   patient-­‐
matched	   non-­‐neoplastic	   pleura	   (NNP)	   from	   MPM	   patients	   undergoing	   tri-­‐modal	  
treatment	  	  and	  whose	  clinicopathological	  characteristics	  are	  specified	  in	  table	  II	  and	  table	  
III.	   The	   preoperative	   diagnostic	   biopsies	   used	   in	   this	   work	   were	   collected	   from	   5	   still	  
chemotherapy-­‐naïve	  MPM	  patients	  that	  were	  subsequently	  included	  in	  the	  cohort	  of	  29	  
patients	   undergoing	   tri-­‐modal	   treatment.	   The	   surgical	   tissue	   samples	   included	   MPM	  
specimens	  from	  29	  patients	  and	  patient-­‐matched	  samples	  of	  NNP	  from	  15	  of	  these	  MPM	  
patients	  (in	  the	  other	  14	  patients,	  no	  NNP	  was	  identified	  after	  histological	  investigation	  of	  
resected	   pleural	   tissue).	   Prior	   to	   surgery,	   all	   MPM	   patients	   in	   this	   group	   received	   1-­‐3	  
series	  of	  cisplatin	  and	  pemetrexed.	  All	  of	  the	  surgical	  MPM	  tissue	  samples	  used	  had	  more	  
than	  50%	  tumor	  cell	  content.	  Finally	  we	  also	   included	  pleura	  specimens	  from	  5	  patients	  
with	  non-­‐neoplastic	  RMP	  in	  the	  pleura	  unrelated	  to	  MPM	  or	  any	  other	  cancer,	  but	  due	  to	  
pneumothorax	  (PTHX).	  
All	   the	   above-­‐mentioned	   pleural	   tissue	   samples	   that	   I	   used	   In	   this	   project	   were	   FFPE	  
processed	  for	  routine	  histopathological	  analysis.	  That	  consisted	  of	  formalin-­‐fixation	  of	  DB	  
or	   surgically	   removed	   resected	   pleura	   from	   MPM	   patients,	   sampling	   the	   surgical	  
specimens	  and	  cutting	  them	  into	  representative	  	  pieces	  that	  were	  placed	  into	  embedding	  
capsules	   and	   then	   	   embedded	   into	   paraffin.	   In	   this	  way	   tissue	   samples	   are	   archived	   in	  
paraffin	  blocks	  that	  allow	  tissue	  storage	  for	  following	  histological,	   immunohistochemical	  
and	  molecular	  analyses.	  
FFPE	   tissue	   can	   therefore	   be	   stored	   for	   years	   and	   has	   low	   costs,	   so	   that	   it	   is	   the	  most	  	  
utilized	  type	  of	  specimen	  for	  tissue-­‐based	  research	  all	  over	  the	  world.	  However	  tehre	  are	  
some	  drawbacks	  when	  using	  FFPE	  tissue.	  For	  instance	  the	  quality	  of	  DNA	  and	  RNA	  can	  be	  
reduced	  over	  time	  if	  the	  paraffin	  blocks	  are	  not	  stored	  in	  cooled	  archives.	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In	   addition,	   altough	   	   formalin-­‐fixation	   preserves	   the	   tissue	   for	   years,	   the	   isolated	   DNA	  
might	  be	  fragmented	  and	  cross-­‐linked	  and	  may	  be	  difficult	  to	  amplify	  by	  PCR.	  
	  
Number	  of	  each	  sample	   Stage	   Histological	  
subtype	  of	  MPM	  
NNP	   DB	   PTHX	  
	   	   EMM	   BMM	   	   	   	  
1	   pT4N2M0	   	   X	   	   	   	  
2	   pT3N0M0	   X	   	   	   	   	  
3	   pT3N0M0	   X	   	   	   	   	  
4	   pT3N0M0	   X	   	   	   	   	  
5	   pT3N0M0	   	   X	   	   	   	  
6	   pT1bN0M0	   X	   	   	   	   	  
7	   pT4N0M0	   	   X	   	   	   	  
8	   pT3N1M0	   X	   	   	   	   	  
9	   pT3N2M0	   X	   	   	   	   	  
10	   pT4N0M0	   X	   	   	   	   	  
11	   pT4N0M0	   X	   	   	   	   	  
12	   pT4N0M0	   X	   	   	   	   	  
13	   pT3N0M0	   	   X	   	   	   	  
14	   pT4NOM0	   X	   	   	   	   	  
15	   pT4N0M0	   	   X	   	   	   	  
16	   pT3N0M0	   X	   	   	   	   	  
17	   pT3N0M0	   	   X	   	   	   	  
18	   pT2N2M0	   	   X	   	   	   	  
19	   pT3N0M0	   	   X	   	   	   	  
20	   pT2N0M0	   	   X	   	   	   	  
21	   pT2N0M0	   	   X	   	   	   	  
22	   pT3N0M0	   	   X	   	   	   	  
23	   pT2N0M0	   	   X	   	   	   	  
24	   pT4N0M1	   	   X	   	   	   	  
25	   pT3N0M0	   	   X	   	   	   	  
26	   pT2N0M0	   	   X	   	   	   	  
27	   pT3N0M0	   X	   	   	   	   	  
28	   pT3N0M0	   X	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29	   pT3N2M0	   X	   	   	   	   	  
30	   pT4N2M0	   	   	   X	   	   	  
31	   pT3N0M0	   	   	   X	   	   	  
32	   pT3N2M0	   	   	   X	   	   	  
33	   pT3N0M0	   	   	   X	   	   	  
34	   pT3N0M0	   	   	   X	   	   	  
35	   pT3N0M0	   	   	   X	   	   	  
36	   pT2N0M0	   	   	   X	   	   	  
37	   pT1bN0M0	   	   	   X	   	   	  
38	   pT3N0M0	   	   	   X	   	   	  
39	   pT3N0M0	   	   	   X	   	   	  
40	   pT2N2M0	   	   	   X	   	   	  
41	   pT3N0M0	   	   	   X	   	   	  
42	   pT3N0M0	   	   	   X	   	   	  
43	   pT2N0M0	   	   	   X	   	   	  
44	   pT2N0M0	   	   	   X	   	   	  
45	   pT2N0M0	   	   	   	   X	   	  
46	   pT3N0M0	   	   	   	   X	   	  
47	   pT2N0M0	   	   	   	   X	   	  
48	   pT3N0M0	   	   	   	   X	   	  
49	   pT3N0M0	   	   	   	   X	   	  
50	   	   	   	   	   	   X	  
51	   	   	   	   	   	   X	  
52	   	   	   	   	   	   X	  
53	   	   	   	   	   	   X	  
54	   	   	   	   	   	   X	  
	  
	  
Table	   II	   	   List	   of	   the	   samples	   analyzed	   with,	   histological	   subtype	   and	   stage*.	   MPM:	  
surgically	   removed	   malignant	   pleural	   mesotheliomas;	   EMM:	   histotype	   epithelioid;	  
BMM:	  histotype	  biphasic;	  DB:	  preoperative	  diagnostic	  biopsies;	  NNP:	  patient	  matched	  
non-­‐neoplastic	  pleura;	  PTHX:	  non-­‐neoplastic	  reactive	  mesothelial	  proliferation	  due	  to	  
pneumothorax.	   *Stage	   according	   to	   the	   recommendations	   of	   the	   International	  
Mesothelioma	  Interest	  Group.	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5.2	  	  	  	  DNA	  extraction	  
	  
The	  first	  step	  was	  to	  cut	  the	  paraffin-­‐embedded	  tissue	  samples	  into	  4	  x	  10	  μm	  thick	  slices	  
on	  a	  microtome	  that	  were	  placed	   in	  1.5	  ml	  sterile	  Eppendorf	  tubes.	   It	  was	  necessary	  to	  
use	  2	  tubes	  for	  each	  FFPE	  tissue	  block,	  one	  for	  DNA	  and	  the	  other	  for	  RNA	  purification.	  
Before	  the	  DNA	  purification,	  paraffin	  was	  removed	  from	  tissues	  (deparaffinization)	  tissues	  
by	  xylene	  in	  order	  to	  facilitate	  the	  release	  of	  DNA	  from	  cells.	  
For	   the	  DNA	  purification	   kit	   the	  QIAmp	  DNA	  minikit	   from	  Quiagen	  was	  used	   to	   extract	  
DNA	  and	  I	  tried	  to	  do	  it	  both	  manually	  and	  automatically	  on	  a	  Quiacube	  system.	  
DNA	   purification	   technique	   took	   about	   2	   days	   including	   an	   overnight	   incubation	   with	  
proteinase	  K	  and	  two	  different	  washing	  buffers	  were	  used	  to	   increase	   the	  purity	  of	   the	  
DNA	  because	   they	  remove	  contaminations	   that	  might	  be	  present,	  without	  affecting	   the	  
DNA.	  
The	  complete	  protocol	  was	  the	  following:	  
Day	  1	  
1. Switch	  on	  the	  heating	  block	  at	  37°C.	  
2. Add	  1000	  (1200)	  μl	  xylene	  to	  the	  tissue	  and	  vortex	  (deparaffinization	  step).	  
3. Centrifuge	  at	  20000x	  g	  (14000	  rpm)	  for	  5	  min.	  
4. Gently	  remove	  supernatant	  by	  pipetting.	  
5. Add	  1000	  (1200)	  μl	  96-­‐100%	  ethanol	  to	  remove	  residual	  xylene	  and	  vortex.	  
6. Centrifuge	  at	  20000x	  g	  (	  14000	  rpm)	  for	  5	  min.	  
Table	  III	  	  Data	  and	  percentages	  regarding	  the	  patients	  examined. 
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7. Carefully	  remove	  supernatant	  (ethanol)	  by	  pipetting.	  
8. Repeat	  steps	  5-­‐7.	  
9. Incubate	  in	  the	  heating	  block	  for	  15	  min.	  and	  check	  whether	  it	  is	  evaporated.	  
10. Resuspend	  the	  tissue	  pellet	  in	  180	  μl	  Buffer	  ATL.	  
11. Add	  20	  μl	  of	  proteinase	  K	  and	  vortex.	  (Proteinase	  K	  is	  for	  degradation	  of	  the	  cell	  
membranes).	  
12. Incubate	  in	  the	  heating	  block	  and	  shake	  over	  night	  at	  56°C.	  
Day	  2:	  can	  be	  done	  manually	  or	  using	  the	  QuiaCube	  system.	  
1. Briefly	  centrifuge	  to	  remove	  drops	  from	  the	  inside	  of	  the	  lid.	  
2. Add	  200	  μl	  AL	  Buffer	  and	  vortex	  for	  15	  sec.	  to	  get	  an	  homogeneous	  solution.	  
3. Incubate	  at	  70°C	  for	  10	  min.	  
4. Briefly	  centrifuge.	  
5. Add	  200	  μl	  96-­‐100%	  ethanol	  and	  vortex	  for	  15	  sec.	  
6. Briefly	  centrifuge.	  
7. Carefully	  apply	  the	  mixture	  from	  step	  6	  to	  the	  column	  without	  touching	  the	  rim.	  
8. 	  Centrifuge	  at	  6000x	  g	  (8000	  rpm)	  for	  2	  min.	  
9. Discard	  the	  excess	  of	  liquid.	  
10. Add	  500	  μl	  AW1	  Buffer	  (washing	  buffer)	  without	  wetting	  the	  rim.	  	  
11. Centifuge	  at	  6000x	  g	  (8000	  rpm)	  for	  2	  min.	  
12. Discard	  the	  excess	  of	  liquid.	  
13. Add	  500	  μl	  AW2	  Buffer	  without	  wetting	  the	  rim.	  
14. Centrifuge	  at	  20000x	  g	  (14000	  rpm)	  for	  4	  min.	  
15. Discard	  the	  excess	  of	  liquid.	  
16. Centrifuge	  at	  20000x	  g	  (14000	  rpm)	  for	  2	  min.	  
17. Place	  the	  column	  in	  a	  new	  collection	  tube.	  
18. Add	  50	  μl	  AE	  Elution	  Buffer	  without	  touching	  the	  rim.	  This	  step	  increase	  the	  DNA	  
yield	  with	  15%.	  
19. Incubate	  for	  5	  minutes	  at	  room	  temperature	  to	  increase	  the	  DNA	  yield.	  
20. Centrifuge	  at	  6000x	  g	  (8000	  rpm)	  for	  2	  min.	  
21. 	  Repeat	  steps	  18-­‐20.	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5.2.1	  	  DNA	  quantification	  and	  quality	  analysis	  
	  
In	  molecular	  biological	   studies,	  quantitation	  of	  nucleic	  acids	  is	  commonly	  used	   to	  detect	  
their	   average	   concentrations,	   as	  well	   as,	   its	   purity.	   Reactions	   that	   utilize	  DNA	  and	  RNA	  
often	   require	   particular	   quantity	   and	   purity	   for	   optimal	   performance.	   There	   are	   many	  
methods	   to	   identify	   the	   concentration	   of	   a	   solution	   of	   nucleic	   acids,	   including	  
spectrophotometrical	   quantification	   that	   I	   used	   in	   my	   work.	   Using	   the	  
spectrophotometer,	   samples	   are	   exposed	   to	   ultraviolet	   light	   at	   260	   nm,	   and	   a	   photo-­‐
detector	  measures	   the	   light	   that	  passes	   through	   them.	  The	  more	   light	  absorbed	  by	   the	  
samples,	   the	   higher	   the	   nucleic	   acid	   concentration	   in	   the	   samples.	   Utilizing	   the	   Beer	  
Lambert	   law	  it	   is	   possible	   to	   obtain	   the	   amount	   of	   light	   absorbed	   related	   to	   the	  
concentration	  of	  the	  absorbing	  molecule.	  	  
The	  concentration	  and	  the	  quality	  of	  nucleic	  acids	  was	  	  determined	  in	  this	  case	  using	  the	  
spectrophotometer	   UV-­‐visible	   NanoDrop	   2000	   (Fig.	   18).	   	   Initially	   I	   loaded	   2	   μl	   of	  
DNase/RNase-­‐free	   water	   to	   get	   a	   blank	  
measurement	   on	   a	   special	   plate	   reader	   that	  
creates	  a	   column	  of	   liquid	   in	  direct	   contact	  with	  
optical	   fibers	   and	   subsequently	   I	   performed	   the	  
measurements	   of	   each	   sample	   loading	   2	   μl	   of	  
solution.	   In	   this	   way	   it	   was	   possible	   to	   obtain	  
the	  absorbance	  and	   then	  directly	  estimate	   the	  
DNA	   concentration.	   The	   purity,	   instead,	   was	  
evaluated	   considering	   the	   ratio	   of	   A260/A280	  
absorbance,	   where	   280	   nm	   is	   the	   wavelength	  
at	   which	   proteins	   absorb.	   This	   ratio	   should	  
optimally	   lie	   between	   1.8	   and	   2	   for	   samples	  
without	   contamination	   with	   other	   molecules	  







Fig.	   18	  The	   surface	   tension	   is	  used	   to	  
maintain	   the	   liquid	   sample	   on	   the	  
column	   of	   spectrophotometer	   UV-­‐
visible	   NanoDrop	   2000	   while	   the	  
measurement	   is	   made.	   This	   is	  
achieved	   by	   pipetting	   the	   sample	  
directly	  on	  the	  base	  of	  measurement.	  
The	   measurement	   is	   revealed	   thanks	  
to	   two	   optical	   fibers	   in	   less	   than	   10	  
seconds	   and	   the	   spectrum	   and	   its	  
analysis	   are	   displayed	   on	   the	   PC.	  
screen.	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5.2.2	  	  Bisulfite	  conversion	  of	  DNA	  
	  
The	   analysis	   of	   DNA	   methylation	   was	   revolutionized	   in	   1992	   by	   the	   introduction	   of	  
sodium	  bisulfite	  conversion	  of	  genomic	  DNA	  (212).	  
Sodium	  bisulfite	   converts	   unmethylated	   cytosines	   into	   uracils	  while	   leaving	  methylated	  
cytosines	   intact,	   therefore	   this	   treatment	   gives	   rise	   to	   different	   DNA	   sequences	   for	  
methylated	  and	  unmethylated	  DNA	  (Fig	  19).	  The	  nucleotide	  differences	  are	  then	  detected	  
by	  pyrosequencing,	  restriction	  enzyme	  analysis,	  PCR,	  and	  other	  methods.	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
The	  most	  critical	  step	  for	  correct	  determination	  of	  a	  methylation	  pattern	  is	  the	  complete	  
conversation	  of	  unmethylated	  cytosines.	  This	   is	  achieved	  by	   incubating	   the	  DNA	   in	  high	  
bisulfite	   salt	   concentrations	   at	   high	   temperature	   and	   low	   pH.	   These	   harsh	   conditions	  
usually	   lead	  to	  a	  high	  degree	  of	  DNA	  fragmentation	  and	  subsequent	   loss	  of	  DNA	  during	  
purification.	  Purification	  is	  necessary	  to	  remove	  bisulfite	  salts	  and	  chemicals	  used	  in	  the	  
conversion	  process	  that	  inhibit	  sequencing	  procedures.	  
In	  my	  studies,	  the	  Epitect	  Bisulfite	  kit	  from	  Quiagen	  was	  used	  for	  the	  bisulfite	  conversion.	  	  
Before	  the	  start	  of	  bisulfite	  conversion	  I	  calculated	  the	  appropriate	  amount	  of	  DNA	  to	  be	  
used	  starting	  from	  the	  initial	  concentrations	  therefore.	  	  	  
In	  this	  work	  100	  ng	  DNA	  was	  used	  for	  each	  sample.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Fig.	   19	   Treatment	   of	   genomic	   DNA	   with	   sodium	   bisulfite	   deaminates	   unmethylated	  
cytosine	   residues	   to	   uracil	  while	   5-­‐methylcytosine	   (in	   red)	   remains	   unaffected.	   After	  
bisulfite	   conversion	   the	   newly	   inserted	   sequence	   differences	   can	   be	   analyzed	   by	  
several	  different	  methods.	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DNA	   fragmentation	   is	   prevented	   during	   the	   bisulfite	   conversion	   reaction	   by	   the	   DNA	  
Protect	   Buffer,	   which	   contains	   a	   pH-­‐indicator	   dye	   as	   a	   mixing	   control	   in	   the	   reaction	  
setup,	  allowing	  confirmation	  of	  the	  correct	  pH	  for	  cytosine	  conversion.	  
Furthermore,	   the	   bisulfite	   thermal	   cycling	   program	   provides	   an	   optimized	   series	   of	  
incubation	   steps	   necessary	   for	   thermal	   DNA	   denaturation	   and	   subsequent	   sulfonation	  
and	   cytosine	   deamination,	   enabling	   hich	   cytosine	   conversion	   rates	   of	   over	   99%.	  
Desulfonation,	   the	   final	   step	   in	   chemical	   conversion	   of	   cytosines	   is	   achieved	   by	   a	  



























Fig.	  20	  Epitect	  Converstion	  Procedure.	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The	   entire	   protocol	   for	   FFPE	   (fomalin-­‐fixed,	   paraffin-­‐embedded)	   tissue	   samples	   that	   I	  
used	  was	  the	  following:	  
1. Thaw	  DNA	   to	  be	  used	   in	   the	  bisulfite	   reaction.	  Dissolve	   the	   required	  number	  of	  
Bisulfite	  Mix	   aliquots	  by	  adding	  800	  μl	  Rnase-­‐free	  water	   to	  each	  aliquot.	  Vortex	  
until	  the	  Bisulfite	  Mix	  is	  completely	  dissolved.	  This	  can	  take	  up	  5	  min.	  
2. Prepare	  the	  bisulfite	  reaction	  in	  200	  μl	  PCR	  tubes	  according	  to	  table	  IV.	  Add	  each	  
component	  in	  the	  order	  listed.	  
	  
Component	   Volume	  per	  reaction	  (μl)	  
DNA	  solution	  (100	  ng)	   Variable	  (maximum	  20	  μl)	  
Rnase-­‐free	  water	   Variable	  
Bisulfite	  Mix	  dissolved	   85	  
DNA	  Protect	  Buffer	   35	  
Total	  volume	   140	  
	  
	  
3. Close	   the	   PCR	   tubes	   and	   mix	   the	   bisulfite	   reactions	   thoroughly.	   Store	   tubes	   at	  
room	  temperature	  (15-­‐25°C).	  
4. Perform	  the	  bisulfite	  DNA	  conversion	  using	  a	  thermal	  cycler.	  Program	  the	  thermal	  
cycler	  according	  to	  table	  V.	  
Step	   Time	   Temperature	  
Denaturation	   5	  min.	   95°C	  
Incubation	   25	  min.	   60°C	  
Denaturation	   5	  min.	   95°C	  
Incubation	   85	  min.	  (1	  h	  25	  min)	   60°C	  
Denaturation	   5	  min.	   95°C	  
Incubation	   175	  min.	   60°C	  
Hold	   60	  min.	   20°C	  
	  
	  
5. Place	  the	  PCR	  tube	  containing	  the	  bisulfite	  reactions	  into	  the	  thermal	  cycler.	  Start	  
the	  thermal	  cycling	  incubation.	  
6. Once	   the	   bisulfite	   conversion	   is	   complete,	   briefly	   centrifuge	   the	   PCR	   tube	  
containing	   the	   bisulfite	   reactions,	   and	   then	   transfer	   the	   complete	   bisulfite	  
reactions	  to	  clean	  1.5	  ml	  microcentrifuge	  tubes.	  
Table	  IV	  Bisulfite	  reaction	  components.	  
Table	  V	  Bisulfite	  conversion	  thermal	  cycler	  conditions.	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7. Add	   560	   μl	   freshly	   prepared	   Buffer	   BL	   containing	   10	   μg/ml	   carrier	   RNA	   to	   each	  
sample.Mix	  the	  solutions	  by	  vortexing	  and	  then	  centrifuge	  briefly.	  
8. Add	   250	   μl	   ethanol	   (96–100%)	   to	   each	   sample.	   Mix	   the	   solutions	   by	   pulse	  
vortexing	  for	  15	  sec.,	  and	  centrifuge	  briefly	  to	  remove	  the	  drops	  from	  inside	  the	  
lid.	  
9. Place	   the	   necessary	   number	   of	   EpiTect	   spin	   columns	   and	   collection	   tubes	   in	   a	  
suitable	   rack.	   Transfer	   the	   entire	   mixture	   from	   the	   tubes	   in	   step	   7	   into	   the	  
corresponding	  EpiTect	  spin	  columns.	  
10. Centrifuge	   the	   spin	   columns	   at	   maximum	   speed	   for	   1	   min.	   Discard	   the	   flow-­‐
through,	  and	  place	  the	  spin	  columns	  back	  into	  the	  collection	  tubes.	  
11. Add	   500	   μl	   Buffer	   BW	   (wash	   buffer)	   to	   each	   spin	   column,	   and	   centrifuge	   at	  
maximum	  speed	  for	  1	  min.	  Discard	  the	  flow-­‐through,	  and	  place	  the	  spin	  columns	  
back	  into	  the	  collection	  tubes.	  
12. Add	  500	  μl	  Buffer	  BD	  (desulfonation	  buffer)	  to	  each	  spin	  column,	  and	  incubate	  for	  
15	  min.	  at	  room	  temperature	  (15–25°C).	  
13. Centrifuge	   the	   spin	   columns	   at	   maximum	   speed	   for	   1	   min.	   Discard	   the	   flow-­‐
through,	  and	  place	  the	  spin	  columns	  back	  into	  the	  collection	  tubes.	  
14. Add	  500	  μl	  Buffer	  BW	  to	  each	  spin	  column	  and	  centrifuge	  at	  maximum	  speed	  for	  1	  
minute.	   Discard	   the	   flow-­‐through,	   and	   place	   the	   spin	   columns	   back	   into	   the	  
collection	  tubes.	  
15. 	  Repeat	  step	  13	  once.	  
16. Place	   the	   spin	   columns	   into	   new	   2	  ml	   collection	   tubes,	   and	   centrifuge	   the	   spin	  
columns	  at	  maximum	  speed	  for	  1	  minute	  to	  remove	  any	  residual	  liquid.	  
17. 	  Recommended:	   Place	   the	   spin	   columns	   with	   open	   lids	   into	   clean	   1.5	   ml	  
microcentrifuge	  tubes,	  and	   incubate	   the	  columns	   for	  5	  min.	  at	  56°C	   in	  a	  heating	  
block.	  
18. Place	   the	   spin	   columns	   into	   clean	   1.5	  ml	  microcentrifuge	   tubes.	   Dispense	   20	   μl	  
Buffer	   EB	   onto	   the	   center	   of	   each	   membrane.	   Elute	   the	   purified	   DNA	   by	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5.2.3	  	  Methylation	  sensitive	  PCR	  (MSP)	  
	  
Methylation	  sensitive	  PCR	  (MSP)	  is	  widely	  used	  to	  study	  the	  methylation	  status	  of	  specific	  
CpG	  sites	  of	  genome	  given	  its	  flexibility,	  its	  relative	  ease	  and	  its	  cost-­‐efficiency.	  
The	   basic	   principle	   of	   this	   techinique	   is	   PCR-­‐based	   discrimination	   between	  methylated	  
and	   unmethylated	   DNA	   in	   bisulfite	   converted	   DNA,	   taking	   advantage	   of	   the	   bisulfite-­‐
induced	  nucleotide	  sequence	  differences	  (Fig.	  21).	  Two	  sets	  of	  primers	  can	  be	  used	  in	  two	  
separate	  reactions:	  	  One	  primer	  set	  is	  complementary	  to	  methylated	  DNA	  (M-­‐MSP	  reaction)	  
while	   the	   other	   primer	   set	   is	   specifically	   complementary	   to	   unmethylated	   DNA	   (U-­‐MSP	  
reaction).	   Finally	   the	   PCR	   products	   are	   then	   analyzed	   manually	   by	   ethidium	   bromide-­‐
stained	  agarose	  gel	  electrophoresis	  or	  automatically	  by	  QIAxcel	  system	  advanced.	  	  
MSP	   requires	   only	   small	   quantities	   of	   DNA	   as	   starting	   template	   and	   represents	   an	  
extremely	  sensitive	  method.	  	  
Probably	  this	  sensitivity	  is	  both	  a	  strength	  and	  a	  weakness.	  	  
MSP	   is	   useful	   as	   a	   screening	   tool	   as	   a	   negative	   M-­‐MSP	   reaction	   suggests	   absence	   of	  
methylation.	   However,	   the	   method	   is	   at	   best	   semi-­‐quantitative	   and	   a	   positive	   M-­‐MSP	  
reaction	  generally	  could	  be	  unable	  to	  distinguish	  between	  samples	  with	  high	  and	  low	  levels	  of	  
methylation.	  	  
	  
Fig.	  21	  Genomic	  DNA	   is	   treated	  with	  bisulfite	   (1)	  and	  used	  as	   template	   in	  a	   two	  PCR	  
reaction,	  each	  containing	  primers	  designed	  to	  amplify	  methylated	  (M)	  or	  unmethylated	  
(U)	   sequences	   (2).	   PCR	   products	   are	   then	   analyzed	   by	   ethidium	   bromide-­‐stained	  
agarose	  gel	  electrophoresis	  (3).	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In	   this	   project	   I	   analyzed	  with	   the	   Epitect	  MSP	   kit	   from	  Quiagen	   the	   DNA	  methylation	  
status	  of	  the	  S2	  (the	  longer	  alternative	  transcript	  of	  EGFL7)	  CpG	  island	  promoter	  (Fig.	  22)	  
in	  all	  samples	  and	  the	  sequence	  of	  the	  primers	  methylated	  or	  unmethylated	  were:	  
§ 5’-­‐TTGGCGGTCGGTTTGGTC-­‐3’	  (methylated	  forward)	  
§ 5’-­‐TAAAACCCCGCGACGAACG-­‐3’	  (methylated	  reverse)	  
§ 5’-­‐TTGGTTTTTGGTGGTTGGGTTTGGTT-­‐3’	  (unmethylated	  forward)	  
§ 5’-­‐CAAACAAAAAAACTAAAACCCCACAACAAACA-­‐3’	  (unmethylated	  reverse)	  
	  
In	  addition	  I	  used	  The	  EpiTect	  PCR	  Control	  DNA	  to	  ensure	  that	  PCR	  primers	  are	  specific	  for	  
the	  detection	  of	  methylated	  or	  unmethylated	  bisulfite	  converted	  DNA	  and	  for	  controlling	  
the	  bisulfite	  conversion.	  	  
The	  set	  consisted	  of	  two	  different	  types	  of	  human	  DNA:	  
■	  Completely	  unmethylated	  human	  genomic	  DNA	  —	  bisulfite	  converted	  
■	  Completely	  methylated	  human	  genomic	  DNA	  —	  bisulfite	  converted.	  
Each	   type	   of	   DNA	   was	   used	   to	   show	   the	   specificity	   of	   the	   PCR	   and	   to	   determine	   the	  







Fig.	   22	   Three	   transcription	   start	   site	   were	   found	   (S1,	   S2,	   S3)	   are	   present	   in	   EGFL7	  
gene.	  MiR-­‐126	  (arrowhead)	  is	  embedded	  within	  intron	  7	  of	  the	  EGFL7	  gene.	  The	  bent	  
arrow	  indicate	  transcription	  start	  site	  of	  S2	  and	  S3,	  whereas	  the	  dotted	  bent	  arrow	  
indicates	   the	   full	   length	   start	   site	   (S1).	   The	   white	   box	   indicates	   exon	   1	   of	   the	   S2	  
alternative	  transcript	  of	  EGFL7.	  	  The	  black	  bars	  indicate	  CpG	  islands.	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The	  complete	  protocol:	  
1. Mix	  the	  EpiTect	  Master	  Mix	  by	  vortexing	  briefly	  and	  dispense	  12.5	  μl	  into	  each	  
PCR	  tube	  according	  to	  table	  VI.	  
2. Add	  the	  diluted	  primer	  mix	  into	  the	  PCR	  tubes	  containing	  the	  master	  mix.	  
3. Add	  template	  DNA	  and	  RNase-­‐free	  water	  to	  the	  individual	  PCR	  tubes.	  
4. Program	  the	  thermal	  cycler	  according	  to	  table	  VII.	  
	  
Step	   Time	   Temperature	  
Inizial	  activation	  step:	   10	  min.	  	  	  	  	   95°C	  
3-­‐step	  cycling:	   	   	  
Denaturing:	   15	  sec.	  	  	  	  	  	   94°C	  
Annealing:	   30	  sec.	  	  	  	  	  	   50-­‐55°C	  
Extension:	   30	  sec.	  	  	  	  	   72°C	  
Number	  of	  cycles:	   30-­‐40	   	  
Final	  extension	   10	  min.	  	  	  	  	  	   72°C	  
	  
	  
5. Place	  the	  PCR	  tubes	  in	  the	  thermal	  cycler	  and	  start	  the	  cycling	  program.	  









Component	   Volume	  per	  reaction	  (μl)	  
Epitect	  Master	  mix	  	   12.5	  	  
Primer	  A	   0.75	  	  
Primer	  B	   0.75	  	  
Template	  DNA	  	   5	  	  
RNase-­‐free	  water	   6	  	  
Total	  volume	   25	  
Table	  VI	  Reaction	  composition	  using	  Epitect	  MSP	  Master	  Mix.	  
Table	  VII	  Optimized	  cycling	  protocol.	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5.2.4	  	  PCR	  of	  bisulfite-­‐treated	  DNA	  for	  pyrosequencing	  
	  
In	  order	   to	  analyze	  methylation	  of	   the	  CpG	   islands	  around	  miR-­‐126,	  DNA	  samples	  were	  
amplified	  by	  PCR	  with	  specific	  primers,	   in	  which	  one	  of	  them	  was	  labelled	  with	  biotin	  in	  
the	  5´-­‐end	  (required	  for	  pyrosequencing	  analysis).	  
A	  negative	  control	  was	  included	  in	  every	  PCR	  performed	  and	  the	  specific	  product	  size	  had	  
to	  be	  230	  bp	  and	  the	  sequence	  of	  the	  primers	  used	  were:	  
§ 5’-­‐GGAGTTTTATATTAGTTAAGAAGGTAGAAG-­‐3’	  (forward)	  
§ 5-­‐/6Bio/ACCACCCTAAAAAAAATCAAAACTAAAATC-­‐3’	  (reverse)	  
	  
The	  complete	  protocol	  that	  I	  utilized	  was	  the	  following:	  
1. Mix	  the	  Master	  Mix	  by	  vortexing	  briefly	  and	  dispense	  10	  μl	  into	  each	  
PCR	  tube	  according	  to	  table	  VIII.	  
2. Add	   the	   appropriate	   volume	   of	   the	   diluted	   primer	   mix	   into	   the	   PCR	   tubes	  
containing	  the	  master	  mix.	  
3. Add	  template	  DNA	  and	  RNase-­‐free	  water	  to	  the	  individual	  PCR	  tubes.	  
4. Program	  the	  thermal	  cycler	  according	  to	  table	  IX	  .	  
Step	   Time	   Temperature	  
Inizial	  activation	  step:	   10	  min.	  	  	  	  	  	   95°C	  
3-­‐step	  cycling:	   	   	  
Denaturing:	   15	  sec.	  	  	  	  	  	   94°C	  
Annealing:	   30	  sec.	  	   50-­‐55°C	  
Extension:	   30	  sec.	  	  	  	  	   72°C	  
Number	  of	  cycles:	   30-­‐40	   	  
Final	  extension	   10	  min.	  	  	  	  	  	   72°C	  
	  
	  
5. Place	  the	  PCR	  tubes	  in	  the	  thermal	  cycler	  and	  start	  the	  cycling	  program.	  
6. Analyze	  7	  μl	  of	  DNA	  product	  with	  QuiAxcel	  system	  advanced.	  
Component	   Volume	  per	  reaction	  (μl)	  
Master	  mix	  	   10	  
Primer	  A	   1	  
Primer	  B	   1	  	  
Template	  DNA	  	   2	  	  
RNase-­‐free	  water	   6	  	  
Total	  volume	   20	  
Table	  VIII	  Reaction	  composition	  of	  PCR.	  
Table	  IX	  Optimized	  cycling	  protocol.	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5.2.5	  	  Pyrosequencing	  
	  
Pyrosequencing	  was	   developed	   as	   a	   real-­‐time	   and	   sensitive	  method	   to	   have	   quantitive	  
measures	   in	   various	   developmental	   and	  pathological	   situations	   and	  nowadays	   it	   is	   also	  
widely	  used	  as	  analysis	  platform	  for	  various	  biological	  and	  diagnostic	  applications,	  such	  as	  
routine	   (multiplex)	   genotyping	   of	   single	   nucleotide	   polymorphisms	   (SNPs),	   bacterial	  
typing,	  or	  mutation	  detection.	  	  
Pyrosequencing	  uses	  biochemical	  reactions	  in	  which	  there	  are	  a	  balanced	  mixture	  of	  four	  
enzymes	   and	   the	   basic	   technique	   is	   based	   on	   incorporation,	   monitored	  
bioluminometrically,	   of	   new	   complementary	   nucleotides	   that	   are	   released	   in	   a	   pre-­‐
determined	   order;	   when	   the	   correct	   nucleotide	   is	   released,	   it	   binds	   to	   the	   template	  
strand	   by	   the	   Klenow	   fragment	   of	   the	   Escherichia	   coli	   DNA	   polymerase	   I,	   releasing	  
pyrophosphate.	  
The	   latter	   is	   used	   by	   an	   ATP	   sulfurylase	   (isolated	   from	   Saccharomyces	   cerevisiae)	   to	  
produce	   ATP	   from	   adenosine-­‐5’-­‐phosphosulfate	   and	   this	   ATP	   provides	   the	   necessary	  
energy	   for	   the	   luciferase	   (isolated	   from	   Photinus	   pyralis)	   to	   oxidize	   D-­‐luciferin.	   The	  
product	  oxyluciferin	   is	   generated	   in	   an	  excited	   state,	  which	  decays	   to	   the	  ground	   state	  
with	   the	   emission	   of	   a	   photon	   that	   can	   be	   detected	   by	   a	   charge-­‐coupled	   device	   (CCD)	  
camera.	  
Unincorporated	  nucleotides	  as	  well	  as	  excess	  ATP	  are	  degraded	  prior	   to	  addition	  of	   the	  
next	  nucleotide	  by	  an	  apyrase	  (isolated	  from	  Solanum	  tuberosum).	  
The	   intensity	  of	   the	  bioluminometric	   response	   is	  directly	  proportional	   to	   the	  amount	  of	  
incorporated	   nucleotides,	   that	   is,	   a	   peak	   corresponding	   to	   the	   incorporation	   of	   two	  
consecutive	   (and	   identical)	   nucleotides	   will	   have	   the	   double	   height	   compared	   to	   the	  
signal	  of	  a	  single	  nucleotide	  incorporation.	  	  
The	  peak	  heights	   in	   the	   resulting	  output	   format,	   termed	  pyrogram,	   thus	   inform	  on	   the	  
extent	  of	  homopolymeric	  sequences	  and	  proportions	  of	  alleles	  can	  be	  deduced	  from	  the	  











In	   contrast	   to	   conventional	   Sanger	   sequencing	   that	   uses	   a	   mixture	   of	   the	   four	  
fluorescently	   labelled	   terminating	   dideoxy-­‐nucleotides	   (ddNTPs)	   and	   strand	   elongating	  
deoxy-­‐nucleotides	   (dNTPs),	  only	  one	  nucleotide	   is	  dispensed	  at	  a	   time	  by	  an	   inkjet-­‐type	  






Fig.	  23	  The	  priciple	  of	  Pyrosequencing.	  	  
1. Nucleotides	  A,	  G,	  F	  and	  T	  are	  dispensed	  in	  sequence.	  For	  each	  nucleotide	  
incorporation,	  a	  pyrophosphate	  molecule	  is	  released.	  
2. An	  enzyme	  cascade	  reaction	  generates	  a	  light	  signal	  proportional	  to	  the	  
amount	  of	  pyrophosphate	  released.	  
3. The	  light	  signal	  is	  displayed	  as	  a	  peak	  in	  the	  Pyrogram	  trace	  
4. Excess	  nucleotides	  and	  ATP	  are	  degraded	  before	  the	  next	  nucleotide	  
dispensation.	  
5. Pyrogram	  trace	  shows	  the	  DNA	  sequence	  of	  the	  template’s	  complement	  
strand.	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The	  carefully	  optimized	  interplay	  of	  the	  kinetics	  of	  the	  four	  enzymes	  ensures	  that	  at	  most	  
one	  nucleotide	  is	  present	  at	  any	  time	  in	  the	  reaction	  mixture	  permitting	  clear	  assignment	  
of	  the	  light	  signal	  to	  the	  incorporation	  of	  a	  specific	  nucleotide	  and	  thereby	  reconstruction	  
of	  the	  sequence	  synthesized	  by	  the	  iterative	  addition	  of	  nucleotides.	  	  
The	  dispensation	  order	  of	  nucleotides	  can	  either	  be	  predefined	  for	  the	  analysis	  of	  known	  
sequences	  or	  consist	  of	  cyclic	  ACGT	  dispensations	  for	  de	  novo	  sequencing.	  	  
The	  procedure	  of	   the	  pyrosequencing	   assay	   is	   simple	   and	   robust	   and	   results	   are	  highly	  
reproducible.	   The	   instrument	   provides	   a	   great	   flexibility	   performing	   either	   different	  
assays	  (up	  to	  24)	  in	  parallel	  or	  analyzing	  up	  to	  96	  samples	  with	  one	  specific	  assay.	  	  
Pyrosequencing	  is	  also	  a	  flexible	  method	  and	  it	  can	  be	  used	  also	  for	  the	  analysis	  of	  DNA	  
methylation	   in	   CpG-­‐rich	   regions	   (Fig.	   24);	   indeed	   it	   has	   allowed	   to	   identify	   and	   study	  
aberrant	  gene	  methylation	   in	  many	  tumours	  and	   in	   the	   imprinting	  disorders,	   showing	  a	  





















Fig.	   24	   An	   example	   of	   a	   DNA	   sequence	   and	   its	   conversion	   by	   bisulfite	  
treatment	   and	   further	   amplification	   by	   PCR.	   By	   Pyrosequencing	   analysis,	  
unmethylated	  Cytosine	   (C)	   is	  measured	  as	   the	   relative	   content	  of	   T	   at	   the	  
CpG	  site,	  and	  methylated	  Cytosine	  (mC)	  is	  measured	  as	  relative	  content	  of	  C	  
at	  the	  CpG	  site.	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Using	  the	  pyrosequensing	  technology,	  the	  protocol	  for	  DNA	  methylation	  analysis	  can	  be	  
subdivided	  into	  different	  steps	  and	  in	  my	  work	  I	  utilized	  the	  Pyromark	  Q24	  CpG	  kit	  from	  
Quiagen	  to	  analyze	  CpG	  islands	  around	  miR-­‐126	  in	  bisulfite-­‐treated	  DNA	  samples	  (Fig	  25).	  
	  
A	   positive	   control	   was	   included	   in	   every	   reaction	   performed	   and	   the	   sequence	   of	   the	  
annealing	  pyrosequencing	  primer	  used	  for	  the	  study	  was:	  	  
1. 5’-­‐ATTAGTTAAGAAGGTAGAAGT-­‐3’	  
	  
The	  entire	  protocol	  applied	  was	  the	  following:	  
1. Set	  up	  an	  assay	  to	  analyze	  the	  CpG	  around	  miR-­‐126	  by	  using	  the	  PyroMark	  Q24	  
Software.	  
2. Gently	  shake	  the	  bottle	  containing	  streptavidin	  sepharose	  Hp	  beads	  until	  a	  
homogenous	  suspension	  is	  obtained.	  
3. For	  each	  sample,	  prepare	  a	  solution	  for	  DNA	  immobilization	  as	  describe	  in	  table	  X.	  
Commponent	   Volume	  per	  reaction	  (μl)	  
Streptavidin	  Sepharose	  HB	  beads	   2	  
PyroMark	  Binding	  Buffer	   40	  
Rnase-­‐free	  water	   0.75	  	  
PCR	  product	   20	  
Total	  volume	   80	  
Fig.	  25	  Outline	  of	  the	  different	  steps	  of	  the	  pyrosequencing	  procedure	  of	  CpG	  islands.	  
A	   target	   region	   is	   amplified	   with	   one	   of	   the	   two	   primers	   being	   biotinylated.	   The	  
biotinylated	   strand	   is	   captured	   on	   streptavidin-­‐coated	   sepharose	   beads	   which	   are	  
retained	   on	   the	   filter	   plate	  while	   the	   non-­‐biotinylated	   strand	   is	   washed	   off	   under	  
denaturing	  conditions.	   In	   the	  end	  a	   sequencing	  primer	   is	  annealed	   to	   the	   template	  
strand	  for	  the	  pyrosequencing	  reaction.	  
Table	  X	  DNA	  immobilization	  components.	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4. Seal	  the	  PCR	  plate	  using	  strip	  caps.	  	  
5. Agitate	   the	   PCR	   plate	   constantly	   for	   5-­‐10	   min.	   at	   room	   temperature	   (15-­‐25°C)	  
using	  a	  mixer	  (1400	  rpm).	  
6. Add	  1	  μl	  diluted	  sequencing	  primer	  and	  24	  μl	  Annealing	  Buffer	  to	  each	  well	  to	  be	  
analyzed	  on	  the	  PyroMark	  Q24	  Plate.	  
7. Place	  the	  PCR	  plate	  and	  PyroMark	  Q24	  Plate	  in	  the	  workstation	  (Fig.	  26)	  
8. Apply	  vacuum	  to	  the	  tool	  by	  opening	  the	  vacuum	  switch.	  
9. Carefully	  lower	  the	  filter	  probes	  into	  the	  PCR	  plate	  (or	  strips)	  to	  capture	  the	  beads	  
containing	   immobilized	   template.	   Hold	   the	  
probes	   in	  place	   for	  15	   sec.	   Take	   care	  when	  
picking	  up	  the	  tool.	  
10. Transfer	   the	   tool	   to	   the	   trough	   containing	  
70	   %	   ethanol	   (trough	   1).	   Flush	   the	   filter	  
probes	  for	  5	  sec.	  
11. Transfer	   the	   tool	   to	   the	   trough	   containing	  
Denaturation	   solution	   (trough	   2).	   Flush	   the	  
filter	  probes	  for	  5	  sec.	  
12. Transfer	   the	   tool	   to	   the	   trough	  containing	  Wash	  
Buffer	  (trough	  3).	  Flush	  the	  filter	  probes	  for	  10	  sec.	  
13. Raise	  the	  tool	  to	  beyond	  90°	  vertical	  for	  5	  sec.,	  
to	  drain	  liquid	  from	  the	  filter	  probes	  (Fig.	  27).	  
14. While	  holding	  the	  tool	  over	  the	  PyroMark	  Q24	  
Plate,	  turn	  the	  vacuum	  switch	  off.	  
15. 	  Release	   the	   beads	   into	   the	   PyroMark	   Q24	  
Plate	  by	  gently	  shaking	  the	  tool	  in	  the	  wells.	  
16. Transfer	   the	   tool	   to	   the	   trough	   containing	  
high-­‐purity	   water	   (trough	   4)	   and	   agitate	   the	  
tool	  for	  10	  sec.	  
17. Wash	   the	   filter	   probes	   by	   lowering	   the	   probes	  
into	   high-­‐purity	   water	   (trough	   5)	   and	   applying	  
vacuum.	  Flush	  the	  probes	  with	  70	  ml	  highpurity	  water.	  
18. Raise	   the	   tool	   to	   beyond	   90°	   vertical	   for	   5	   sec.,	   to	   drain	   liquid	   from	   the	   filter	  
probes.	  
Fig.	   26	  PyroMark	  Q24	  Vacuum	  
Workstation.	  
Fig.	   27	   Vacuum	   tool	   raised	   to	  
beyond	  90°	  vertical.	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19. Close	   the	   vacuum	   switch	   on	   the	   tool	   (Off)	   and	   place	   the	   tool	   in	   the	   Parking	   (P)	  
position.	  
20. 	  Turn	  off	  the	  vacuum	  pump.	  
21. Heat	  the	  PyroMark	  Q24	  Plate	  containing	  the	  samples	  at	  80°C	  for	  2	  min.	  using	  the	  
PyroMark	  Q24	  plate	  holder.	  
22. Allow	  the	  samples	  to	  cool	  to	  room	  temperature	  (15–25°C)	  for	  at	  least	  5	  min.	  
23. Place	  the	  reagent	  cartridge	  with	  the	   label	   facing	  you	  and	   load	  the	  cartridge	  with	  
the	  appropriate	  volumes	  of	  nucleotides,	  enzyme	  and	  substrate	  mixtures.	  	  
24. Open	  the	  instrument	  lid	  and	  insert	  the	  reagent	  filled	  cartridge.	  
25. Open	  the	  plate-­‐holding	   frame	  and	  place	   the	  PyroMark	  Q24	  Plate	  on	   the	  heating	  
block.	  Close	  the	  plate-­‐holding	  frame	  and	  the	  instrument	  lid.	  
26. Insert	   the	   USB	   stick	   with	   the	   run	   file	   into	   the	   USB	   port	   at	   the	   front	   of	   the	  
instrument.	  
27. When	  the	  run	   is	   finished	  and	  the	   instrument	  confirms	  that	  the	  run	  file	  has	  been	  
saved	  to	  the	  USB	  stick	  open	  and	  analyze	  the	  processed	  run	  file	  in	  the	  CpG	  mode	  in	  
PyroMark	   Q24	   Software.	   The	   quantification	   of	   CpG	   methylation	   and	   quality	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5.3	  	  	  	  RNA	  purification	  
	  
The	   RNA	   purification	   was	   a	   critical	   part	   of	   work	   because	   this	  molecule	   is	  more	   fragile	  
compared	  to	  DNA	  and	  requires	  to	  stay	  on	  ice	  to	  avoid	  breakdown.	  
Working	   with	   RNA	   requires	   to	   create	   a	   Rnase-­‐free	   environment	   because	   Rnases	   or	  	  
ribonucleases	  are	  everywhere	  and	  are	  very	  stable	  and	  difficult	  to	  inactivate.	  
In	  this	  project	  I	  used	  the	  RNeasy	  FFPE	  kit	  from	  Quiagen	  to	  extract	  RNA	  from	  FFPE	  tissue	  
sections	  and	  the	  kit	   is	  specially	  designed	  to	  reverse	  as	  much	  formaldehyde	  modification	  
(such	   as	   nucleic-­‐acid	   	   and	   protein	   cross-­‐links)	   as	   possible	   without	   further	   RNA	  
degradation.	  
The	  complete	  protocol	  utilized	  was	  as	  follows:	  
1. Deparaffinize	   the	   sections	   by	   adding	   1000	   (1200)	   μl	   xylene	   to	   the	   tissue	   and	  
vortex.	  
2. Centrifuge	  at	  20000x	  g	  (14000	  rpm)	  for	  5	  min.	  
3. Gently	  remove	  supernatant	  by	  pipetting.	  
4. Add	  1000	  (1200)	  μl	  96-­‐100%	  ethanol	  to	  remove	  residual	  xylene	  and	  vortex.	  
5. Centrifuge	  at	  20000x	  g	  (	  14000	  rpm)	  for	  5	  min.	  
6. Carefully	  remove	  supernatant	  (ethanol)	  by	  pipetting.	  
7. Add	  240	  μl	  Buffer	  PKD,	  and	  mix	  by	  vortexing.	  
8. Centrifuge	  for	  1	  min.	  at	  11000	  x	  g	  (10000	  rpm).	  
9. Add	  10	  μl	  proteinase	  K	   to	   the	   lower,	   clear	  phase.	  Mix	  gently	  by	  pipetting	  up	  and	  down.	  
10. Incubate	  at	  56°C	  for	  15	  min.,	  then	  at	  80°C	  for	  15	  min.	  
11. Transfer	  the	  lower,	  uncolored	  phase	  into	  a	  new	  2	  ml	  microcentrifuge	  tube.	  
12. Incubate	  on	   ice	   for	  3	  min.	  Then,	   centrifuge	   for	  15	  min.	   at	  20000	  x	  g	   (13500	  rpm).	  
13. Transfer	   the	   supernatant	   to	   a	   new	   microcentrifuge	   tube	   taking	   care	   not	   to	  disturb	  the	  pellet.	  
14. Add	   DNase	   Booster	   Buffer	   equivalent	   to	   a	   tenth	   of	   the	   total	   sample	   volume	  
approximately	  25	  μl	  and	  10	  μl	  DNase	   I	  stock	  solution.	  Mix	  by	   inverting	  the	  tube.	  
Centrifuge	  briefly	  to	  collect	  residual	  liquid	  from	  the	  sides	  of	  the	  tube.	  
15. Incubate	  at	  room	  temperature	  for	  15	  min.	  
16. Add	  500	  μl	  Buffer	  RBC	  to	  adjust	  binding	  conditions,	  and	  mix	  the	  lysate	  thoroughly.	  
17. Add	   1200	   μl	   ethanol	   (100%)	   to	   the	   sample,	   and	   mix	   well	   by	   pipetting.	   Do	   not	  
centrifuge.	  Proceed	  immediately	  to	  step	  18.	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18. Transfer	  700	  μl	  of	  the	  sample,	  including	  any	  precipitate	  that	  may	  have	  formed,	  to	  
an	   RNeasy	  MinElute	   spin	   column	   placed	   in	   a	   2	  ml	   collection	   tube.	   Close	   the	   lid	  
gently,	   and	   centrifuge	   for	   15	   sec.	   at	   ≥8000	   x	  g	   (≥10000	   rpm).	   Discard	   the	   flow-­‐
through.	  
19. Repeat	  step	  18	  until	   the	  entire	  sample	  has	  passed	  through	  the	  RNeasy	  MinElute	  
spin	  column.	  
20. Add	  500	  μl	  Buffer	  RPE	  to	  the	  RNeasy	  MinElute	  spin	  column.	  Close	  the	   lid	  gently,	  
and	  centrifuge	  for	  15	  sec.	  at	  ≥8000	  x	  g	  (≥10000	  rpm).	  Discard	  the	  flow-­‐through.	  
21. Add	  500	  μl	  Buffer	  RPE	  to	  the	  RNeasy	  MinElute	  spin	  column.	  Close	  the	   lid	  gently,	  
and	   centrifuge	   for	   2	  min.	   at	   ≥8000	   x	   g	   (≥10000	   rpm)	   to	   wash	   the	   spin	   column	  
membrane.	  Discard	  the	  collection	  tube	  with	  the	  flow-­‐through.	  
	  
5.3.1	  	  RNA	  quantification	  and	  quality	  analysis	  
	  
The	   measurements	   of	   concentration	   and	   the	   quality	   of	   purified	   RNA	   were	   performed	  
utilizing	   the	   spectrophotometer	  UV-­‐visible	  NanoDrop	   2000	   and	   the	   same	   procedure	   as	  
described	  for	  DNA	  analysis.	  
	  
5.3.2	  	  Reverse	  Transcriptase	  PCR	  (RT-­‐PCR)	  
	  
The	  reverse	  transcription	  reaction	  was	  performed	  to	  obtain	  complementary	  DNA	  (cDNA)	  
using	  reverse	  transcriptase	  (RT),	  which	  is	  an	  enzyme	  that	  translates	  RNA	  to	  DNA.	  	  
This	   creates	   one	   DNA	   (cDNA)	   strand	   complementary	   to	   the	   RNA	   strand	   in	   a	   DNA-­‐RNA	  
hybrid	  and	  then	  the	  RNA	  strand	  is	  degraded,	  leaving	  single	  stranded	  cDNA	  ready	  for	  PCR.	  	  
Like	  the	  DNA	  polymerase,	  RT	  needs	  a	  primer	  to	  start	  the	  DNA	  synthesis.	  	  
There	  are	  usually	  three	  alternative	  primer	  methods:	  	  
1. Gene	  specific	  primers	  can	  be	  used	  to	  synthesise	  cDNA	  when	  the	  mRNA	  sequence	  
is	  known.	  In	  this	  way	  only	  the	  fragment	  in	  question	  is	  synthesised.	  	  
2. Oligo-­‐deoxy-­‐thymine	  (oligo-­‐dT)	  primers	  consists	  of	  a	  number	  of	  thymine	  residues.	  
These	  primers	  bind	  the	  3´	  poly(A)	  tails	  of	  the	  mRNA	  and	  cDNA	  synthesis	  starts	  at	  
the	  end	  of	  the	  mRNA.	  It	  may	  be	  difficult	  to	  get	  transcripts	  of	  the	  entire	  5´	  end	  of	  
the	  mRNA	  when	  oligo-­‐dT	  primers	  are	  used	  in	  FFPE	  tissue	  because	  total	  RNA	  could	  
be	  often	  fragmented	  does	  not	  necessarily	  contain	  a	  poly	  (A),	  but	  that	  depends	  on	  
the	  length	  of	  the	  template.	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3. Random	  hexamers	  are	  (as	  given	  by	  the	  name)	  six	  and	  six	  nucleotides	  put	  together	  
at	  random.	  These	  primers	  will	  bind	  at	  several	  locations	  in	  the	  total	  RNA	  and	  cDNA	  
synthesis	  starts	  from	  there.	  	  
In	   this	   study	   random	   hexamers	   were	   used	   and	   200	   ng	   of	   RNA	   for	   each	   sample	   were	  
utilized	  to	  have	  a	  total	  volume	  of	  20	  μl.	  Calculations	  have	  been	  done	  before	  starting	  the	  
experiment.	  
The	  protocol,	  Affinity	  Script	  QPCR	  cDNA	  synthesis	  Kit	   from	  Agilent	  Technologies,	  was	  as	  
follows:	  
1. Prepare	  the	  first	  strand	  cDNA	  synthesis	  in	  0.2	  ml	  microcentrifuge	  tubes	  by	  adding	  
the	  following	  components	  in	  order.	  
1. RNase-­‐free	  water	  to	  a	  total	  volume	  of	  20	  µl	  
2. 10	  µl	  First	  strand	  master	  mix	  (a	  reaction	  buffer)	  
3. 3	  µl	  Random	  primers	  
4. 1	  µl	  AffinityScript	  RT/RNase	  Block	  enzyme	  
5. X	  variable	  µl	  of	  RNA	  
2. Spin	  down	  the	  samples	  and	  run	  the	  cDNA	  synthesis	  program	  (20-­‐30	  min)	  
1. 25	  ºC	  for	  5	  min.	  Primer	  binding	  to	  the	  RNA	  template.	  
2. 42	  ºC	  for	  15	  min.	  cDNA	  synthesis.	  
3. 95	  ºC	  for	  5	  min.	  Terminates	  elongation.	  
	  
5.3.3	  	  Real	  time	  quantitative	  PCR	  (qPCR)	  
	  
Real-­‐Time	   qPCR	  (Real	   Time	   quantitative	   PCR)	   is	   a	   major	   development	   of	   thePCR	  
technology	  that	  enables	  reliable	  detection	  and	  measurement	  of	  gene	  products	  generated	  
during	  each	  cycle	  of	  PCR	  process.	  This	  technhique	  is	  commonly	  used	  for	  both	  diagnostic	  
and	  basic	   research	  because	   it	   is	   very	   sensitive	   and	  gives	   the	  possibility	   to	   compare	   the	  
expression	  levels	  of	  different	  genes	  and	  to	  rapidly	  detect	  nucleic	  acids	  that	  are	  diagnostic	  
of,	  for	  example,	  infectious	  diseases,	  cancer	  and	  genetic	  abnormalities.	  
The	   procedure	   follows	   the	   general	   principle	   of	   PCR,	   its	   key	   characteristic	   is	   that	   the	  
amplified	   DNA	   is	   detected	   as	   the	   reaction	   progresses	   in	   “real	   time”.	   This	   is	   a	   new	  
approach	  compared	  to	  standard	  PCR,	  where	  the	  product	  of	  the	  reaction	  is	  detected	  at	  its	  
end.	   Two	   common	  methods	   for	   the	   detection	   of	   products	   in	   quantitative	   PCR	   are:	   (1)	  
non-­‐specific	  fluorescent	  dyes	  that	  intercalate	  with	  any	  double-­‐stranded	  DNA	  (dsDNA)	  like	  
for	   example	   the	   dye	   SYBR	   green,	   and	   (2)	   sequence-­‐specific	  DNA	   probes	   consisting	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of	  oligonucleotides	  that	  are	  labelled	  with	  a	  fluorescent	  reporter	  which	  permits	  detection	  
only	  after	  hybridization	  of	  the	  probe	  with	  its	  complementary	  sequence.	  
In	   this	   study	   was	   utilized	   qPCR	   using	   RotorGene	   6000	   instrument	   (Quiagen)	   and	   SYBR	  
green	   that	   is	   a	   fluorophore	   that	   binds	   to	   all	   dsDNA	  in	   PCR,	   causing	   fluorescence	  of	   the	  
dye.	   The	   increase	   of	   DNA	   product	   during	   PCR	   determines	   an	   increase	   in	   fluorescence	  
intensity	   and	   is	   measured	   at	   each	   cycle,	   thus	   allowing	   DNA	   concentrations	   to	   be	  
quantified.	  However	  there	  are	  disadvantages	  because	  SYBR	  green	  binds	  to	  all	  dsDNA	  PCR	  
products,	   including	   nonspecific	   PCR	   products	   (like	   primer	   dimer).	   This	   could	   possibly	  
interfere	  with,	  or	  impede,	  accurate	  measurement	  of	  the	  expected	  target	  sequence.	  
For	  this	  reason	  qPCR	  allows	  the	  identification	  of	  specific,	  amplified	  DNA	  fragments	  using	  
analysis	   of	   their	  melting	   temperature	   (also	   called	  Tm	  value,	   from	  melting	   temperature).	  
The	  DNA	  melting	  temperature	  is	  specific	  to	  the	  amplified	  product	  and	  the	  results	  of	  this	  
technique	  are	  obtained	  by	  comparing	   the	  dissociation	  curves,	   called	  melting	  curves,	   for	  










For	  measuring	  the	  expression	  of	  S2	  transcript	  of	  EGFL7,	  GAPDH	  was	  used	  as	  endogenous	  
control	  and	  the	  primers	  utilized	  were:	  
1. EGFL7	  S2	  	  	  	  5’-­‐CCCCGGATCCGGCGGCCA-­‐3’	  (forward)	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  5’-­‐TGCGGCGGTAGGCGGTCCTA-­‐3’	  (reverse)	  
2. GAPDH	  	  	  	  	  	  	  5’-­‐GAAGGTGAAGGTCGGAGTC-­‐3’	  (forward)	  






Fig.	  28	  Rapresentation	  of	  melting	  curve	  for	  an	  amplicon	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The	   protocol,	   Brilliant	   III	   Ultra	   Fast	   SYBR	   Green	   QPCR	   master	   mix	   kit	   from	   Agilent	  
Technologies,	  was	  the	  following:	  
1. Thaw	  the	  qPCR	  master	  mix,	  which	  includes	  a	  mix	  of	  DNA	  polymerases,	  buffer,	  
dNTPs	  and	  primers	  and	  store	  them	  on	  ice.	  They	  are	  temperature-­‐sensitive	  and	  
therefore	  are	  always	  kept	  on	  ice.	  
2. Briefly	  vortex	  the	  tubes	  
3. Prepare	  the	  master	  mix	  containing	  dye	  and	  primers	  for	  each	  primer-­‐pair	  (GAPDH	  
and	  EGFL7	  S2).	  Keep	  it	  on	  ice.	  
4. Add	  12	  µl	  mastermix	  to	  0.2	  ml	  tubes.	  
5. Prepare	  the	  master	  mix	  containing	  cDNA	  and	  water.	  
6. Place	  the	  0.2	  ml	  tubes	  and	  cDNA	  master	  mix	  in	  cooling	  elements,	  mix	  and	  pipet	  8	  
µl	  cDNA	  to	  the	  tubes.	  
7. Loading	  of	  endogenous	  controls	  are	  8	  µl,	  water	  samples	  are	  0	  µl	  DNA	  but	  8	  µl	  of	  
water.	  Positive	  controls	  are	  1	  µl	  cDNA	  and	  7	  µl	  water.	  
8. Close	  the	  lids	  and	  centrifuge	  briefly	  to	  avoid	  air	  bubbles	  in	  the	  samples	  and	  to	  spin	  
down	  drops	  in	  the	  lid.	  Bubbles	  results	  in	  false	  results.	  
9. Load	  the	  samples	  in	  a	  36	  well	  rotor	  and	  insert	  in	  Rotor-­‐Gene	  machine.	  Make	  sure	  
that	  the	  lids	  are	  closed	  and	  sample	  1	  in	  well	  number	  1.	  
10. Select	  the	  specific	  program	  that	  follows:	  
1. Hold	  95	  °C	  for	  3	  min.	  
2. Cycling	  45x	  (the	  enzymes	  can	  maximum	  run	  for	  about	  50	  times)	  
1. 95	  °C	  for	  10	  sec.	  
2. 62	  °C	  for	  20	  sec.	  
3. Add	  Melt	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6.	  Results	  
6.1	  	  	  Methylation	  sensitive	  PCR	  (MSP)	  results	  
	  
The	  DNA	  methylation	  status	  of	  the	  CpG	  island	  in	  the	  S2	  promoter	  was	  examined	  in	  all	  54	  
samples	  by	  MSP	  after	  bisulfite	  treatment	  and	  the	  DNA	  products	  were	  analyzed	  by	  QIAxcel	  
system	  advanced.	  
Here	   are	   shown	   the	   methylation	   status	   of	   S2	   by	   MSP	   in	   some	   tumor	   samples	   from	  
surgically	  removed	  MPM	  (MPM)	  and	  preoperative	  diagnostic	  biopsy	  (DB),	  non-­‐neoplastic	  
pleura	  from	  MPM	  patients	  (NNP),	  non-­‐neoplastic	  reactive	  mesothelial	  proliferation	  after	  
pneumothorax	  (PTHX),	  and	  in	  positive	  and	  negative	  controls,	   i.e.	  completely	  methylated	  
or	  completely	  unmethylated	  human	  genomic	  DNA	  after	  bisulfite	  conversion	   (EMCD	  and	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Fig.	   	  28	  MSP	  analysis	  of	  the	  EGFL7	  S2	  CpG	  island	  promoter	  in	  MPM	  samples	  (B),	  
DB,	  NNP	  and	  PTHX	   (C)	  using	  as	  positive	   controls	   EMCD	  and	  as	  negative	   control	  
EUCD	   (A).	   MPM:	   surgically	   removed	   malignant	   pleural	   mesotheliomas;	   DB:	  
preoperative	   diagnostic	   biopsies;	   NNP:	   patient-­‐matched	   non-­‐neoplastic	   pleura	  
from	   patients	   operated	   for	   MPM;	   PTHX:	   non-­‐neoplastic	   reactive	   mesothelial	  
proliferation	   due	   to	   pneumothorax;	   EMCD:	   Completely	   methylated	   human	  
genomic	   DNA	   bisulfite	   converted;	   EUCD	   Completely	   unmethylated	   human	  
genomic	  DNA	  	  bisulfite	  converted.	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The	  results	  showed	  the	  presence	  of	  a	  methylated	  S2	  band	  in	  the	  majority	  of	  MPM	  and	  DB	  
specimens	  that	  was	  absent	  in	  all	  other	  the	  tested	  NPP	  and	  PTHX	  samples.	  	  
Data	   are	   summarized	   the	   data	   in	   table	   XI	   dividing	   them	   in	   two	   	   groups:	   samples	   with	  
neoplastic	  pleura	  (MPM	  and	  DB)	  and	  samples	  with	  non	  neoplastic	  pleura	  (NNP	  and	  PTHX).	  
	  
Presence	  of	  
methylated	  band	  S2	  
MPM/	  DB	   NNP/	  PTHX	   TOTAL	  
YES	   24	   0	   24	  
NO	   10	   20	   30	  




By	  Analyzing	  data	  from	  contingency	  table	  XI,	   I	   tried	  to	  see	   if	   It	  was	  possible	  to	  measure	  
the	   association	   between	   the	   two	   groups	   ,	   by	   using	   the	   	   Pearson's	   chi-­‐squared	   test	  (χ2)	  
which	   is	   a	   	   test	   of	   independence	   that	   assesses	   whether	   paired	   observations	   on	   two	  
variables,	  expressed	  in	  a	  contingency	  table,	  are	  independent	  of	  each	  other.	  
The	   value	   of	   this	   test	   statistic	   test	   was	   25.47	   and	   afterwards	   I	   utilized	   this	   value	   to	  
calculate	  the	  Cramer’s	  V	  contingency	  coefficient	  φc	  (Cramér's	  phi)	  that	  ranges	  from	  0	  to	  1.	  
The	  closer	   to	  0	   the	  value	  of	  φc	   is,	   the	  weaker	  dependence	   joins	   the	  analysed	  variables,	  
and	  the	  closer	  to	  1,	  the	  stronger	  dependence	  joins	  the	  analysed	  variables.	  	  
In	  this	  case	  φc	  	  was	  0.47	  showing	  a	  good	  correlation	  between	  the	  two	  groups	  studied	  and	  













Table	  XI	  Data	  of	  samples	  examined	  by	  MSP.	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6.2	  	  Pyrosequencing	  results	  
	  
Pyrosequencing	  analysis	  was	  performed	  to	  examine	  the	  level	  of	  DNA	  methylation	  of	  CpG	  
islands	  around	  miR-­‐126.	   	  By	  using	  the	  pyrosequencing	  technique	  8	  representative	  MPM	  
samples	   and	   5	   NNP	   were	   analysed,	   since	   due	   to	   lack	   of	   time	   during	   my	   stay	   in	   the	  
laboratory	   in	  Copenhagen	   it	  was	  not	  possible	   to	  study	  all	   the	  MPM,	  DB,	  NNP	  and	  PTHX	  
specimens.	  
The	  sequence-­‐to-­‐analyze	  generated	  by	  the	  choice	  of	  primers	  was	   inserted	  into	  software	  
PyroMark	   Q24	   version	   1.0	   to	   create	   the	   assay	   setup.	   In	   each	   assay	   setup	   at	   least	   one	  
bisulfite	  control	  was	  added	  as	  early	  on	  in	  the	  dispensation	  order	  as	  possible.	  A	  complete	  
conversion	   of	   unmethylated	   CpG-­‐sites	   by	   bisulfite	   treatment	   is	   critical	   for	   obtaining	  
accurate	   results	   on	   methylation	   levels.	   For	   example,	   the	   assay	   setup	   used	   to	   analyze	  
methylation	   level	   in	  the	  flanking	  region	  of	  miR-­‐126	  had	  two	  bisulfite	  controls	   located	   in	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Fig.	   29	   The	   assay	   setup	   contains	   information	   on	   the	   expected	   peak	   pattern	   and	   the	  
dispensation	   order	   used	   for	   each	   assay.	   The	   image	   here	   shows	   the	   assay	   setup	   for	   the	  
flanking	  region	  of	  miR-­‐126.	  Letters	  on	  the	  X-­‐axis	  specify	  the	  nucleotide	  being	  dispensed	  
in	   the	   order	   from	   left	   to	   right.	   The	   bars	   illustrate	   the	   expected	   relative	   signal	   peak	  
heights	   in	   the	   Pyrogram	   trace	   (y-­‐axis	   gives	   the	   number	   of	   a	   specific	   nucleotide).	   The	  
bisulfite-­‐control	  is	  positioned	  at	  dispensation	  number	  16	  and	  25	  (also	  indicated	  by	  a	  pale	  
yellow	  colour).	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Illustrative	   examples	   of	   pyrosequencing	   results	   for	   DNA	   methylation	   in	   CpG	   islands	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A2: TTTC/ TGTTTC/ TGGGGTTTGTTTGTATTAGC/ TGTAG
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A7: TTTC/ TGTTTC/ TGGGGTTTGTTTGTATTAGC/ TGTAG
Fig.30	   Pyrogram	   traces	   for	   DNA	  methylation	   of	   CpG	   islands	   around	  miR-­‐126	   of	  
two	  (A)	  and	  (B)	  MPM	  samples	  and	  two	  NNP	  (C)	  and	  (D)	  samples.	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By	   analyzing	   all	   pyrogram	   traces	   It	   was	   possible	   to	   observe	   a	   different	   degree	   of	   DNA	  
methylation	  in	  the	  three	  CpG	  islands	  around	  miR-­‐126.	  
For	   this	   reason	   I	   calculated	   the	   average	   methylation	   for	   the	   region	   analyzed	   in	   each	  
samples	   (table	   XII	   and	   table	   XIII	   )	   and	   the	   results	   have	   shown	   that	  MPM	   samples	   have	  
average	  methylation	  higher	  than	  respective	  NNP	  samples.	  
	  
	  MPM	  samples	   CpG	  1	   CpG	  2	   CpG	  3	   Average	  
1	   76	   73	   42	   63,7	  
2	   74	   65	   47	   62	  
3	   76	   96	   37	   69,7	  
4	   89	   93	   13	   65	  
5	   86	   68	   38	   64	  
6	   79	   55	   49	   61	  
7	   68	   80	   32	   60	  
8	   75	   76	   41	   64	  
	  
NPM	  	  samples	   CpG	  1	   CpG	  2	   CpG	  3	   Average	  
30	   44	   56	   15	   38,3	  
31	   58	   56	   10	   41,4	  
32	   59	   32	   38	   43	  
33	   68	   45	   19	   44	  









Table	  XII	  Summary	  of	  pyrosequencing	  results	  in	  MPM	  samples.	  
Table	  XIII	  Summary	  of	  pyrosequencing	  results	  in	  NNP	  samples.	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6.3	  	  	  	  Real	  Time	  quantitative	  (qPCR)	  PCR	  results	  
	  
When	  we	  have	  to	  quantify	  gene	  expression	   level	  with	  qPCR,	   it	   is	  necessary	  to	  know	  the	  
mechanism	  of	  cycles	  and	  curves.	  	  
In	  this	  context	  the	  value	  of	  Ct	  (threshold	  cycle)	  is	   	  very	  important,	  beacuse	  is	  defined	  as	  
the	   PCR	   cycle	   at	   which	   the	   fluorescent	   signal	   of	   the	   dye	   crosses	   an	   arbitrarily	   placed	  
threshold	  and	  this	  one	  allows	  to	  verify	  if	  PCR	  is	  in	  the	  exponential	  phase	  of	  amplification	  
(213).	  
In	   other	  words,	   the	   Ct	   value	   is	   inversely	   connected	   to	   the	   quantity	   of	   template	   in	   the	  
reaction	  in	  fact	  the	  lower	  the	  Ct,	  the	  more	  amount	  of	  PCR	  product	  in	  the	  reaction.	  
Data	   from	   qPCR	   can	   be	   elaborated	   as	   absolute	   or	   relative	   expression	   levels;	   absolute	  
expression	  gives	  information	  about	  the	  exact	  copy	  number	  but	  it	   is	  used	  rarely	  whereas	  
relative	  quantification	  provides	  data	  referred	  to	  an	  internal	  control.	  
When	  qPCR	  data	  are	  shown	  as	  individual	  point	  the	  2-­‐ΔCT	   	  method	  is	  utilized	  to	  normalize	  
them	  to	  an	  internal	  control	  (in	  my	  project	  GAPDH	  is	  used	  as	  endogenous	  control).	  
ΔCT	  is	  termed	  as	  Ct	  gene	  of	  interest	  –	  Ct	  internal	  control.	  	  
In	  this	  project	  I	  worked	  with	  tissue	  samples	  in	  doublets	  and	  then	  I	  calculated	  the	  mean	  for	  
the	  calculation	  of	  the	  2-­‐ΔCT	  and	  in	  addition	  I	  analyzed	  all	  data	  by	  differest	  statical	  tests	  like	  
Student’t-­‐test,	  Mann	  Whitney	  U	  test	  and	  one	  way	  ANOVA.	  
The	  main	  purpose	  of	  the	  experiments	  was	  to	  study	  the	  expression	  of	  EGFL7	  S2	  transcript	  
in	  MPM	  compared	  to	  NNP,	  DB	  and	  PTHX	  samples	  and	  to	  correlate	  these	  results	  with	  the	  
expression	   of	   miR-­‐126.	   Furthermore	   qPCR	   was	   used	   to	   examine	   the	   differences	   in	  
expression	  level	  in	  the	  histological	  MPM	  subtypes.	  
The	  first	  experiment	  with	  qPCR	  was	  designed	  to	  calculate	  the	  expression	  level	  	  of	  miR-­‐126	  
in	   MPM	   tissue	   samples	   (n=	   29)	   and	   NNP	   tissue	   samples	   (15)	   and	   to	   asses	   a	   possible	  
correlation	  with	  EGFL7	  S2	  expression	  in	  the	  same	  samples.	  
Thanks	   to	  data	  gently	   received	   from	  Morten	  Andersen,	   a	  PhD	   student	  of	   Laboratory	  of	  
Molecular	  Pathology	  at	  Rigshospitalet,	  I	  had	  the	  possibility	  to	  evaluate	  by	  unpaired	  T-­‐test	  
miR-­‐126	   mRNA	   expression.	   The	   result	   of	   this	   analysis	   (Fig.31)	   showed	   that	   there	   is	   a	  
significant	   difference	   of	   miR-­‐126	   expression	   in	   MPM	   as	   compared	   to	   NNP	   samples.	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Afterwards	  I	  examined	  the	  expression	  of	  EGFL7	  S2	  mRNA	  expression	  and	  I	  observed	  that	  
it	  was	  deregulated	  in	  MPM	  tumors	  samples.	  Indeed,	  the	  results,	  indicated	  that	  also	  for	  S2	  
there	  was	  a	  significant	  difference	  of	  expression	  between	  MPM	  and	  NNP	  samples	  and	  that	  




	  	  	  
	  	  	  
	  	  	  
	  	  	  












P	  Value	  =	  0,0001	  
Fig.	  31	  Mann	  Whytney	  test	  of	  miR-­‐126	  expression	  in	  malignant	  pleural	  mesothelioma	  
(MPM)	   and	   non-­‐neoplastic	   pleura	   (NNP)	   tissue	   samples.	   The	   test	   indicates	   a	  
statistically	  difference	   in	  miR-­‐126	  expression	   level	  between	  MPM	  samples	  and	  NNP	  
control	  samples	  (P-­‐value	  of	  0,0001).	  This	  leads	  to	  the	  conclusion	  that	  miR-­‐126	  mRNA	  
levels	  are	  downregulated	  in	  MPM	  tissue	  samples.	  The	  black	  horizontal	  line	  indicates	  
the	  median	  of	  either	  MPM	  or	  NNP;	  data	  were	  normalized	  with	  RNU49,	  endogenous	  
miRNA	  control.	  
miR-­‐126	  expression,	  comparison	  between	  MPM	  and	  NNP	  control	  tissue	  
Histosubtype	  




In	   the	   second	   analysis,	   I	   estimated	  with	   the	   Student’t-­‐test	  miR-­‐126	   and	   S2	  mRNA	   levels	  
expression	   in	  MPM	  samples	  compared	  to	  patient-­‐matched	  NNP	  paired	  samples	  and	  the	  
results	  confirmed	  the	  same	  correlation	  as	  the	  previous	  study	  (Fig.33	  and	  Fig	  34).	  
	  
	  
	  	  	  
	  	  	  
	  	  	  
	  	  	  












P	  Value	  =	  0,0001	  
S2	  expression,	  comparison	  between	  MPM	  and	  NNP	  control	  tissue	  
Histosubtype	  
Fig.	  32	  Mann	  Whytney	  test	  of	  S2	  (alternative	  transcript	  of	  EGFL7)	  mRNA	  expression	  in	  
malignant	   pleural	   mesothelioma	   (MPM)	   and	   non-­‐neoplastic	   pleura	   (NNP)	   tissue	  
samples.	   The	   test	   indicates	   a	   statistically	   difference	   in	   S2	   mRNA	   between	   MPM	  
samples	  and	  NNP	  control	  samples	  (P-­‐value	  of	  0,0001).	  	  Thus,	  similary	  to	  miR-­‐126,	  S2	  
levels	  are	  downregulated	  in	  MPM	  tissue	  samples.	  The	  black	  horizontal	  line	  indicates	  
the	  median	  of	  either	  MPM	  or	  NNP;	  data	  were	  normalized	  with	  GAPDH,	  endogenous	  
mRNA	  control.	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P	  Value	  =	  0,0014	  
miR-­‐126	  expression,	  comparison	  between	  paired	  MPM	  and	  NNP	  control	  tissue	  
Histosubtype	  
	  	  	  
	  	  	  
	  	  	  
	  	  	  













Fig.	   33	   A	   paired	   T-­‐test	   of	   miR-­‐126	   expression	   in	   malignant	   pleural	   mesothelioma	  
(MPM)	  and	  patient-­‐matched	  non-­‐neoplastic	  pleura	  (NNP)	  paired	  tissue	  samples.	  The	  
test	   indicates	   a	   statistically	   difference	   in	   miR-­‐126	   expression	   level	   between	   MPM	  
samples	   and	   NNP	   control	   samples	   (P-­‐value	   of	   0,0014).	   	   MiR-­‐126	   mRNA	   level	   are	  
downregulated	   in	  MPM	   tissue	   samples	   and	  a	  paired	  T-­‐Test	  has	   a	   significant	  higher	  
power	   when	   compared	   to	   unpaired	   test.	   	   The	   black	   horizontal	   line	   indicates	   the	  
median	  of	  either	  MPM	  or	  NNP;	  data	  were	  normalized	  with	  RNU49.	  
P	  Value	  =	  0,0027	  
	  	  	  
	  	  	  
	  	  	  
	  	  	  












Fig.	   34	   A	   paired	   T-­‐test	   of	   S2	  mRNA	   expression	   in	  malignant	   pleural	  mesothelioma	  
(MPM)	  and	  patient-­‐matched	  non-­‐neoplastic	  pleura	  (NNP)	  paired	  tissue	  samples.	  The	  
test	  indicates	  a	  statistically	  difference	  in	  S2	  mRNA	  between	  MPM	  samples	  and	  NNP	  
control	   samples	   (P-­‐value	   of	   0,0027).	   	   S2	   mRNA	   levels	   are	   downregulated	   in	  MPM	  
tissue	  samples	  and	  a	  paired	  T-­‐Test	  has	  a	  significant	  higher	  power	  when	  compared	  to	  
unpaired	  test.	  The	  black	  horizontal	  line	  indicates	  the	  median	  of	  either	  MPM	  or	  NNP;	  
data	  were	  normalized	  with	  GAPDH.	  
	  
Histosubtype	  
	  	  	  	  	  	  	  	  	  	  	  S2	  expression,	  comparison	  between	  paired	  MPM	  and	  NNP	  control	  tissue	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In	  the	  third	  analysis	  I	  studied	  the	  correlation	  between	  S2	  expression	  and	  the	  histological	  
subtypes	  of	  MPM	   (EMM	  and	  BMM).	   In	   this	   case	   I	   used	   the	  Mann	  Whitney	  U	   test.	   The	  
result	  showed	  a	  significantly	  higher	  expression	  of	  S2	  in	  BMM	  when	  compared	  to	  the	  EMM	  
group	  (Fig.	  35),	  which	  correlates	  with	  the	  higher	  expression	  of	  miR126	  in	  BMM	  vs.	  EMM	  
recently	   reported	   by	   the	   Laboratory	   of	   Mol.	   Pathol.	   at	   Rigshospitalet	   Copenhagen	  
University	  Hospital	  (169)	  
	  
Finally,	  I	  analyzed	  with	  One	  way	  ANOVA	  test	  S2	  mRNA	  expression	  in	  all	  54	  samples	  with	  
neoplastic	   pleura	   and	   non-­‐neoplastic	   pleura	   and	   I	   tried	   to	   see	   if	   there	   was	   a	   possible	  
correlation	  between	  them.	  	  	  
The	   results	   showed,	   like	   the	  analysis	   regarding	  miR-­‐126	  previously	  described	   in	   Fig.	   11,	  
that	  there	  was	  a	  EGFL7	  S2	  downregulation	  in	  MMP	  and	  DB	  samples	  compared	  to	  NNP	  and	  





Fig.	   35	  Mann	  Whitney	  U	   test	  of	   S2	  mRNA	  expression	  when	  histological	   subtypes	  are	  
compared.	  An	   increase	  of	   the	  median	  of	   the	  S2	  mRNA	  was	  seen	   in	  BMM	  (P	  value	  of	  
0,00195).	  The	  black	  horizontal	   line	   indicates	  the	  median	  of	  either	  MPM	  or	  NNP;	  data	  
were	  normalized	  with	  GAPDH.	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S2	  expression,	  comparison	  between	  DB,	  MMP,	  NNP	  and	  PTHX	  
P	  Value	  =	  0,0001	  
Histosubtype	  
	  	  	  
	  	  	  
	  	  	  
	  	  	  












Fig.	   	   36	   One	   way	   ANOVA	   test	   of	   S2	   mRNA	   expression	   in	   preoperative	   diagnostic	  
biopsies	   (DB)	  malignant	   pleural	  mesothelioma	   (MPM)	   non-­‐neoplastic	   pleura	   (NNP)	  
and	   	   in	   non-­‐neoplastic	   reactive	   mesothelial	   proliferation	   due	   to	   pneumothorax	  
(PTHX)	   tissue	   samples.	   The	   test	   indicates	   a	   statistically	   difference	   in	   S2	   mRNA	  
expression	  levels	  (P-­‐value	  of	  0,0001).	  	  S2	  mRNA	  levels	  are	  downregulated	  in	  DB	  and	  
MPM	  tissue	  samples	  compared	  to	  NNP	  and	  PTHX.	  The	  black	  horizontal	  line	  indicates	  
the	  median	  of	  either	  MPM	  or	  NNP;	  data	  were	  normalized	  with	  GAPDH.	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7.	  Discussion	  
	  
The	  aims	  of	   thys	  study	  were	  to	  see	   if	   it	  was	  possible	   to	  analyze	  epigenetic	  mechanisms	  
like	  DNA	  methylation	  in	  malignant	  pleural	  mesothelioma	  (MPM.	  
Many	   articles	   have	   reported	   that	   miRNAs	   are	   often	   involved	   in	   the	   progression	   of	  
tumours	   due	   to	   aberrant	   methylation	   of	   their	   own	   promoters	   or	   their	   host	   gene	  
promoters.	  	  
The	  Laboratory	  of	  Molecular	  Pathology	  at	  the	  Department	  of	  Pathology	  of	  Rigshospitalet	  
Copenhagen	  University	  hospital	  has	  recently	  identified	  deregulated	  expression	  of	  a	  group	  
of	   miRNAs	   that	   may	   have	   a	   pathogenetic	   role	   and	   have	   diagnostic	   potential	   in	   MPM	  
(169).	   Among	   them,	   the	   cancer-­‐related	   miR-­‐126	   has	   been	   found	   significantly	  
downregulated	  in	  MPM	  as	  compared	  to	  nonneoplastic	  pleura.	  	  
Interestingly,	  the	  miR-­‐126	  is	  located	  within	  intron	  7	  of	  the	  proangiogenic	  EGFL7	  gene	  that	  
is	  highly	  expressed	  in	  endothelial	  cells	  and	  vascularized	  tissues.	  MiR-­‐126	  acts	  as	  a	  tumor	  
suppressor	   gene	   in	   certain	   types	   of	   cancers	   	   while	   other	   reports	   have	   described	   an	  
oncogenic	  role	  (186,187,200-­‐206).	  These	  findings	  suggest	  that	  miR-­‐126	  may	  have	  several	  
functions	  specific	  to	  different	  types	  of	  malignancy.	  	  
Mature	  miR-­‐126	   can	   be	   generated	   from	   three	   different	   transcripts	   of	  EGFL7	  with	   each	  
one	  having	   its	   own	  promoter	  with	  CpG	   island.	   Previous	   studies	   have	   shown	  expression	  
correlation	   between	   the	   miR-­‐126	   and	   its	   host	   gene	   in	   certain	   cancer	   types	   (176,200).	  
Therefore,	  we	  have	  decided	  to	  study	  methylation	  status	  and	  expression	  pattern	  of	  miR-­‐
126	   and	   its	   host	   gene	   EGFL7	   to	   understand	   their	   possible	   reciprocal	   mechanism	   of	  
regulation	  in	  MPM.	  	  
In	  the	  first	  part	  of	  work	  I	  focused	  on	  the	  analysis	  of	  DNA	  methylation	  status	  within	  the	  S2	  
(an	  alternative	  transcript	  of	  EGFL7)	  CpG	  island	  promoter	  by	  MSP	  and	  the	  results	  show	  a	  
possible	  correlation	  between	  methylated	  status	  of	  this	  region	  and	  the	  type	  of	  samples.	  
Indeed,	   the	  S2	  CpG	   island	  promoter	  of	  MPM	  and	  DB	  samples	   containing	  mesothelioma	  
tumor	   tissue	   appears	   to	   be	   more	   methylated	   compared	   to	   NNP	   and	   PTHX	   samples	  
containing	  nonneplastic	  tissue.	  
This	   situation	  was	   also	   observed	  with	   pyrosequencing-­‐based	   analysis	   of	   the	   CpG	   island	  
around	  miR-­‐126;	  also	  here	  the	  methylation	  degree	  of	  MPM	  was	  higher	  compared	  to	  NNP	  
paired	  samples.	  
	  I	   also	   examined	   the	   expression	   pattern	   of	   miR-­‐126	   and	   S2	   transcript	   by	   real-­‐time	  
quantitative	  RT-­‐PCR	  (RT-­‐qPCR)	  	  to	  correlate	  the	  expression	  of	  miR-­‐126	  with	  that	  of	  the	  S2	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in	   patient-­‐matched	   preoperative	   DB	   and	   surgical	   tissue	   specimens	   of	   MPM	   as	   well	   as	  
corresponding	  NNP	  and	  in	  indipendent	  non-­‐neoplastic	  reactive	  mesothelial	  proliferations	  
due	  to	  pneumothorax.	  	  
After	  using	  different	  statistical	  analyses,	  miR-­‐126	  and	  the	  S2	  alternative	  transcript	  of	   its	  
host	  gene	  EGFL7	  appeared	  downregulated	  in	  DB	  and	  in	  MPM	  samples	  compared	  to	  NNP	  
and	  PTHX	  samples.	  	  
These	  results	  indicate:	  1)	  that	  in	  MPM	  the	  primary	  transcript	  of	  miR-­‐126	  is	  located	  in	  an	  
alternative	  transcript	  of	  EGFL7	  (S2)	  with	  a	  CpG	  island	  	  promoter;	  2)	  that	  both	  miR-­‐126	  and	  
S2	  are	  concomitantly	  downregulated	  in	  MPM;	  3)	  that	  they	  may	  be	  co-­‐expressed	  in	  MPM	  
and	  that	  this	  could	  be	  due	  to	  regulation	  by	  DNA	  methylation	  of	  the	  CpG	  islands	  in	  the	  S2	  
promoter,	  like	  some	  articles	  have	  already	  showed	  in	  certain	  other	  cancer	  types	  (176,200).	  
Thus,	   the	   fact	   that	   MPM	   and	   DB	   samples	   have	   a	   greater	   level	   of	   S2	   and	   miR-­‐126	  
methylation	  than	  NNP	  and	  PTHX	  samples	  suggests	  that	  mRNA	  and	  miRNA	  expression	  can	  
be	  controlled	  by	  epigenetic	  mechanisms	  in	  this	  cancer	  type.	  
MiR-­‐126	  acts	  as	  tumor	  suppressor	  in	  many	  tumoral	  processes	  compared	  to	  EGFL7	  that	  is	  
often	   considered	   an	  oncogene	  but	   in	  MPM	   their	   deregulation	   could	   somehow	  have	   an	  
important	   role	   in	   maintaining	   vascular	   integrity	   and	   driving	   angiogenesis	   in	   order	   to	  
stabilize	  the	  cellular	  environment	  around	  the	  tumor	  (171,	  178,	  181).	  Further	  studies	  are	  
needed	  to	  clarify	  the	  pathogenetic	  role	  of	  EGFL7	  and	  miR-­‐126	  deregulation	  in	  MPM.	  
This	   work	   has	   improved	   our	   understanding	   of	   the	   mechanism	   by	   which	   miR-­‐126	   and	  
EGFL7	  are	  regulated	  in	  MPM	  and	  it	  would	  be	  interesting	  in	  the	  future	  to	  analyze	  histone	  
modifications	   in	   chromatin	   structure	   to	   confirm	   the	   importance	   of	   epigenetic	  
mechanisms	   regulating	   miRNAs	   expression	   in	   MPM.	   This	   could	   also	   pave	   the	   way	   to	  
better	   treatment	   strategies	   against	   this	   dismal	   disease,	   aimed	   at	   reestablishing	   the	  
expression	   of	   tumor	   suppressor	   miRNAs	   such	   as	   miR-­‐126,	   through	   the	   usage	   of	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Figure	  legends	  
	  
Fig.	  1	  A	  multiple	  ferruginous	  bodies	  with	  inflammatory	  	  reaction.	  
Reference	  47	  
	  
Fig.	  2	  A	  hypothetical	  model	  of	  MPM	  pathogenesis.	  
Reference	  19	  
	  
Fig.	  3	  Pathophysiology	  of	  mesothelioma.	  
My	  picture	  
	  
Fig.	  4	  Molecular	  pathways	  altered	  by	  SV40	  infection.	  
Reference	  59	  
	  








Fig.	  7	  Normal	  condition	  of	  pleura	  (A).	  Under	  abnormal	  conditions,	   like	  malignancies,	  the	  
pleural	  space	  can	  be	  filled	  with	  up	  to	  several	  liters	  of	  fluid	  (B).	  
http://medicdaily.co/combination-­‐therapy-­‐provides-­‐hope-­‐for-­‐mesothelioma-­‐patients/	  
	  
Fig.	  8	  Genomic	  locations	  of	  miRNAs.	  miRNAs	  may	  be	  located	  in	  almost	  any	  region	  of	  the	  
genome.	  They	  may	  be	  grouped	  into	  clusters	  or	  situated	  alone.	  	  
A,	  an	  intergenic	  miRNA	  may	  be	  located	  many	  kb	  away	  from	  coding	  genes	  and	  transcribed	  
as	  a	  pri-­‐miRNA,	  such	  as	  in	  miR-­‐203.	  	  
B,	  polycistronic	  miRNAs	  may	  be	  grouped	   into	  a	   cluster	   and	   transcribed	  as	  a	  pri-­‐miRNA,	  
which	  yields	  several	  miRNAs.	  This	  occurs	  with	  the	  miR-­‐431~136	  cluster.	  	  
C,	   intronic	  miRNAs	  are	  located	  in	  canonical	  genes	  and	  are	  part	  of	  an	  intron.	  The	  mature	  
miRNA	  may	  be	  processed	  from	  the	  intron	  of	  the	  host	  gene	  
transcript.	   This	   occurs	   when	   miR-­‐126	   is	   processed	   from	   the	   EGFL7	   transcript.	   Arrow,	  
transcription	  start	  site;	  rectangle,	  exon;	  hairpin,	  pre-­‐miRNA.	  
My	  picture	  
	  
Fig.	  9	  miRNA	  biogenesis.	  MiRNAs	  are	  transcribed	  by	  RNA	  polymerase	  II	  as	  long	  precursors	  
(pri-­‐miRNA).	  Precursors	  are	  processed	  twice,	  once	  in	  the	  nucleous	  by	  the	  Drosha	  enzyme	  
that	   gives	   rise	   to	   the	   pre-­‐miRNA,	   and	   finally	   in	   the	   cytoplasm	   by	   the	   Dicer	   enzyme	   in	  
order	  to	  obtain	  the	  short	  duplex	  microRNA	  molecule.	  One	  of	  the	  two	  strands	  of	  the	  miR	  




Fig.	  10	  MiRNAs	  can	  function	  as	  tumour	  suppressors	  and	  oncogenes.	  
Reference	  124	  
	  
Fig.	  11	  Tukey-­‐boxplots	  of	  miR-­‐126	  (A),	  miR-­‐143	  (B),	  miR-­‐145	  (C),	  and	  miR-­‐652	  (F)	  levels	  in	  
tissue	  samples	  of	  diagnostic	  biopsies	  (DB),	  malignant	  pleural	  mesothelioma	  (MPM),	  non-­‐
neoplastic	   pleura	   (NNP)	   and	   reactive	   mesothelial	   proliferation	   after	   pneumothorax	  
(PTHX).	   Plots	   are	   based	   on	   real-­‐time	   qPCR	   data.	   The	   box	   delimits	   the	   25th	   and	   75th	  
	   89	  
percentiles.	   Horizontal	   lines	   inside	   the	   boxes	  mark	   the	  median.	   Vertical	   lines	  mark	   the	  
interval	  between	  10th	  and	  90th	  percentiles.	  
Reference	  169	  
	  
Fig.	   12	   Domain	   organization	   of	   EGFL7.	   The	   modular	   assembly	   of	   EGFL7's	   domains	   is	  
conserved	   among	   vertebrate	   species.	   The	   EGFL7	   orthologue	   CG7447	   in	   Drosophila	  
melanogaster	  shares	  the	  same	  overall	  structure	  but	  differs	  in	  total	  length.	  
Reference	  198	  
	  
Fig.	  13	  Localization	  of	  miR-­‐126/miR-­‐126*	  within	  the	  primary	  human	  EGFL7	  transcript.	  This	  
is	   a	   schematic	   representation	   of	   three	   alternative	   primary	   human	   EGFL7	   transcripts,	  
which	  initiate	  from	  separate	  promoters	  but	  contain	  the	  same	  open	  reading	  frame.	  Non-­‐
coding	   exons	   are	   indicated	   in	   uncolored	   boxes,	   coding	   exons	   in	   colored	   ones.	  miR-­‐126	  
and	  miR-­‐126*	  are	  localized	  within	  intron	  7	  of	  EGFL7	  in	  all	  vertebrates.	  
Reference	  198	  
	  
Fig.	   14	  Model	   depicting	   the	   role	   of	   EGFL7	   in	   angiogenesis.	   (A-­‐B)	   EGFL7	   is	   a	   secreted	  
protein	  that	  is	  expressed	  by	  endothelial	  cells,	  including	  the	  stalk	  and	  tip	  cells	  of	  sprouting	  
vessels.	  Once	  secreted,	  EGFL7	  binds	  to	  the	  ECM	  and	  shows	  overlapping	  expression	  with	  
fibronectin	  and	  collagen	  type	  IV.	  (A)	  EGFL7	  controls	  endothelial	  cell	  sprouting,	  migration,	  
and	   proliferation.	   (B).	   EGFL7	   also	   signals	   to	   the	   ECM	   and	   modulates	   its	   rigidity	   by	  
inhibiting	  lysyl	  oxidase	  (LOX)–mediated	  conversion	  of	  tropoelastin	  into	  elastin.	  
Reference	  182	  
	  
Fig.	  15	  Model	  describing	  the	  putative	  role	  of	  EGFL7	  in	  Notch	  signaling.	  EGFL7	  antagonizes	  
Notch/ligand	  interaction	  by	  either	  binding	  to	  the	  receptor	  or	  its	  corresponding	  ligand	  and	  
inhibits	  target	  gene	  expression	  
Reference	  182	  
	  
Fig.	   16	   Putative	   Model	   of	   miR-­‐126	   function	   in	   endothelial	   cells.	   MiR-­‐126	   represses	  
SPRED1	  and	  PIK3R2,	  which	  negatively	  regulate	  VEGF	  signaling	  (and	  possibly	  other	  growth	  
factor	   signaling	   pathways)	   via	   the	   MAP	   kinase	   and	   PI3	   kinase	   pathways,	   respectively.	  
Thus,	  miR-­‐126	  promotes	  VEGF	  signaling,	  angiogenesis	  and	  vascular	  integrity	  by	  inhibiting	  
protein	  production	  of	  endogenous	  VEGF	  repressors	  within	  endothelial	  cells.	  
Reference	  173	  
	  
Fig.	  17	  Putative	  effects	  of	  miR-­‐126/miR-­‐126*	  on	  the	  progression	  of	  cancer.	  (A)	  High	  levels	  
of	   miR-­‐126/miR-­‐126*	   drive	   proper	   vessel	   formation	   by	  modulation	   of	   the	   response	   of	  
endothelial	  cells	  to	  vascular	  growth	  factors	  and	  restriction	  of	  leukocyte	  adhesion.	  (B)	  Loss	  
of	   the	   tumor-­‐suppressor	   miR-­‐126/miR-­‐126*	   during	   cancer	   progression	   may	   result	   in	  
elevated	   tumor	   cell	   proliferation,	   migration,	   and	   survival,	   enhanced	   formation	   of	  
metastasis	   and	  an	   increase	   in	   leukocyte	   adhesion	   followed	  by	   their	   infiltration	   into	   the	  
vascular	  wall.	  Further,	  loss	  of	  miR-­‐126/miR-­‐126*	  might	  disturb	  vascular	  integrity,	  leading	  
to	  a	  disorganized	  and	  abnormal	  tumor	  vasculature.	  	  
Reference	  210	  
	  
Fig.	  18	  The	  surface	  tension	  is	  used	  to	  maintain	  the	  liquid	  sample	  on	  the	  column	  while	  the	  
measurement	   is	  made.	  This	   is	   achieved	  by	  pipetting	   the	   sample	  directly	  on	   the	  base	  of	  
measurement.	  The	  measurement	  is	  revealed	  thanks	  to	  two	  optical	  fibers	  in	  less	  than	  10	  




	   90	  
Fig.	   19	   Treatment	   of	   genomic	   DNA	   with	   sodium	   bisulfite	   deaminates	   unmethylated	  
cytosine	   residues	   to	   uracil	   while	   5-­‐methylcytosine	   (in	   red)	   remains	   unaffected.	   After	  




Fig.	  20	  Epitect	  Converstion	  Procedure	  
Epitect	  Bisulfite	  Handbook	  2009	  
	  
Fig.	   22	   Three	   transcription	   start	   site	   were	   found	   (S1,	   S2,	   S3).	   Mir-­‐126	   (arrowhead)	   is	  
embedded	  within	  intron	  7	  of	  the	  EGFL7	  gene.	  The	  bent	  arrow	  indicate	  transciption	  start	  
site	  of	  S2	  and	  S3,	  whereas	  the	  dotted	  bent	  arrow	  indicates	  the	  full	  length	  start	  site	  (S1).	  
Reference	  176	  
	  
Fig.	  23	  The	  priciple	  of	  Pyrosequencing.	  	  
http://www.clinchem.org/content/55/5/856/F1.expansion	  
	  
Fig.	   24	   An	   example	   of	   a	   DNA	   sequence	   and	   its	   conversion	   by	   bisulfite	   treatment	   and	  
further	   amplification	  by	   PCR.	   By	   Pyrosequencing	   analysis,	   unmethylated	  Cyeosine	   (C)	   is	  
measured	  as	  the	  relative	  content	  of	  T	  at	   the	  CpG	  site,	  and	  methylated	  Cystosine	  (mC)	   is	  
measure	  as	  relative	  content	  of	  C	  at	  the	  CpG	  site.	  
http://www.ncbi.nlm.nih.gov/pubmed/17185754	  
	  
Fig.	  25	  Outline	  of	  the	  different	  steps	  of	  the	  pyrosequencing	  procedure.	  A	  target	  region	  is	  
amplified	   with	   one	   of	   the	   two	   primers	   being	   biotinylated.	   The	   biotinylated	   strand	   is	  
captured	  on	   streptavidin-­‐coated	   sepharose	  beads	  which	  are	   retained	  on	   the	   filter	  plate	  
while	  the	  non-­‐biotinylated	  strand	  is	  washed	  off	  under	  denaturing	  conditions.	  In	  the	  end	  a	  
sequencing	  primer	  is	  annealed	  to	  the	  template	  strand	  for	  the	  pyrosequencing	  reaction.	  
http://www.ncbi.nlm.nih.gov/pubmed/18987816	  
	  
Fig.	  26	  PyroMark	  Q24	  Vacuum	  Workstation.	  
PyroMark	  Q24	  CpG	  LINE-­‐1	  Handbook	  
	  
Fig.	  27	  Vacuum	  tool	  raised	  to	  beyond	  90°	  vertical.	  
PyroMark	  Q24	  CpG	  LINE-­‐1	  Handbook	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